[
  {
    "nctId": "NCT05369065",
    "statement": "Age ≥ 21 and ≤ 65 years at time of enrollment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Diagnosed with T2DM with baseline:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Fasting plasma glucose ≥ 140 mg/dl (7.8 mmol/l) and ≤ 270 mg/dL (15 mmol/L)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "HbA1c levels ≥ 7.0% and ≤ 9.0% (53-75 mmol/mol)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Triglyceride level < 400 mg/dL (4.52 mmol/L)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "On oral anti-hyperglycemic drug regimen of metformin. Subjects may be on additional oral anti-hyperglycemic drug of a different drug class",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Years of T2DM ≤ 10 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Diagnosed hypertension with baseline:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Office blood pressure of SBP of ≥ 140 mmHg and ≤ 180 mmHg and DBP ≥ 90 mmHg",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Mean 24-hour ambulatory SBP of ≥ 130 mmHg and ≤ 170 mmHg with ≥ 75% valid readings",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "On stable oral anti-hypertension drug regimen consisting of up to a maximum of three drugs",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "BMI between 27.5 and 40 kg/m2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "C-peptide testing: non-fasting random or stimulated C-peptide ≥ 2 ng/mL (660 pmol/L)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Vessel diameter of 3 mm to 6.5 mm inclusively with a minimum arterial treatable length of 20 mm in one or more of the following arteries:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Renal",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Hepatic",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "T1DM or poorly controlled T2DM (defined as HbA1c > 9.0% or use insulin as medication to control glucose level).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Office diastolic blood pressure < 90 mmHg.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Current use of > 3 hypertension medications.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Currently on beta blockers or alpha blockers.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "One or more documented hyperglycemia episodes requiring hospitalization in the 180-day prior to screening date.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Prior evidence of hypoglycemia unawareness or serious hypoglycemia with loss of consciousness or confusion sufficient to prevent self-treatment in last 6 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "BMI > 40 kg/m2.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Diagnosed proliferative retinopathy or evidence of peripheral neuropathy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Lack of appropriate treatment site or anatomy precluding the intervention of the target arteries (renal and hepatic artery).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "History of prior renal or hepatic artery intervention including balloon angioplasty, stenting, etc.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Arterial stenosis >50% of the normal diameter segment (diameter stenosis, compared to the angiographically normal proximal or distal segment).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Any abnormality or disease in one or more of the target arteries that, per the physician assessment, precludes the safe insertion of the guiding catheter (including, but not limited to, artery aneurysm, excessive tortuosity, calcification).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Occlusive peripheral vascular disease that would preclude percutaneous femoral access for the procedure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Known or suspected secondary hypertension, such as Cushing's disease or Cushing's Syndrome, hyperaldosteronism, pheochromocytoma, thyroid and parathyroid abnormalities, history of pre-eclampsia, onset of hypertension prior to the age of 18.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Use of nonsteroidal anti-inflammatory drugs (NSAIDs) for two or more days per week over the month prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Severe or unstable cardiovascular comorbidities, such as AMI or ACS, cardiac valve stenosis, pulmonary embolism, heart failure with NYHA Class III or IV, chronic atrial fibrillation, primary pulmonary hypertension, COPD.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Renal transplant, history of nephrectomy or single kidney, renal tumor/cancer, known non-functioning kidney, unequal renal size (>2 cm difference in renal length between kidneys associated with a chronic kidney disease or a deterioration of the kidney function), chronic renal deficiency with eGFR ≤ 60ml/min/1.73m2, or on chronic renal replacement therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Prior liver transplant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Any organ transplantation procedures are planned in the 365 days following Index Procedure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Gastrointestinal permanent anatomic alteration surgery.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Any surgical procedure within 30 days prior to Index Procedure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Currently taking the following medications within 90 days prior to screening and/or there is a need or anticipated need for these medications during the study:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Systemic Corticosteroids",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Anticonvulsants",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Centrally acting sympatholytics",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Bleeding disorders, such as bleeding diathesis, thrombocytopenia, and severe anemia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Use of anticoagulation therapy which cannot be discontinued from 7 days before or 14 days after the Index Procedure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Any other condition(s) that would compromise the safety of the Subject or compromise study quality as judged by the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Significant alcohol consumption, defined as more than 2 drink units per day (equivalent to 20 g) in women and 3 drink units per day (equivalent to 30 g) in men, or inability to reliably quantify alcohol intake.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Active substance abuse, based on Investigator judgement, including inhaled or injected drugs, within 1 year prior to the initial screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Significant weight loss within the last 6 months (e.g., > 10% total body weight loss).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Hepatic decompensation defined as the presence of any of the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Serum albumin less than 3.5 g/dL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "International normalization ratio (INR) greater than 1.4 (unless due to therapeutic anticoagulants)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Total bilirubin greater than 2 mg/dL with the exception of Gilbert syndrome",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "History of esophageal varices, ascites, or hepatic encephalopathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "ALT or AST greater than 200 U/L.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Diagnosis of liver cirrhosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Chronic liver or biliary disease of the following etiology:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "History or diagnosis of Hepatitis B",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "History or diagnosis of Hepatitis C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "History or diagnosis of current active autoimmune hepatitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "History or diagnosis of primary biliary cholangitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "History or diagnosis of primary sclerosing cholangitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "History or diagnosis of Wilson's disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "History or diagnosis of alpha-1-antitrypsin deficiency",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "History or diagnosis of hemochromatosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "History or diagnosis of drug-induced liver disease, as defined on the basis of typical exposure and history.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Known bile duct obstruction.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Suspected or proven liver cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "History of acute or chronic pancreatitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Human immunodeficiency virus (HIV).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Subjects with a history of adverse reaction to heparin or heparin induced thrombocytopenia (HIT).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Systemic infection that the investigator judges would pose unacceptable procedural risks to the subject.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Known hypersensitivity to contrast media, nickel and ethanol that cannot be adequately pre-medicated.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Subject is depressed or on antidepressants.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Pregnancy or breastfeeding or plan to get pregnant in next 12 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Life expectancy of less than 5 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Unwilling or unable to comply with the follow-up study requirements.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Lacking capacity to provide informed consent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Concurrent medical condition that would affect the investigator's ability to evaluate the patient's condition or could compromise patient safety.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05369065",
    "statement": "Currently participation in another pre-market drug or medical device clinical study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "1.Subjects have diagnosed with type 2 diabetes according to the Guidelines for prevention and treatment of type 2 diabetes in China (2020 Edition), and have been diagnosed with T2DM for at least 8 weeks before screening;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "2.Aged 18 to 75 years (inclusive), no gender limitation;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "3. Body Mass Index (BMI): 18.5≤BMI≤40;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "4. No hypoglycemic drugs have been used within 8 weeks before screening, and the blood glucose control is poor after diet and exercise therapy alone",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "5.The continuous use of insulin ≤14 days (except gestational diabetes), and/or the types of hypoglycemic drugs used in combination <3 with the continuous use time ≤4 weeks within 1 year (more than 8 weeks) before screening;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "6.HbA1c must meet the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "Screening: 7.5% ≤ HbA1c ≤ 11.0% (Local laboratory)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "Baseline: 7.0% ≤ HbA1c ≤ 10.5% (Central laboratory)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "7.Subjects of childbearing potential must use reliable methods of contraception throughout the study period and at least 3 months after the last dose to avoid pregnancy in female subjects or pregnancy in the male subject's partner;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "8. Willing and able to accurately use home glucose meter for self-glucose monitoring;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "9. Be able to understand and follow the trial procedure, voluntarily participate in the trial and sign the informed consent form.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "1. Type 1 diabetes;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "2. Body weight change more than 5% within 1 month prior to screening;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "3. Received any of the following medications:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "Prior discontinuation of DPP-4 inhibitors or GLP-1 receptor agonists for efficacy, tolerability, and safety reasons;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "Systemic glucocorticoid and growth hormone have been used within 8 weeks before screening;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "4. History of ≥2 episodes of grade 3 hypoglycemia within 6 months prior to screening, or grade 3 hypoglycemia between screening to randomization;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "5. Acute complications of diabetes, such as diabetic ketoacidosis and hyperglycemic hyperosmolar status, occurred ≥1 time within 6 months prior to screening;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "6. Severe chronic complications of diabetes (e.g., proliferative diabetic retinopathy, severe diabetic neuropathy, diabetic foot, etc.) within 6 months prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "7. History of acute or chronic pancreatitis prior to screening;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "8. Subjects with clinically significant gastric emptying abnormalities (e.g., gastric outlet obstruction), severe chronic gastrointestinal diseases (e.g., gastroparesis, inflammatory bowel disease, or intestinal obstruction) within 6 months prior to screening, or who have undergone gastrointestinal surgery that affects gastric emptying;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "9. Any of the following cardiovascular events within 6 months prior to screening: decompensated cardiac insufficiency (NYHA class III or IV); history of unstable angina pectoris, myocardial infarction, coronary artery bypass grafting, or coronary stent implantation; long QT syndrome or prolonged QTcF interval (QTcF: male >450 ms, female >470 ms) on 12-lead ECG; severe arrhythmias that are evaluated by the investigator to be inappropriate for participation in this clinical trial;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "10. Hemorrhagic stroke or acute ischemic stroke disease occurred within 6 months prior to screening;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "11. History of psychiatric diseases (such as depression, anxiety, etc.) during screening; or symptomatic gallbladder disease; or history of other diseases that may endanger the safety of the subject and that the investigator deems inappropriate for enrollment;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "12. Any type of malignant tumor treated or untreated within 5 years prior to screening (except for clinically cured basal cell carcinoma or carcinoma in situ);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "13. Severe or acute infection within 4 weeks prior to screening, or refractory urinary tract or genital infection within 6 months prior to screening;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "14. Having a significant blood system disease (e.g., aplastic anemia, myelodysplastic syndrome) or any disease causing hemolysis or red blood cell instability (e.g., malaria) at screening;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "15. Subjects with thyroid dysfunction that cannot be controlled by a stable drug dose at screening, or with clinically significant abnormalities in thyroid function examination results requiring drug treatment at screening;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "16. Personal or family history of medullary thyroid cancer (MTC) or type 2 multiple endocrine tumor syndrome at screening;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "17. Any of the indicators meet the following criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "i. Systolic blood pressure ≥ 160mmHg or diastolic blood pressure ≥ 100mmHg at screening or before randomization;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "ii. Laboratory tests show any of the following abnormalities:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "FPG≥13.9 mmol/L;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "ALT or AST≥2.5×ULN;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "Total bilirubin (TBiL) ≥2.0×ULN;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "Triglyceride >5.7 mmol/L;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "eGFR<45 mL/(min*1.73 m^2);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "Serum amylase and/or lipase ≥3×ULN;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "Hemoglobin <100 g/L;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "Calcitonin≥50 ng/L(pg/mL);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "iii. Serological examination:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "Human immunodeficiency virus antibody or treponema pallidum antibody is positive;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "Hepatitis C antibody is positive, and HCV RNA was higher than the lower limit of the detection reference range;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "Hepatitis B surface antigen is positive, and the quantitative detection result of HBV DNA was higher than the lower limit of the detection reference range;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "18. Known allergy to the test drug, Empagliflozin, or related excipients;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "19. Subjects who have lost more than 400 mL blood due to blood donation or other reasons within 3 months prior to screening;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "20. Average alcohol intake more than 21 units of alcohol (male)/14 units of alcohol (female) per week within the 3 months prior to screening (1 unit ≈360 mL beer, or 45 mL spirits with 40% alcohol content, or 150 mL wine);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "21. Subject participated in any drug or medical device clinical study within 3 months prior to screening (except for screening failure);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "22. Pregnant or lactating female;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06258148",
    "statement": "23. Not suitable for this study in the investigator's opinion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01865474",
    "statement": "Diagnosed as type 2 diabetes mellitus with A1c > 7.0% at Screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01865474",
    "statement": "Men or women, between 25-65 years of age.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01865474",
    "statement": "Have been being treated with lifestyle intervention and/or any oral anti-diabetic agents and/or insulin.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01865474",
    "statement": "Adequate liver function: ALT and AST ≤ 2.5 times upper limit of normal.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01865474",
    "statement": "Adequate renal function: serum creatinine < 2.0 times upper limit of normal.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01865474",
    "statement": "Able to take oral medication.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01865474",
    "statement": "For females of childbearing potential: Pregnancy, breast-feeding, the intention of becoming pregnant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01865474",
    "statement": "Patients must accept pregnancy tests during the trial if menstrual cycle is missed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01865474",
    "statement": "Fertile patients must use a reliable and effective contraceptive.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01865474",
    "statement": "The presence of clinically significant electrocardiographic abnormality",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01865474",
    "statement": "History of acute coronary syndrome (myocardial infarction, stroke, unstable angina pectoris), peripheral arterial diseases, venous thromboembolism or other cardiovascular events.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01865474",
    "statement": "History of other arteriosclerotic disease necessitating medical or pharmacological treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01865474",
    "statement": "Severe hypertension (systolic blood pressure ≥ 180 mm Hg, diastolic ≥ 110 mm Hg).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01865474",
    "statement": "Treatment with antiplatelets or antithrombotic agents, including other oral lumbrokinase products within 14 days prior to Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01865474",
    "statement": "Subjects with prior experience with DLBS1033.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01865474",
    "statement": "Subjects with high-risk of bleeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01865474",
    "statement": "Presence of malignancies as observed clinically or by anamnesis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01865474",
    "statement": "Subjects with any other disease state, including chronic or acute systemic infections, or uncontrolled illnesses, which judged by the investigator, could interfere with trial participation or trial evaluation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01865474",
    "statement": "Subjects with known or suspected allergy to study medication or similar products.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01865474",
    "statement": "Subjects with concurrent herbal (alternative) medicines or food supplements suspected to have effect on the primary efficacy endpoint.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01865474",
    "statement": "Subjects enrolled in another experimental (interventional) protocol within the past 30 days prior to Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05925920",
    "statement": "Subjects aged 18-70 years, both genders.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05925920",
    "statement": "Healthy as determined by a physician, based on history, medical examination, vital signs, and laboratory tests.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05925920",
    "statement": "Males that agree to use condoms for the duration of participation in the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05925920",
    "statement": "Females of non-child-bearing potential (i.e., tubal ligation, hysterectomy, or postmenopausal).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05925920",
    "statement": "Female patients of child-bearing potential with negative serum pregnancy tests and who agree to use double-barrier contraception during the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05925920",
    "statement": "Subjects must be able to read, speak, and understand English and/or Spanish and provide written informed consent, and be willing and able to comply with study procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05925920",
    "statement": "Subjects must have a BMI 30-35 kg/m2 inclusive assessed immediately prior to screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05925920",
    "statement": "Fasting insulin level ≥11 mIU/L.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05925920",
    "statement": "HbA1c < 8.5% (diabetic subjects only).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05925920",
    "statement": "Subjects with Type 2 diabetes on no anti-diabetic medication or on stable doses of metformin for 4 weeks or more (diabetic cohorts only).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05925920",
    "statement": "No history of active or chronic disease other than that allowed by study: hypertension, hyperlipidemia, hyperglycemia, GERD, heartburn, or Type 2 diabetes (cohorts 6 and 7 only).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05925920",
    "statement": "History of excessive alcohol use (defined as >21 drinks per week for males and >14 drinks per week for females), recreational drug use within the past three months, or failure on urinary drug screen.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05925920",
    "statement": "Pregnant or breastfeeding within six months of screening assessment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05925920",
    "statement": "Substantial changes in eating habits or exercise routine within the preceding three months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05925920",
    "statement": "Evidence of eating disorders.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05925920",
    "statement": ">5% weight change in the past three months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05925920",
    "statement": "Bariatric surgery within the past five years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05925920",
    "statement": "Significant renal impairment (eGFR <60 mg/mL/1.73m2).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05925920",
    "statement": "Patients on anti-diabetic medications other than metformin.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05925920",
    "statement": "Patients with gastroparesis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05925920",
    "statement": "Liver function tests (i.e., ALT, AST, alkaline phosphatase) greater than twice the upper limit of normal upon repeated measurements.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05925920",
    "statement": "Diseases interfering with metabolism and/or ingestive behavior (e.g., myxedema, Cushing's disease, schizophrenia, major psychoses).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05925920",
    "statement": "History of major depressive disorder within the previous two years, a lifetime history of suicide attempt, suicidal behavior within the previous month, or history of other severe psychiatric disorders.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05925920",
    "statement": "Score of >15 on the Columbia Suicide Severity Rating Scale (C-SSRS).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05925920",
    "statement": "Use of medications affecting body weight within the past three months:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05925920",
    "statement": "Drugs approved for the treatment of obesity",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05925920",
    "statement": "Cyproheptadine or medroxyprogesterone",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05925920",
    "statement": "Atypical anti-psychotic drugs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05925920",
    "statement": "Tricyclic antidepressants",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05925920",
    "statement": "Lithium, MAO's, glucocorticoids",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05925920",
    "statement": "SSRI's or SNRI's",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05925920",
    "statement": "Antiepileptic drugs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05925920",
    "statement": "Any clinically significant abnormality following the Investigator's review of the physical examination and clinical laboratory tests.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05925920",
    "statement": "A baseline prolongation of QT/QTc interval after repeated measurements of >450 ms; a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmias or torsades de pointes, structural heart disease, or a family history of Long QT Syndrome (LQTS).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05925920",
    "statement": "Participation in an investigational drug trial within the month prior to dosing in the present study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Females must be non-pregnant, non-lactating and post-menopausal.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "A glycosylated hemoglobin level greater than 7.5% and less than 10%.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Has an age of onset of Type 2 Diabetes greater than 35 years of age.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Is on metformin monotherapy up to the maximum tolerated daily dose.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Has a normal or only slightly impaired renal function (a modification of diet in renal disease estimated glomerular filtration rate greater than 60 ml/min/1.73m2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Antihypertensives, statins and any other hypolipidemic medications have been initiated at least three months prior to enrollment; no dose modifications are allowed during the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Has one or more cardiovascular comorbidities as follows:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "stable angina pectoris",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "previous (greater than three months) transient ischemic attack, cerebrovascular accident or carotid atherosclerosis as assessed by bilateral carotid artery ultrasonography",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "peripheral vascular complications documented by a history of claudication or rest pain, ultrasonography or angiography.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "and/or two or more of the following major cardiovascular risk factors:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "hypertension (blood pressure >130/80 mmHg or treatment)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "dyslipidemia (low-density lipoprotein-cholesterol >100 mg/dl or treatment and/or high-density lipoprotein-cholesterol <40 mg/dl in men and <45 mg/dl in women or treatment)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "smoking (>10 cigarettes/day)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Has Type 1 Diabetes.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Is on insulin therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Is severely obese defined as a body mass index greater than or equal to 40mg/m2",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Has diabetic retinopathy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Has evidence of hepatic dysfunction including liver transaminase greater than three times the upper limit of normal.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Is unable to remain on a stable dose of the following class of medications 30 days prior to randomization and throughout the six months of the study:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "antihypertensives",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "statins",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "other hypolipidemic and antiplatelet drugs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Has a history of alcohol or other drug abuse.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Has had a new diagnosis of cancer or recurrent cancer within five years of screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Has a need for chronic (greater than two weeks) immunosuppressive therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Has had heart failure based on the New York Heart Association Functional Class I through IV.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Other antidiabetic drugs (except metformin)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Fibrates",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Rifampicin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Glibenclamide interacting drugs, including nonsteroidal anti-inflammatory agents",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Other drugs that are highly protein bound, including:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "sulphonamides",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "chloramphenicol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "probenecid",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "monoamine oxidase inhibitors",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "fluoroquinolones antibiotics",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "oral miconazole",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770835",
    "statement": "Has participated in another clinical study within the past three months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "(Post-menopausal is defined as after one year without menses with an appropriate clinical profile, e.g.\nage appropriate, >45 years, in the absence of hormone replacement therapy.\nIn addition to the above criteria, if the post-menopausal status is still questionable, a blood sample should be drawn for simultaneous measurement of follicle stimulating hormone and estradiol; values considered to confirm the post-menopausal state are respectively: FSH >40 MIU/mL and estradiol <40pg/mL (<140 pmol/L)).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Has a diagnosis of active hepatitis (hepatitis B surface antigen or hepatitis C antibody), or clinically significant hepatic enzyme elevation including:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Any one of the following enzymes greater than 2 times the upper limit of the reference range (ULRR) value at Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Glomerular filtration rate (GFR) <60mL/min (as estimated from serum creatinine at Visit 1 and demographic data using the MDRD equation).For the MDRD equation, please refer to the study procedures manual.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Proteinuria of ≥1+ by urinary dipstick",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Subjects with a documented diagnosis of T2DM and have an HbA1c level at Visit 1 of ≥7.0% and ≤9.5% as measured by a central laboratory. Subjects with HbA1c <7.5% must have a fasting fingerstick glucose ≥7 mmol/L (126 mg/dL) at Week 0 prior to randomization.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Subjects who are treatment-naïve and have not taken insulin, or any oral or injectable anti-diabetic medication in the past 3 months and have not taken a glucose lowering agent for ≥4 weeks at any time in the past, or Subjects who are newly diagnosed and treated with diet and exercise for a minimum of 6 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Subjects who are 18 to 70 years of age inclusive at the time of Screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Females of non-childbearing and childbearing potential are eligible to participate as follows:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Women of childbearing potential must be willing to use one of the following contraception methods: intrauterine device, condom or occlusive cap (diaphragm or cervical/vault caps) plus spermicidal agent for at least 30 days prior to the start of study medication, throughout the study and the follow-up visit. Note: use of oral contraceptives is not permitted.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Women of non-child bearing potential are defined as follows: females regardless of age, with functioning ovaries and who have a current documented tubal ligation [Hatcher, 2004] bilateral oophorectomy or total hysterectomy, or females who are post-menopausal).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Informed Consent: a signed and dated written consent must be obtained from the subject before any procedures are performed.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Metabolic Disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Diagnosis of Type 1 diabetes mellitus.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "History of ketoacidosis which has required hospitalization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Thyroid disorder [TSH below the lower limit of the reference range (LLRR) of 0.4mIU/L or above the upper limit of the reference range (ULRR) of >5.5 mIU/L at Screening]. Hypothyroidism treated with the same dose and regimen of thyroid hormone replacement for at least 3 months prior to Screening is allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "BMI of <22 or >43 kg/m2.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Significant weight gain or loss (as defined as >5% of total body weight) in the 3 months prior to Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Diabetic Medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Has taken insulin or any oral or injectable anti-diabetic medication ≥4 weeks at any time prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Has taken insulin or any oral or injectable anti-diabetic medication within 3 months of screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Cardiovascular Disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Recent history or presence of clinically significant acute cardiovascular disease including:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Documented myocardial infarction in the 6 months prior to Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Coronary revascularization including percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) surgery either planned and/or occurred in the 6 months prior to Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Unstable angina in the 6 months prior to Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Clinically significant supraventricular arrhythmias requiring medical therapy, or history of nonsustained or sustained ventricular tachycardia. Symptomatic valvular heart disease or valvular heart disease requiring therapy other than endocarditis prophylaxis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Congestive heart failure (CHF, New York Heart Association (NYHA) Class II to IV) requiring pharmacologic treatment. NYHA Class I may be included in accordance with the local prescribing information for pioglitazone.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Blood pressure (BP) >150/100mmHg. If a subject is receiving permitted antihypertensive therapy, then they must be on stable dose(s) of therapy for at least 4 weeks prior to Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Has a QTc interval (Bazett's) ≥450msec at Screening on a single ECG or an average value from 3 ECGs taken 5 minutes apart (on local reading of ECG).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Other clinically significant ECG abnormalities which, in the opinion of the investigator, may affect the interpretation of efficacy and safety data, or which otherwise contraindicates participation in a clinical trial with a new chemical entity.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Fasting triglycerides ≥400mg/dL (4.56mmol/L) at Screening. If a subject is receiving permitted lipid-lowering therapy, then they must be on a stable dose(s) of therapy for at least 6 weeks prior to Screening. Niacin and bile acid sequestrants are prohibited.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Hepatic Disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "alanine transaminase (ALT).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "aspartate transaminase (AST).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "alkaline phosphatase (AP). Has a total bilirubin level that is >1.5 times the ULRR at Screening with the exception of suspected or confirmed Gilbert's disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Pancreatic Disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Secondary causes of diabetes:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "history of chronic or acute pancreatitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Renal Disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Significant renal disease at Screening as manifested by:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Recurrent genitourinary tract infections defined as ≥2 episodes of complicated or uncomplicated cystitis or pyelonephritis in the 6 months prior to Screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "A positive qualitative urinary dipstick for leukocytes, red blood cells (RBC) or nitrites at Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Concurrent Disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Has any concurrent condition or any clinically significant abnormality identified on the screening physical examination, laboratory tests (including blood electrolytes), electrocardiogram, including pulmonary, neurological or inflammatory diseases, which, in the opinion of the investigator, may affect the interpretation of efficacy and safety data, or which otherwise contraindicates participation in a clinical trial with a new chemical entity",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "History of significant co-morbid diseases active in the 6 months prior to Screening (e.g., cholecystitis, acute pancreatitis, gastrointestinal disease, chronic diarrhea, etc.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Has a history of malignancy within the past five years [other than superficial squamous cell carcinoma which is non-invasive on pathology or basal cell carcinoma which is successfully treated with local excision] and cervical cancer in situ treated definitively at least 6 months prior to Screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Concurrent Medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Is currently taking or has taken any of the following medications in the 8 weeks prior to Screening:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Digoxin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Warfarin and other oral anticoagulants (aspirin and non-steroidal anti-inflammatory drugs are permitted)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Bile acid sequestrants",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Niacin (excluding routine vitamin supplementation)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Antiobesity agents (including fat absorption blocking agents)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Oral or injectable corticosteroids (inhaled and intranasal corticosteroids are permitted)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Loop diuretics",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Monoamine oxidase inhibitors and tricyclic amines",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Antiretroviral drugs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "St John's Wort",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Oral chromium",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Pregnancy & Breast Feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Is currently lactating or pregnant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Other",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Current smoker who is unable to abstain from smoking while in the clinic at each visit",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Has a history of alcohol or substance abuse within the past year at Screening or alcohol or substance abuse during treatment, as determined by the investigator:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Unwilling to refrain from the use of illicit drugs and adhere to other protocol-stated restrictions while participating in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Has an average weekly intake of greater than 21 units or an average daily intake of greater than 3 units (males) or an average weekly intake of greater than 14 units or an average daily intake of greater than 2 units (females). One unit is equivalent to a half-pint of beer or 1 measure of spirits or 1 glass of wine",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Has participated in any study with an investigational or marketed drug in the 3 months prior to Screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "In the opinion of the investigator has a risk of non-compliance with study procedures, or cannot read, understand, or complete study related materials, particularly the informed consent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00500331",
    "statement": "Known allergy to any of the tablet excipients, or history of drug or other allergy, which, in the opinion of the responsible study physician",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05362058",
    "statement": "Exceptions:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05362058",
    "statement": "Have diagnosis of Type 2 diabetes (T2D) according to the World Health Organization Criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05362058",
    "statement": "Have an Hemoglobin A1c (HbA1c) of 7.0 percent (%) - 10.5% inclusive, at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05362058",
    "statement": "Are on a stable treatment with 1 to 3 antihyperglycemic medication for at least 3 months prior to screening and willing to continue the stable treatment for the duration of the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05362058",
    "statement": "These antihyperglycemic medications are accepted in the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05362058",
    "statement": "dipeptidyl peptidase-4 (DPP-4) inhibitors",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05362058",
    "statement": "sodium-glucose cotransporter 2 (SGLT2) inhibitors",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05362058",
    "statement": "biguanides, such as metformin",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05362058",
    "statement": "alpha-glucosidase inhibitors",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05362058",
    "statement": "glucagon-like peptide-1 (GLP-1) receptor agonists, oral or injectable",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05362058",
    "statement": "Sulfonylureas, or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05362058",
    "statement": "Thiazolidinediones.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05362058",
    "statement": "Are insulin naïve.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05362058",
    "statement": "short-term insulin treatment for a maximum of 14 days, prior to screening, and prior insulin treatment for gestational diabetes",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05362058",
    "statement": "Have a body mass index of less than or equal to (≤) 45 kilogram/square meter (kg/m²).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05362058",
    "statement": "Have a diagnosis of Type 1 diabetes (T1D), latent autoimmune diabetes, or a specific type of diabetes other than T2D, for example, monogenic diabetes, diseases of the exocrine pancreas, or drug-induced or chemical-induced diabetes.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05362058",
    "statement": "Have a history of greater than (>) 1 episode of ketoacidosis or hyperosmolar state or coma requiring hospitalization within 6 months prior to screening. Have had severe hypoglycemia episodes within 6 months prior to screening. Have a history of renal transplantation, are currently receiving renal dialysis, or have an estimated glomerular filtration rate.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05362058",
    "statement": "Have known hemoglobinopathy, hemolytic anemia or sickle cell anemia, or any other traits of hemoglobin abnormalities known to interfere with the measurement of HbA1c.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05362058",
    "statement": "Have had New York Heart Association Class IV heart failure or any of these cardiovascular conditions within 3 months prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05362058",
    "statement": "Acute myocardial infarction",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05362058",
    "statement": "Cerebrovascular accident (stroke), or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05362058",
    "statement": "Coronary bypass surgery.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05362058",
    "statement": "Have had gastric bypass (bariatric) surgery, restrictive bariatric surgery, for example Lap-Band, or sleeve gastrectomy within 1 year prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05362058",
    "statement": "Have had significant weight gain or loss within 3 months prior to screening, for example, greater than or equal to (≥) 5%.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00570739",
    "statement": "Age 18 to 79 years, inclusive.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00570739",
    "statement": "HbA1C in the range of greater than or equal to 6.5 percent to small than or equal to 10.0 percent, to be enrolled in the T2DM cohort.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00570739",
    "statement": "2-hour post 75 g OGTT glucose levels in the range of:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00570739",
    "statement": "greater than or equal to 200 mg/dL to be enrolled in the T2DM cohort, or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00570739",
    "statement": "greater than or equal to 140 to 200 mg/dL to be enrolled in the pre-diabetes cohort.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00570739",
    "statement": "FPG levels in the range of:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00570739",
    "statement": "greater than or equal to 126 mg/dL to be enrolled in the T2DM cohort, or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00570739",
    "statement": "greater than or equal to 110 to smaller than or equal to 125 mg/dL to be enrolled in the pre-diabetes cohort.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00570739",
    "statement": "LDL-C levels greater than or equal to 100 mg/dL.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00570739",
    "statement": "Drug-naïve, defined as having never received treatment for T2DM or not having received antidiabetic drug therapy during the 3 months prior to screening visit.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00570739",
    "statement": "Previous diagnosis of:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00570739",
    "statement": "T2DM or prediabetes, to be enrolled in the respective cohorts, or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00570739",
    "statement": "CHD, CVD, and/or primary hypercholesterolemia + BMI greater than or equal to 25 mg/kg2 to be screened for T2DM or pre-diabetes.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00570739",
    "statement": "Understanding of the study procedures and agreement to participate in the study by giving written informed consent at screening visit.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00570739",
    "statement": "Women may be enrolled if all 3 of the following criteria (in addition to the above criteria)are met:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00570739",
    "statement": "They are not pregnant (women of childbearing potential must have a negative serum pregnancy test [serum beta human chorionic gonadotropin )] at screening visit);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00570739",
    "statement": "They are not breast-feeding; and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00570739",
    "statement": "They do not plan to become pregnant during the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00570739",
    "statement": "In addition to all of the above criteria, women must also meet 1 of the following 3 criteria to be enrolled:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00570739",
    "statement": "They have been post-menopausal for at least 1 year; or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00570739",
    "statement": "They are of childbearing potential and will practice 1 of the following methods of birth control throughout the study: oral, injectable, or implantable hormonal contraceptives; intrauterine device; diaphragm plus spermicide; or female condom plus spermicide. Methods of contraception that are not acceptable are partner's use of condoms or partner's vasectomy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00570739",
    "statement": "History of type 1 diabetes and/or history of acute or chronic metabolic acidosis, including diabetic ketoacidosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00570739",
    "statement": "History of chronic (requiring daily for greater than 2 months) use of insulin therapy, except for the treatment of gestational diabetes.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00570739",
    "statement": "Current or prior (within the past 3 months) treatment with an oral antidiabetic drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00570739",
    "statement": "Current or prior (within the past 3 months) treatment with colesevelam HCl (WelChol), colestipol, colestimide, or cholestyramine.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00570739",
    "statement": "History of dysphagia, swallowing disorders, or intestinal motility disorder.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00570739",
    "statement": "Any serious disorder, including pulmonary, hepatic, gastrointestinal (including clinically significant malabsorption), uncontrolled endocrine/metabolic, hematologic/oncologic (within the last 5 years), neurologic, and psychiatric diseases, that would interfere with the conduct of the study or interpretation of the data.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00570739",
    "statement": "Acute coronary syndrome (eg, myocardial infarction or unstable angina), coronary intervention (coronary artery bypass graft or percutaneous transluminal coronary angioplasty or similar procedure), congestive heart failure (requiring pharmacological treatment), or transient ischemic attack within 3 months of screening visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00570739",
    "statement": "History of pancreatitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00570739",
    "statement": "History of acquired immune deficiency syndrome or human immunodeficiency virus.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00570739",
    "statement": "History of drug or alcohol abuse within the past 2 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00570739",
    "statement": "Hospitalization for any cause within 14 days prior to screening visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00570739",
    "statement": "History of an allergic or toxic response to colesevelam HCl or any of its components.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00570739",
    "statement": "Known hypersensitivity to metformin HCl.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00570739",
    "statement": "Serum TG greater than or equal to 500 mg/dL.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00570739",
    "statement": "Body mass index (BMI) greater than 40 kg/m2 .",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Patients with type 2 diabetes mellitus of 20~70years of age at the time of Visit 1 (Screening)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Patients with HbA1c measured in the local lab ranged from 7 to 11%satisfying the following conditions at the time of Visit 1(Screening)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Type 2 diabetes mellitus medication naïve patients or patients who had not taken diabetes medication other than metformin within 8 weeks prior to Visit 1(Screening)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "For patients who have been taking metformin alone within 12 weeks prior to visit 1(Screening) and had taken at least 1000 mg of metformin daily without dose adjustment for 4 weeks prior to Visit 1(Screening)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Patients who have signed an informed consent themselves after receiving explanation about the objectives, methods, effects, etc. of the clinical study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Patients who are applicable to one of the three in the following. 1) Surgically infertile patients 2) Postmenopausal female patients of ≥45 years of age for whom ≥2 years elapsed since their last menstruation 3) Premenopausal fertile female patients or surgically non-infertile male patients who have agreed to use at least 2 kinds of contraceptive measures (certainly including one of the barrier methods) to avoid pregnancy until 14 days after the last dose of the investigational product",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Barrier methods: Condom, Diaphragm, Cervical cap(Pessary), Spermicide",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Hormonal methods: Pills, Injection(Depot), Skin patch, Hormonal implant(Implanon), Vaginal ring",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Intrauterine Devices(IUDs): Cooper IUD(Loop), Hormonal IUD(Mirena)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Natural methods: Basic body temperature, Ovulation period, Coitus interruptus, Abstinence",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Patients with type 1 diabetes mellitus*, Diabetic ketoacidosis, Diabetic coma, Diabetic pre-coma",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Patients with Gestational diabetes, or secondary diabetes",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Patients with Body Mass Index(BMI) >40 kg/m2 at the time of Visit 1(Screening)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Patients with a history of the following",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Patients with NYHA Class III, IV congestive heart failure or arrhythmia requiring treatment at the time of Visit 1(Screening)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Patients whose TSH level is out of the normal range and who have thyroidal dysfunction requiring drug therapy at the time of Visit 1(Screening) (However, those who have been taking thyroid hormone at a fixed dose since previous 6 weeks prior to Visit 1[Screening] and whose TSH level is within the normal range can participate in the study.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Patients with a glomerular filtration rate (eGFR) less than 60 mL/min /1.73 m2, dnd stage renal disease, dialysis or with renal disease that may result from conditions such as cardiovascular shock, acute myocardial infarction and sepsis, or patients with renal insufficiency at the time of Visit 1(Screening)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Patients who are receiving intravenous iodine contrast agents at the time of visit 1(Screening) or planned during the clinical trial period (eg, intravenous urography, venous cholangiography, angiography, computed tomography using contrast media, etc.) ). For patients who have received this test, they can re-evaluate the renal function 48 hours after the test and only participate in clinical trials after they have been found to be normal.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Patients with pulmonary embolism, severe pulmonary dysfunction, or who are susceptible to be accompanied by hypoxemia at the time of Visit 1(Screening)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Patients on drug therapy due to gastrointestinal disturbance including dehydration, diarrhea, and vomiting at the time of Visit 1(Screening) Patients with severe infection or severe trauma at the time of Visit 1(Screening)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Patients with malnutrition status, starvation status, weakness status, pituitary insufficiency or adrenal insufficiency at the time of Visit 1(Screening)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Patients with a history of diabetic ketoacidosis or hyperosmolar non-ketotic coma within 12 weeks prior to Visit 1(Screening)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Patients with a history of myocardial infarction, unstable angina, and coronary artery bypass graft(CABG) within 12 weeks prior to Visit 1(Screening)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Patients who had had a surgical operation within 4 weeks prior to Visit 1(Screening) (excluding minor surgeries without restriction on food and fluid intake) or who are scheduled to have a significant surgery during the study period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Patients with a history of alcoholism or drug addiction within 12weaks prior to Visit 1(Screening)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Patients with a history of malignant tumors within 5 years prior to Visit 1(Screening). However, patients with basal cell or squamous cell skin cancer, or in situ cervical cancer treated properly can participate in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Patients with the outcomes of the laboratory tests performed at Visit 1(Screening) applicable to the criteria below",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Bilirubin >2 × upper limit of normal(ULN)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "AST/ALT >3 × ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Patients with a history of hypersensitivity reactions to the drugs below",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Gemigliptin or drugs belonging to dipeptidyl-peptidase4(DPP4) inhibitors",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Dapagliflozin or drugs belonging to Sodium/glucose co transport-2(SGLT-2) inhibitor",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Metformin or drugs belonging to biguanides",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Patients who were administered the drugs below",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Patients who had been administered anti-obesity drugs within 4 weeks prior to Visit 1(Screening)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Patients who had been administered insulin or GLP-1 analogues within 8 weeks prior to Visit 1(Screening)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Patients who had been administered warfarin, dicoumarin, and digoxin within 4 weeks prior to Visit 1(Screening)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Patients who are being administered any of the strong CYP3A4 inducers (rifampicin[rifampin], dexamethasone, phenytoin, carbamazepine, rifabutin, phenobarbital) at the time of Visit 1(Screening)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Patients who had been being administered glucocorticoids continuously within 2 weeks prior to Visit 1(Screening) or who are required to take glucocorticoids continuously in the future",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Patients with a genetic problems such as Galactose intolerance, Lapp lactose deficiency, Glucose-galactose malabsorption)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Female patients who are pregnant or lactating",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Patients who have an experience of participation in another clinical study within 12 weeks prior to Visit1(screening)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03202563",
    "statement": "Patients who are otherwise considered to be ineligible for this study on investigators' judgment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05564039",
    "statement": "Have type 2 diabetes",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05564039",
    "statement": "Have HbA1c ≥7.0% (≥53 mmol/mol) to ≤9.5% (≤80 mmol/mol)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05564039",
    "statement": "Are currently on a stable dose of dulaglutide weekly (0.75 mg or 1.5 mg) for at least 6 months prior to screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05564039",
    "statement": "No treatment with oral antihyperglycemic medication (OAM), or on a stable dose of up to 3 OAMs, which may include metformin, sodium glucose cotransporter-2 inhibitors (SGLT-2i), and/or sulfonylurea, for at least 3 months before screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05564039",
    "statement": "Have had stable body weight (±5%) during the 90 days preceding screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05564039",
    "statement": "Have BMI ≥25 kilogram/square meter (kg/m²)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05564039",
    "statement": "Have type 1 diabetes",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05564039",
    "statement": "Have a history of chronic or acute pancreatitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05564039",
    "statement": "Have a history of",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05564039",
    "statement": "proliferative diabetic retinopathy, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05564039",
    "statement": "diabetic maculopathy, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05564039",
    "statement": "nonproliferative diabetic retinopathy that requires acute treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05564039",
    "statement": "Have any of these cardiovascular (CV) conditions within 60 days prior to screening:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05564039",
    "statement": "acute myocardial infarction,",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05564039",
    "statement": "cerebrovascular accident (stroke), or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05564039",
    "statement": "hospitalization due to congestive heart failure (CHF).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05564039",
    "statement": "Have New York Heart Assocation (NYHA) Functional Classification Class IV CHF",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05564039",
    "statement": "Have family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05564039",
    "statement": "Have within 90 days prior to screening received treatment with medications intended to promote weight loss. This includes prescribed, over-the-counter, or alternative remedies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05564039",
    "statement": "Have an estimated glomerular filtration rate (eGFR) <30 mL/minute/1.73 m2 (or lower than the country-specific threshold for discontinuing metformin therapy per local label)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05564039",
    "statement": "Have been treated with insulin prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05564039",
    "statement": "Exception: use of insulin for gestational diabetes or short-term use (<14 days) for acute conditions such as acute illness, hospitalization, or elective surgery.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05564039",
    "statement": "Have a history of reduction of dose of dulaglutide, due to intolerability, without successful reescalation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Subjects with T2DM as defined by the criteria of the ADA and/or recognized by WHO Expert Committee on the Diagnosis and Classification of Diabetes Mellitus [American Diabetes Association, 2004], for at least 3 months preceding screening (see Section 15.3, Appendix 3:, \"Diagnosis and Classification of Diabetes Mellitus\").",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "To be eligible for Randomization into the trial, a subject must satisfy all of the following glycemic criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "HbA1c level via central laboratory at the pre-screening visit",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "If HbA1c ≥ 8.0% but ≤ 10.0%: subject may proceed to Randomization;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "If HbA1c ≥ 7.8% but < 8.0%, subject not eligible to proceed, but may be retested once to establish eligibility (or lack thereof). If HbA1c level ≥ 8.0% upon retest, subject is eligible to proceed; otherwise they should be withdrawn.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "If HbA1c < 7.8%, subject not eligible to proceed (no retest allowed).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "FPG level via central laboratory at the pre-screening visit must be < 270 mg/dL (15.0 mmol/L). FPG may be retested within a week to confirm eligibility (or lack thereof).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Concurrent T2DM therapy:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Diet and/or exercise treated: Must not have taken antidiabetic medication for at least 2 months prior to the pre-screening visit, OR",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Metformin monotherapy: Subjects entering the study on metformin must be on the same dose, formulation and regimen of metformin for at least 2 months prior to the pre-screening visit, AND",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "TZDs and insulin are excluded in the 3 months prior to the Screening visit for all subjects.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Males and females who are 18 to 70 years of age inclusive at the time of Screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "If female, eligible to enter and participate in this study:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "If of non-childbearing potential (i.e., physiologically incapable of becoming pregnant (tubal ligation), including any female who is post-menopausal [>1 year without menstrual period]); or,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "If of child-bearing potential, has a negative pregnancy test at Screening (serum), at Randomization (urine) and:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Has a male partner who is sterile prior to the female subject's entry into the study and is the sole sexual partner for that female subject, or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Uses double-barrier methods of contraception; condoms with the use of caps (with spermicide) and IUDs are acceptable, or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Uses hormonal contraceptives (oral, depots, patches etc) with double- barrier methods of contraception as outlined above, or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Abstains from sexual intercourse, or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Is with a same sex partner and does not participate in bisexual activities where there is any risk of pregnancy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Body Mass Index (BMI): ≥25 and ≤40 kg/m² and weigh at least 50 kg at Screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "If subject is a smoker, must be able to abstain while in clinic at each visit.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Subject has given full written informed consent prior to any study related procedures are performed.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Metabolic Disease including:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Diagnosis of Type 1 diabetes mellitus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Uncorrected thyroid dysfunction. (NOTE: subjects with hypothyroidism on a stable dose of thyroid replacement therapy for at least 1 month prior to Screening, and who have a screening thyroid stimulating hormone (TSH) within the upper limit of normal may participate).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Significant weight gain or loss (defined as > 5% of total body weight) within the 3 months prior to Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Previous use of insulin for treatment of hyperglycemia within 3 months of Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "History of recent clinically significant cardiovascular disease including:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "History or ECG evidence of prior myocardial infarction within 6 months prior to Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Current unstable angina or history of unstable angina in past 6 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Coronary revascularization including percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) surgery that is either planned or occurred in the 6 months prior to Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Clinically significant arrhythmia or valvular heart disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Congestive heart failure (CHF) with New York Heart Association (NYHA) Class II-IV symptoms (see Section 15.4, Appendix 4).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Blood pressure > 160/100 mmHg or resting heart rate > 100 bpm. Note: subjects using antihypertensives [e.g., beta blockers, angiotensin converting enzyme (ACE) inhibitors, angiotensin II antagonists, calcium channel blockers and diuretics] must be on stable doses during the 30 days prior to Screening and during the trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Has a QTc interval (Bazett's) > 440 msec in males and > 450 msec in females at Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Clinically significant ECG abnormalities which, in the opinion of the Investigator, may affect the interpretation of safety data, or which otherwise, contraindicates participation in a clinical trial with a new chemical entity.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "History of chronic pancreatitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Familial hypercholesterolemia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "TGs ≥800 mg/dL (8.96 mmol/L) at Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Serum creatinine at screening > 1.4 mg/dL (124 µmol/L) for women, or > 1.5 mg/dL (133 µmol/L) for men.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Clinically significant anemia defined by hemoglobin concentrations <12.0 g/dL or < 120.0 g/L for males and < 11.0 g/dL or < 110.0 g/L for females.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "History of significant co-morbid diseases (e.g., cholelithiasis, gastrointestinal disease, etc.) that would preclude participation in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Documented history of hepato-biliary disease including a history of, or positive laboratory results for hepatitis (hepatitis B surface antigen and/or hepatitis C antibody) at Screening, and/or clinically significant hepatic enzyme elevation including: •Any one of the following enzymes greater than 2.5 times the upper limit of normal (ULN) value at Screening:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Alanine aminotransferase (ALT)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Aspartate aminotransferase (AST)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Alkaline phosphatase (ALP)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Total or direct bilirubin > 1.5 times the ULN at Screening, unless consistent with presumed or diagnosed Gilbert's disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "History of metabolic acidosis, rhabdomyolysis, myalgia, myositis or myopathy after taking statins or fibrates.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Any subject who has withdrawn therapy due to AEs after taking a PPARγ or a PPARα/γ dual agonist, either marketed (e.g., troglitazone, rosiglitazone or pioglitazone) or under current or previous clinical investigation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Signs or symptoms of myositis at Screening (or upon 1 repeat test), and/or creatinine phosphokinase (CPK)≥3.0 times ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Is currently taking or has taken any of the following medications in the 3 months prior to the pre-screening visit:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Anti-obesity agents (including fat absorption blocking agents)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "St. John's Wort",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Warfarin and other oral anticoagulants (excluding aspirin and non-steroidal anti-inflammatory drugs)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Digoxin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Oral or injectable corticosteroids (inhaled and intranasal steroids are acceptable)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Use of antidiabetic agents (other than metformin) in the 2 months prior to the pre-screening visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Use of TZDs in the 3 months prior to the pre-screening visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Methotrexate, cyclosporine or monoclonal antibodies (e.g., alemtuzumab, gemtuzumab ozogamicin, rituximab, trastuzumab, ibritumomab, tiuxetan) for rheumatoid arthritis or psoriasis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Atypical antipsychotic medications [e.g., aripiprazole (Abilify), risperidone (Risperdal), clozapine (Clozaril), olanzapine (Zyprexa), quetiapine (Seroquel), and ziprasidone (Geodon)].",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Antiretroviral drugs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Use of lipid lowering agents within 3 months prior to the pre-screening visit. This includes statins, fibrates, ezetimibe (Zetia), niacin and bile acid sequestrants.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Monoamine oxidase inhibitors",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "History of cancer except for the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Basal cell carcinoma or superficial squamous cell carcinoma treated by local excision.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Cervical cancer in situ treated definitively more than 6 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Women who are lactating, pregnant, or planning to become pregnant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Known immediate or delayed hypersensitivity reaction or idiosyncrasy to any drug chemically related to the study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Known allergy to any of the capsule excipients, or history of drug or other allergy, which, in the opinion of the responsible study physician, contradicts participation. Hypersensitivity to metformin or any of its components (for subjects entering on metformin).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Has a history of substance and/or alcohol abuse within the past year as determined by the Investigator at screening or during treatment:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Unwilling to refrain from the use of illicit drugs and adhere to other protocol-stated restrictions while participating in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "History of alcohol abuse defined as an average weekly intake of greater than 21 units or an average daily intake of greater than 3 units (males) or defined as an average weekly intake of greater than 14 units or an average daily intake of greater than 2 units (females). One unit is equivalent to a half-pint of beer or 1 measure of spirits or 1 glass of wine.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Received treatment with a new molecular entity (investigational drug) during the previous 4 months or participated in any other trial during the previous 3 months, or has participated in a previous study with GW677954. A new molecular entity is defined as any compound not in Phase 3. (The washout is from last dose of investigational product in the previous study until the first dose of investigational product.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Likely to be non-compliant, in the investigator's opinion, with respect to the protocol and related scheduled visits.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Subject has any concomitant medical condition which in the opinion of the investigator makes them unsuitable to participate in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00196989",
    "statement": "Subject is either an immediate family member of a participating investigator, study coordinator, employee of an investigator; or is a member of the staff conducting the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183350",
    "statement": "Male patients with proven diagnose of type 2 diabetes mellitus treated with diet and exercise only or with one (or two) oral hypoglycaemic agents besides glitazones",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183350",
    "statement": "Glycosylated haemoglobin A1 (HbA1c)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183350",
    "statement": "≤ 8.5 % at screening for patients treated with diet and exercise and/or one oral hypoglycaemic agent or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183350",
    "statement": "≤ 8.0 % at screening for patients treated with two oral hypoglycaemic agents",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183350",
    "statement": "Age ≥21 and Age ≤65 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183350",
    "statement": "BMI ≥18.5 and BMI ≤35 kg/m2 (Body Mass Index)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183350",
    "statement": "Caucasian ethnicity",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183350",
    "statement": "Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice GCP and the local legislation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183350",
    "statement": "Any finding of the medical examination (including Blood Pressure (BP), Pulse Rate (PR) and Electrocardiogram (ECG)) deviating from normal and of not acceptable clinical relevance",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183350",
    "statement": "Clinically relevant concomitant diseases like renal insufficiency, cardiac insufficiency New York Heart Association (NYHA) II-IV, known cardiovascular diseases including hypertension > 160/110 mmHg, stroke and Transient ischaemic attack (TIA)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183350",
    "statement": "Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders besides type 2 diabetes, hyperlipidaemia and medically treated hypertension",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183350",
    "statement": "Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or relevant neurological disorders besides polyneuropathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183350",
    "statement": "Chronic or relevant acute infections (e.g. Human immunodeficiency virus (HIV), Hepatitis)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183350",
    "statement": "History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183350",
    "statement": "Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial except allowed co-medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183350",
    "statement": "Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183350",
    "statement": "Participation in another trial with an investigational drug within two months prior to administration or during the trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183350",
    "statement": "Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183350",
    "statement": "Inability to refrain from smoking on trial days",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183350",
    "statement": "Alcohol abuse (more than 60 g/day)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183350",
    "statement": "Drug abuse",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183350",
    "statement": "Blood donation (more than 100 mL within four weeks prior to administration or during the trial)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183350",
    "statement": "Excessive physical activities (within one week prior to administration or during the trial)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183350",
    "statement": "Any laboratory value outside the reference range that is of not acceptable clinical relevance",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183350",
    "statement": "Change of drug dosing of allowed co-medication (anti-hypertensive agents, acetylic salicylic acid and statins) within the last 3 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183350",
    "statement": "Any ECG value outside of the reference range and of clinical relevance including, but not limited to QRS interval > 120 ms or QTcB > 450 ms or QT >500 ms",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183350",
    "statement": "Fasted blood glucose > 240 mg/dl (=13.3 mmol/L) on two consecutive days during washout",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183350",
    "statement": "Serum creatinine above upper limit of normal at screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02175121",
    "statement": "Male subjects and non-childbearing potential female subjects between the ages of 18 and 70 years old.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02175121",
    "statement": "Body Mass Index of 18.0 to 45.4 kg/m2; and a total body weight of >50 kg",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02175121",
    "statement": "HbA1c value at the screening visit meeting once of the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02175121",
    "statement": "Currently taking acceptable oral antiglycemic drug therapy within 6.5 to 9.5%",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02175121",
    "statement": "Not currently taking any oral antiglycemic drug therapy within 7 to 10.5%",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02175121",
    "statement": "Fasting plasma glucose concentrations<270mg/dL at the screening and run-in visit, confirmed by a single repeat, if deemed necessary.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02175121",
    "statement": "Subjects must be willing and able to perform self-tests of blood glucose at least 4 times per day, and maintain a diary for the duration of participation in the study; and therefore, subjects must be literate.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02175121",
    "statement": "History of Type 1 diabetes mellitus or secondary forms of diabetes",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02175121",
    "statement": "One or more self-reported hypoglycemic episodes of sever intensity within 3 months of screening; or 2 or more self-reported hypoglycemic episodes of severe intensity within the previous 6 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02175121",
    "statement": "History of myocardial infarction, unstable angina, arterial revascularization, stroke, New York Heart Association Functional Class II-IV heart failure, or transient ischemic attach within 6 months of screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02175121",
    "statement": "History or evidence of diabetic complications with significant end organ damage, such as",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02175121",
    "statement": "Proliferative retinopathy and/or macular edema;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02175121",
    "statement": "Diabetic neuropathy complicated by neuropathic ulcers;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02175121",
    "statement": "Screening seated systolic blood pressure >160 mm Hg and/or diastolic blood pressure >100 mm Hg after at least a 5 minute seated rest. If the blood pressure exceeds this limit, the blood pressure may be repeated 2 more times following approximately 2 minutes of rest between measurements and the median of the 3 values should be used to determine subject eligibility;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02175121",
    "statement": "Male subjects with partners currently pregnant; or male subjects capable of conceiving children who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of investigational product.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "All females must have a negative urine pregnancy test on the day of, and prior to randomization.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Recent history or presence of clinically significant acute cardiovascular disease including:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Has a diagnosis of active hepatitis (hepatitis B surface antigen or hepatitis C antibody), or clinically significant hepatic enzyme elevation including:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Any one of the following enzymes greater than 2 times the upper limit of the reference range (ULRR) value at Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Significant renal disease at Screening as manifested by:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Is currently taking or has taken any of the following medications in the 8 weeks prior to Screening:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Subjects with a documented diagnosis of T2DM and HbA1c ≥7.0% and ≤9.5% measured by the central laboratory at Visit 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Note: Subjects with HbA1c <7.5% must have a fasting fingerstick glucose ≥7 mmol/L (126 mg/dL) at Week 0, prior to randomization.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Note: The proportion of subjects who are randomized with an HbA1c <7.5% will be limited to be no more than 20% (approximately 51 subjects)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Subjects who are treatment-naïve, and have not taken insulin, or any oral or injectable anti-diabetic medication in the past 3 months and have not taken a glucose lowering agent for ≥4 weeks at any time in the past, or subjects who are newly diagnosed and treated with diet and exercise for a minimum of 6 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Subjects who are 18 to 70 years of age inclusive at the time of Screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Females of childbearing and non-childbearing and potential are eligible to participate as follows:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Women of childbearing potential must be willing to use one of the following contraception methods: intrauterine device, condom or occlusive cap (diaphragm or cervical/vault caps) plus spermicidal agent for at least 30 days prior to the start of study medication, throughout the study and the follow-up visit. Note: use of oral contraceptives is not permitted.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Women of non-child bearing potential are defined as follows: females regardless of age, with functioning ovaries who have a current documented tubal ligation, or who are surgically sterile (i.e. documented total hysterectomy or bilateral oophorectomy), or females who are post-menopausal.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Informed Consent: a signed and dated written consent must be obtained from the subject before any procedures are performed.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Metabolic Disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Diagnosis of Type 1 diabetes mellitus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "History of ketoacidosis which has required hospitalization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Thyroid disorder",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "TSH <0.4 MIU/L (<0.4 MCIU/mL) or >5.5 mIU/L (>5.5 MCIU/mL) at Screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "BMI of <22 kg/m2 or >43 kg/m2",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Significant weight gain or loss (as defined as >5% of total body weight) in the 3 months prior to Screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Diabetic Medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Has taken insulin, or any oral or injectable anti-diabetic medication within 3 months of screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Has taken insulin or any oral or injectable anti-diabetic medication ≥4 weeks at any time in the past",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Cardiovascular Disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Documented myocardial infarction in the 6 months prior to Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Coronary revascularization including percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) surgery either planned and/or occurred in the 6 months prior to Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Unstable angina in the 6 months prior to Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Clinically significant supraventricular arrhythmias requiring medical therapy, or history of nonsustained or sustained ventricular tachycardia. Symptomatic valvular heart disease or valvular heart disease requiring therapy other than endocarditis prophylaxis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Congestive heart failure (CHF, New York Heart Association (NYHA) Class II to IV) requiring pharmacologic treatment or the NYHA Class criteria in accordance with the local prescribing information for pioglitazone.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Blood pressure (BP) >150/100mmHg. If a subject is receiving permitted antihypertensive therapy, then they must be on stable dose(s) of therapy for at least 4 weeks prior to Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Based on local readings, the subject has an initial QTc interval (Bazett's)≥450msec at Screening, and after two additional ECGs taken 5 minutes apart, the average of the QTC interval from the three ECGs is ≥450msec.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Other clinically significant ECG abnormalities which, in the opinion of the Investigator, may affect the interpretation of efficacy or safety data, or which otherwise contraindicates participation in a clinical trial with a new chemical entity.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Fasting triglycerides ≥400mg/dL (4.56mmol/L) at Screening. If a subject is receiving permitted lipid-lowering therapy, then they must be on a stable dose(s) of therapy for at least 6 weeks prior to Screening. Niacin and bile acid sequestrants are prohibited.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Hepatic Disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "alanine aminotransferase (ALT)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "aspartate aminotransferase (AST)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "alkaline phosphatase (AP) Has a total bilirubin level that is >1.5 times the ULRR at Screening with the exception of suspected or confirmed Gilbert's disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Pancreatic Disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Secondary causes of diabetes:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "history of chronic or acute pancreatitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Renal Disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Glomerular filtration rate (GFR) <60mL/min (as calculated by Quest at Visit using the Modification of Diet in Renal Disease (MDRD) equation •≥1+ protein on urine dipstick",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Trace or ≥1+ leukocyte esterase on urine dipstick",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Trace or ≥1+ blood on urine dipstick",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Positive nitrite on urine dipstick",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Recurrent genitourinary tract infections defined as ≥2 episodes of complicated or uncomplicated cystitis or pyelonephritis in the 6 months prior to Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Concurrent Disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Has any concurrent condition or any clinically significant abnormality identified on the screening physical examination, laboratory tests (including blood electrolytes), ECG, including pulmonary, neurological or inflammatory diseases, which, in the opinion of the investigator, may affect the interpretation of efficacy and safety data, or which otherwise contraindicates participation in a clinical trial with a new chemical entity.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "History of significant co-morbid diseases active in the 6 months prior to Screening (e.g., cholecystitis, acute pancreatitis, gastrointestinal disease, chronic diarrhea, etc.).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "History of malignancy within the past 5 years other than superficial squamous cell carcinoma (non-invasive on pathology) or basal cell carcinoma (successfully treated with local excision).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "History of cervical cancer in situ treated definitively at least 6 months prior to Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Concurrent Medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Digoxin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Warfarin and other oral anticoagulants (aspirin and non-steroidal anti-inflammatory drugs are permitted)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Bile acid sequestrants",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Niacin (excluding routine vitamin supplementation)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Antiobesity agents (including fat absorption blocking agents)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Oral or injectable corticosteroids (inhaled, topical and intranasal corticosteroids are permitted)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Loop diuretics",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Monoamine oxidase inhibitors and tricyclic amines",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Antiretroviral drugs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "St John's Wort",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Oral chromium 9.Breast Feeding 10.Other",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Current smoker who is unable to abstain from smoking while in the clinic at each visit",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Has a history of alcohol or substance abuse within the past year at Screening or alcohol or substance abuse during treatment, as determined by the investigator:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Unwilling to refrain from the use of illicit drugs and adhere to other protocol-stated restrictions while participating in the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Has an average weekly intake of alcohol of >21 units or an average daily intake of >3 units (males) or an average weekly intake of >14 units or an average daily intake of >2 units (females). One unit is equivalent to a half pint of beer or 1 measure of spirits or 1 glass of wine",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Has participated in any study with an investigational or marketed drug in the 3 months prior to Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "In the opinion of the investigator has a risk of non-compliance with study procedures, or cannot read, understand, or complete study related materials, particularly the informed consent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00495469",
    "statement": "Known allergy to any of the tablet or capsule excipients, or history of drug or other allergy, which, in the opinion of the responsible study physician, contraindicates participation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Males or females, age ≥18 and ≤70 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Diagnosed with stage 3 T1D within the following timeframes:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Part 1 Cohort 1: Participants diagnosed within 3 years prior to screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Part 1 Cohort 2: Participants diagnosed between 3 to 15 years prior to screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Part 2 : Participants diagnosed within 15 years prior to screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Treated with insulin only for at least 2 months prior to screening and proficient in the following in the opinion of the investigator:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Counting carbohydrates",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Adjusting meal and correction boluses based on glucose readings with a stable insulin/carbohydrate ratio as well as correction factors",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Adjusting insulin and dietary therapy during special situations (eg, exercise, stress, intermittent diseases)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "HbA1c ≥6.5 and ≤10.0% at screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Fasting or stimulated C-peptide Concentration at Screening as follows:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "C-peptide concentration ≥0.2 nmol/L if diagnosed within 3 years prior to screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "C-peptide concentration ≥0.08 nmol/L if diagnosed between 3 and 15 years prior to screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Documented history of at least 1 T1D1-related autoantibody.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "If treated with lipid-lowering therapy, the dose must be stable for at least 30 days prior to screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Men and women of childbearing potential must use adequate birth control measures for the duration of the trial and at least 90 days after discontinuing study treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Women who are not pregnant or lactating.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Diagnosis of MODY, T2D or any other subtype of diabetes mellitus other than T1D.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Have had recurrence (≥2 episodes) of severe hypoglycemia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Known self or family history (first-degree relative) of multiple endocrine neoplasia Type 1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Use of diabetes medications except insulin within 2 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Any significant cardiovascular disease or QTcF prolongation within the last 6 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Participants with fasting triglyceride ≥500 mg/dL.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Have an eGFR <60 mL/min/1.73 m2 by the CKDEPI Creatinine Equation at screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Impaired liver function, defined as screening AST or ALT >1.5 × ULN, Total bilirubin >1.5 × ULN with the exception of Gilbert's Syndrome.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "History of acute or chronic pancreatitis, complete pancreatectomy or pancreas transplants.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Serum lipase and/or amylase above 1.5 x ULN.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Known positive test for HIV, HBV surface antigen and COVID-19.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Diagnosis of, or treatment for, any cancer within the last 2 years with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ, melanoma in situ) treated with potentially curative therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Active (symptomatic) celiac disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "History of stomach or intestinal surgery that would potentially alter absorption and/or excretion of orally administered drugs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "History of cirrhosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Currently participating in a formal weight loss program and/or are currently using any drugs for weight management within 2 months of screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Use of Proton pump inhibitors (PPIs) is prohibited.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06152042",
    "statement": "Treatment with a moderate or strong CYP3A4 inhibitor, inducer, or substrate within a week prior to dosing on Day 1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02426541",
    "statement": "Provision of signed informed consent prior to any study specific procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02426541",
    "statement": "Female or male aged 35 to 70 years inclusive with suitable veins for cannulation or repeated venipuncture",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02426541",
    "statement": "Type 2 Diabetes mellitus defined as HbA1c of ≥ 6.5% and ≤ 10.5%.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02426541",
    "statement": "Stable (≥ 3 months) T2D treatment with metformin and/or metformin+dipeptidyl peptidase-4 inhibitors (DPP-IV)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02426541",
    "statement": "Body mass index (BMI) ≤ 40 kg/m2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02426541",
    "statement": "Female subjects must be of non-childbearing potential, meeting at least one of the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02426541",
    "statement": "Hysterectomized females",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02426541",
    "statement": "Postmenopausal women, defined as women who have not had a menstrual period within 1 year",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02426541",
    "statement": "Any condition that is contraindicated with MRI such as, but not limited to, having a pacemaker or claustrophobia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02426541",
    "statement": "Volume depleted patients. Patients at risk for volume depletion due to co-existing conditions or concomitant medications, such as loop diuretics should have careful monitoring of their volume status.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02426541",
    "statement": "Recent Cardiovascular Events in a patient:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02426541",
    "statement": "Acute Coronary Syndrome (ACS) within 2 months prior to enrolment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02426541",
    "statement": "Hospitalization for unstable angina or acute myocardial infarction within 2 months prior to enrolment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02426541",
    "statement": "Acute Stroke or Transient Ischemic Attack (TIA) within two months prior to enrolment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02426541",
    "statement": "Less than two months post coronary artery revascularization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02426541",
    "statement": "Congestive heart failure defined as New York Heart Association (NYHA) class IV, unstable or acute congestive heart failure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02426541",
    "statement": "Blood pressure at enrolment: Systolic BP ≥165 mm Hg and/or diastolic BP ≥100 mm Hg",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02426541",
    "statement": "Any clinically significant illness, medical or surgical procedure or trauma within 4 weeks of the first administration of the investigational product.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02426541",
    "statement": "On insulin, GLP-1 or other oral antidiabetic drug treatment (metformin or both metformin and DPP-IV allowed) or using other medications known to affect glucose metabolism.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02426541",
    "statement": "Any clinically significant abnormalities in physical examination, Electrocardiography (ECG) or clinical chemistry results as judged by the investigator. The following specific exclusion criteria apply to the selected Clinical Chemistry results:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02426541",
    "statement": "Creatinine clearance <60mL/min (estimated with Cockroft-Gault formula).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02426541",
    "statement": "Severe hepatic insufficiency and/or significant abnormal liver function defined as aspartate aminotransferase (AST) >3x upper limit of normal (ULN) and/or alanine aminotransferase (ALT) >3x ULN.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02426541",
    "statement": "Total bilirubin (TB) >2.0 mg/dL (34.2 µmol/L).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02426541",
    "statement": "Body weight loss greater than 5% within 3 months prior to Visit 1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02426541",
    "statement": "Previous PET scan",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02426541",
    "statement": "History of or presence of (as found at Visit 1) any clinically significant disease, disorder or condition which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183324",
    "statement": "Japanese patients with a diagnosis of type 2 diabetes mellitus treated with diet and/or exercise only or with one or two oral hypoglycaemic agents except glitazones",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183324",
    "statement": "Glycosylated haemoglobin A1 (HbA1c)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183324",
    "statement": "<= 8.5% at screening for patients treated with diet and/or exercise and/or one oral hypoglycaemic agent or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183324",
    "statement": "<= 8.0% at screening for patients treated with two oral hypoglycaemic agents",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183324",
    "statement": "Age ≥21 and ≤ 70 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183324",
    "statement": "BMI ≥ 17.6 and ≤ 35 kg/m2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183324",
    "statement": "Any finding of the medical examination including blood pressure, pulse rate and electrocardiogram (ECG) deviating from normal and of not acceptable clinical relevance",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183324",
    "statement": "Clinically relevant concomitant diseases like renal insufficiency, cardiac insufficiency (NYHA II-IV), known cardiovascular diseases including hypertension (>150/95 mmHg), stroke, and transient ischemic attack (TIA).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183324",
    "statement": "Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders, except for type 2 diabetes mellitus, hyperlipidaemia and medically treated hypertension",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183324",
    "statement": "Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or relevant neurological disorders except polyneuropathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183324",
    "statement": "Chronic or relevant acute infections (e.g., human immunodeficiency virus (HIV), hepatitis)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183324",
    "statement": "History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183324",
    "statement": "Intake of drugs with a long half-life (>24 hours) within at least one month or less than 10 half-lives of the respective drug before drug administration except anti-hypertensives, acetylsalicylic acid, and statins",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183324",
    "statement": "Use of drugs decreasing blood glucose within 10 days before drug administration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183324",
    "statement": "Participation in another trial with an investigational drug within two months before drug administration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183324",
    "statement": "Alcohol abuse",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183324",
    "statement": "Drug abuse",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183324",
    "statement": "Blood donation (100 mL or more within four weeks before drug administration)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183324",
    "statement": "Excessive physical activities (within one week before drug administration or during the trial)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183324",
    "statement": "Any laboratory value outside the reference range and the clinical relevance is not acceptable (or the value is more than three times higher than the upper limit of the normal range, e.g., liver enzymes such as aspartate aminotransferase (AST(serum glutamate oxaloacetate transaminase/ SGOT)), alanine transaminase (ALT(serum glutamate pyruvate transaminase/ SGPT)), alkaline phosphatase (γALP), and lactate dehydrogenase (LDH)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183324",
    "statement": "Fasted blood glucose >240 mg/dL (=13.3 mmol/L) on two consecutive days during washout",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183324",
    "statement": "Serum creatinine above 1.3 mg/dL at screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183324",
    "statement": "Pregnancy or child-bearing potential patients and breast-feeding patients",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183324",
    "statement": "Not willing to use adequate contraception (condom use plus another form of contraception, e.g., spermicide, oral contraceptive taken by female partner, sterilisation, intrauterine device) during the whole study period from the time of the first intake of study drug until one month after the last intake",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "Diagnosed with type 2 diabetes mellitus.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "Naive to oral antidiabetic pharmacologic therapy, who were currently taking sulfonylurea monotherapy, who were currently taking sulfonylurea/metformin combination therapy, or who were currently taking metformin monotherapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "Mild cardiac disease New York Heart Association functional Class I.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "Participated in dietary counseling.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "Glycosylated hemoglobin greater than or equal to 7.5% and less than 12% at Screening if naïve to oral antidiabetic pharmacologic therapy or taking metformin monotherapy, or greater than or equal to 6.5% and less than 12% if currently taking sulfonylurea monotherapy or taking ulfonylurea/metformin combination therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "Stable therapy for cardiovascular dysfunction, defined as no change in therapy for greater than or equal to 4 weeks prior to Randomization.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "Within the past 30 days treated with rosiglitazone, pioglitazone, or troglitazone or those previously treated with rosiglitazone, pioglitazone, or troglitazone but discontinued from therapy because of lack of efficacy or clinical or laboratory signs of intolerance.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "Treated with a sulfonylurea but discontinued for lack of efficacy or clinical or laboratory intolerance.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "Currently taking insulin or on continuous insulin therapy for control of their diabetes",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "Type 1 (insulin-dependent) diabetes mellitus or a history of ketoacidosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "Any other investigational drug during the 30 days prior to Visit 1 or who will receive such a drug during the time-frame of this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "History of chronic alcoholism or drug abuse during the 6 months prior to the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "New York Heart Association functional Class II, III, or IV cardiac disease at Screening, or previous history of Class III or IV.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "Any of the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "myocardial infarction",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "coronary angioplasty or bypass graft",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "unstable angina pectoris",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "transient ischemic attacks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "documented cerebrovascular accident. 9. Abdominal, thoracic, or vascular surgery during the 3 months prior to Visit 1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "Planned surgical or catheterization intervention within 6 months following Visit 1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "Awaiting cardiac transplantation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "Intercurrent illness severe enough to require hospitalization during the 3 weeks prior to Visit 1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "Body mass index greater than 48 kg/m2 as calculated by [weight (kg)/height (m)2].",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "Anemia having hemoglobin less than 10.5 g per dL for men and 10.0 g per dL for women.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "Triglyceride level greater than 500 mg per dL.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "Clinical evidence of active liver disease or alanine transaminase levels greater than 2.5 times the upper limit of normal.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "Serum creatinine greater than 2.0 mg per dL for men and 1.8 mg per dL for women or urinalysis protein (albumin) excretion levels greater than 2 plus on Combistix or equivalent and on repeat 24-hour results with greater than 3 g macroproteinuria.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "Unstable coronary syndromes.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "Systolic blood pressure greater than 160 mm Hg or diastolic blood pressure greater than 90 mm Hg at Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "Serious uncontrolled cardiac rhythm disturbances.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "Symptomatic orthostatic hypotension or systolic blood pressure less than 90 mm Hg.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "Severe, advanced peripheral vascular disease (limb-threatening ischemia) or claudication resulting in the inability to walk greater than 1 block or to climb 10 stairs without interruption.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "Lower extremity amputation that would prevent the patient from performing the exercise test.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "Any other serious disease or condition which might affect life-expectancy or make it difficult to successfully manage and follow the subjects according to the protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "Unexplained clinically significant findings on chest x-ray.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "Oral, injected, or inhaled corticosteroids of greater than 2 week duration, or the need for recurrent us of corticosteroids.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "Prescription niacin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "Anti-diabetic medications except metformin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "Cardiovascular medications must remain stable for at least 4 weeks prior to Randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "Non-steroidal anti-inflammatory drugs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00521742",
    "statement": "Aspirin greater than 325 mg per day",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Is age 18 - 80 years at time of screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Has a clinical diagnosis of type 2 diabetes for 2 years or more as determined via medical record or source documentation by an individual qualified to make a medical diagnosis.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Is on MDI regimen (basal/bolus regimen with long-acting insulin and rapid-acting analogs), defined as greater than or equal to 2 injections per day for at least 3 months prior signing the informed consent, or CSII pump therapy with or without CGM. The investigator will use their discretion to verify that insulin requirements have been stable for the last 3 months prior to screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Is able to comply with technology, according to Investigator's judgment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Does not require a legally authorized representative to consent on their behalf due to mental or intellectual disability.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Is willing to perform fingerstick blood glucose measurements as needed.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Is willing to wear the system continuously throughout the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Has a Glycosylated hemoglobin (HbA1c) of less than 10% (as processed by Central Lab) at time of screening visit. Note: All HbA1c blood specimens will be sent to and tested by a National Glycohemoglobin Standardization Program (NGSP) certified Central Laboratory. HbA1c testing must follow NGSP standards.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Has thyroid-stimulating hormone (TSH) in the normal range OR if the TSH is out of normal reference range the Free T3 is below or within the lab's reference range and Free T4 is within the normal reference range.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Is willing to upload data from the study pump, must have Internet access, and a computer system, or compatible smartphone that meets the requirements for uploading the study pump.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Is willing to take one of the following insulins and can financially support the use of insulin preparations as required by the study:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Humalog (insulin lispro injection)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "NovoLog/NovoRapid (insulin aspart injection)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Admelog (insulin lispro injection)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Has a history of 2 or more episodes of severe hypoglycemia, which resulted in any the following during the 6 months prior to screening:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Medical assistance (i.e., Paramedics, Emergency Room [ER] or Hospitalization)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Coma",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Seizures",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Has been hospitalized or has visited the ER in the 6 months prior to screening resulting in a primary diagnosis of uncontrolled diabetes.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Has had diabetic ketoacidosis (DKA) or hyperglycemic hyperosmolar syndrome (HHS) in the last 6 months prior to screening visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Will not tolerate tape adhesive in the area of sensor placement as assessed by a qualified individual.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Has any unresolved adverse skin condition in the area of sensor placement (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection) at time of screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Has (Total Daily Dose) of less than 8 units or greater than 250 units at time of screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Has positive GAD (Glutamic Acid Decarboxylase) Antibody test",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Is female of child-bearing potential and result of pregnancy test is positive at screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Is sexually active female of child-bearing potential and is not using a form of contraception deemed reliable by the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Is female and plans to become pregnant during the course of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Is being treated for hyperthyroidism at time of screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Has diagnosis of adrenal insufficiency at time of screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Has taken any oral, injectable, or intravenous (IV) glucocorticoids within 8 weeks from time of screening visit, or plans to take any oral, injectable, or IV glucocorticoids during the course of the study. Note: Intra-articular injections to treat pain (e.g., joint pain, bursitis, etc.) are permitted",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Is using hydroxyurea at time of screening or plans to use it during the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Is actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or investigational study device in the last 2 weeks prior to screening.(Note: Did not apply to subjects who transitioned from Phase 1 to Phase 2)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Is currently abusing illicit drugs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Is currently abusing marijuana.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Is currently abusing prescription drugs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Is currently abusing alcohol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Has a history of visual impairment which would not allow subject to participate in the study and perform all study procedures safely, as determined by the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Has elective surgery planned that requires general anesthesia during the course of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Has sickle cell disease, hemoglobinopathy; or has received red blood cell transfusion or erythropoietin within 3 months prior to time of screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Plans to receive red blood cell transfusion or erythropoietin over the course of study participation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Is diagnosed with current eating disorder such as anorexia or bulimia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Has been diagnosed with chronic kidney disease greater than CKD2 that results in chronic anemia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Has a hematocrit that is below the normal reference range of lab used.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Is on dialysis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Has serum creatinine of >2 mg/dL.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Has celiac disease that is not adequately treated as determined by the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Has had any of the following cardiovascular events within 1 year of screening: myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, or ventricular rhythm disturbances.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Has had any of the following cardiovascular events 1 year or more prior to screening: Myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, or ventricular rhythm disturbances. Subject may be enrolled if clearance from a board-certified cardiologist is provided prior to or at Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Is a member of the research staff involved with the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05238142",
    "statement": "Has used a MiniMed 780G pump prior to screening (Note: In Phase 2, this applies to new subjects only).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "<Exclusion Criteria in whole pre-treatment period>",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "<Exclusion Criteria at the start of the pre-treatment period (Week -8)>",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "<Exclusion Criteria at Week -4>",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "In the opinion of the investigator or the sub-investigator, the participant is capable of understanding and complying with protocol requirements.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "The participant signs and dates a written, informed consent form prior to the initiation of any study procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "The participant is either male or female and aged 20 to less than 75 years at signing of informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "The participant is an early-stage nephropathy (Stage 2) patient with type 2 diabetes mellitus.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "Inpatient/outpatient: outpatient",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "The participant is a patient with type 2 diabetes mellitus on a certain diet therapy and/or exercise therapy (if any).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "The participant has stability controlled blood glucose, blood pressure and lipid, and does not need any change in the drug and the dose of any antihypertensive, antidiabetic and antidyslipidemia or antihyperlipidemic drugs throughout the study period as judged by the investigator or the sub-investigator.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "The participant has urine albumin/creatinine ratio (UACR) of the first morning urine (the first urine immediately after rising prior to activities in standing position in the morning) is ≥30 to <300 mg/gCr on at least two of three measurements at the start of the pre-treatment period (Week -8), at Week -4 or Week -2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "The participant has estimated glomerular filtration rate according to creatinine (eGFRcreat) ≥45 mL/min/1.73 m^2 at Week -4.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "A male participant who is nonsterilized and sexually active with a female partner of childbearing potential agrees to use adequate contraception from signing of informed consent throughout the study period and for 12 weeks after the completion of the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "A female participant of childbearing potential who is sexually active with a nonsterilized male partner who agrees to routinely use adequate contraception from signing of informed consent until 1 month after the completion of the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "The participant received TAK-272 in a previous clinical study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "The participant is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in the conduct of this study (e.g., spouse, parent, child, sibling) or may consent to participate under duress.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "The participant has a history of hypersensitivity or allergies to TAK-272, candesartan cilexetil and other renin-angiotensin system (RAS) inhibitors (angiotensin converting enzyme [ACE] inhibitors, angiotensin II receptor blocker [ARBs] or direct renin inhibitor [DRIs]).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "The participant needs to take the prohibited medications during the study period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "The participant has hyperkalemia (e.g., serum potassium ≥ 5.0 mEq/L at the start of the pretreatment period (Week -8) and Week -4 or requiring regular use of a potassium adsorbent) or onset of hyperkalemia within 2 years prior to starting the pre-treatment period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "The participant has at least class II hypertension (e.g., sitting systolic blood pressure [SBP] ≥160 mmHg or sitting diastolic blood pressure [DBP] ≥100 mmHg in the pre-treatment period) or malignant hypertension.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "The participant has a renal disease other than type 2 diabetic nephropathy (e.g., patients with renal sclerosis, acute or chronic glomerular nephritis, or polycystic kidney).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "The participant has bilateral or unilateral renal artery stenosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "The participant requires regular use of nonsteroidal anti-inflammatory drugs (excluding low-dose aspirin and locally-acting agents such as topical drugs) (e.g., rheumatoid arthritis patients, osteoarthritis patients, and low back pain patients).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "The participant has a history of any of the cardiovascular diseases listed below within 2 years prior to starting the pre-treatment period:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "Cardiac diseases: myocardial infarction, coronary arterial revascularization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "Cerebrovascular diseases: cerebral infarction (excluding lacunar infarction), cerebral hemorrhage, transient ischemic attack",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "The participant has any of the cardiovascular diseases listed below:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "Cardiac diseases: angina pectoris, arrhythmia, and congested heart failure that requires medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "Vascular diseases: arteriosclerosis obliterans with symptoms (e.g., intermittent claudication)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "The participant has a clinically significant hepatic disorder (e.g., either of alanine aminotransferase [ALT] or aspartate aminotransferase [AST] is ≥ 2.5 times the upper limit of normal at the start of the pre-treatment period (Week -8) or at Week -4).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "The participant has a complication of malignant tumor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "If female, the participant is pregnant, lactating, or is intending to become pregnant before, during or within 1 month after participating in this study; or intending to donate ova during such time period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "If male, the participant intends to donate sperm during the course of this study or for 12 weeks thereafter.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "The participant is judged by the investigator or the sub-investigator as being ineligible for any other reason.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "The participant has participated in another clinical study or post-marketing study within 30 days prior to starting the pre-treatment period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "The participant has received the study medication within 12 weeks prior to starting the pre-treatment period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "The participant has a history of drug abuse (defined as the use of an illicit drug) or history of alcohol abuse within 2 years prior to starting the pre-treatment period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "The participant has changed the renin angiotensin system (RAS) inhibitor (angiotensin-converting enzyme [ACE] inhibitor, angiotensin II receptor blocker [ARB] or direct renin inhibitors [DRI]) or its dose and regimen within 12 weeks prior to starting the pre-treatment period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "The participant is treated with any RAS inhibitor (ACE inhibitor, ARB or DRI) at signing of informed consent, and whose UACR is <30 mg/gCr at the start of the pre-treatment period (Week -8).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "The participant has hemoglobin A1c (HbA1c) (National Glycohemoglobin Standardization Program [NGSP]) ≥9.0% at Week -4.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "The participant has change in HbA1c (NGSP) from the start of the pre-treatment period (Week -8) to Week -4 by ≥10.0%* compared to the higher value of them. *Second decimal place to be rounded off <Exclusion Criteria at the end of the Pre-treatment period (Week 0)>",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "The participant's sitting SBP and sitting DBP changed by ≥20 mmHg or ≥10 mmHg, respectively, at the end of the pre-treatment period (Week 0) compared to Week -2.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "The participant's sitting SBP is <130 mmHg at the end of the pre-treatment period (Week 0).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "The participant's study drug compliance rate* during the pre-treatment period is <80.0%.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02332824",
    "statement": "Compliance rate (%)=(Prescribed amount-Retrieved amount)/ {(Completion date of study drug for the pre-treatment period-Starting date of study drug for the pre-treatment period+1)×5}×100, second decimal place to be rounded off.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05816759",
    "statement": "Those who voluntarily decide to participate and agree to comply with the cautions after fully understand the detailed description of this clinical trial.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05816759",
    "statement": "Healthy adult who aged 19 to 55 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05816759",
    "statement": "Those who meet the criteria of anthropometric data",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05816759",
    "statement": "Man: Body weight ≥ 50 kg, Body mass index 18 to 30 kg/m2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05816759",
    "statement": "Woman: Body weight ≥ 45 kg, Body mass index 18 to 30 kg/m2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05816759",
    "statement": "Those who have medical history of hypersensitivity to active pharmaceutical ingredient (Lobeglitazone, Sitagliptin, Metformin) or additives.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05816759",
    "statement": "Those who have clinically significant disease or medical history of Hepatopathy, Renal dysfunction, Neurological disorder, Immunity disorder, Respiratory disorder, Genitourinary system disorder, Digestive system disorder, Endocrine system disorder, Cardiovascular disorder, Blood tumor, Psychical disorder, Severe urinary tract infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05816759",
    "statement": "Those who have past medical history of gastrointestinal disorder (Crohn's disease, ulcerative colitis, etc. except simple appendectomy or hernia surgery), which affect the absorption of drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05816759",
    "statement": "Those who have Drug abuse (especially sleeping drugs, central analgesics, opiates or psychotropic drugs such as psychotropic drugs) or persons with a history of substance abuse.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05816759",
    "statement": "Those who have the test results written below",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05816759",
    "statement": "AST, ALT > 2 times higher than upper normal level",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05816759",
    "statement": "Total bilirubin > 2 times higher than upper normal level",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05816759",
    "statement": "eGFR (estimated Glomerular Filtration Rate, which is calculated by MDRD) < 60 mL/min/1.73m2",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05816759",
    "statement": "\"Positive\" or \"Reactive\" test result of Hepatitis B & C, HIV, RPR",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05816759",
    "statement": "Under 5 min resting condition, systolic blood pressure >160 mmHg or <90 mmHg, diastolic blood pressure >100 mmHg or <50 mmHg",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05816759",
    "statement": "Those who have determined that the abnormal results are clinically significant in the screening test items (question, vital signs, electrocardiogram, physical test, blood, urine test, etc.).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05816759",
    "statement": "Those who participated in other clinical trials within 180 days of the intended study drug administration and have been administered clinical trial medications (except for those who have not taken the study medication).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05816759",
    "statement": "Those who has taken a drug (Ethical drug, over the counter drug, herbal medicine, or nutritional supplement (vitamin, etc.)) within 14 days prior to screening (however, if it is considered that it does not affect the safety and research results of the subject, as determined by the investigator).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05816759",
    "statement": "Those who donated whole blood within 8 weeks prior to screening, or who donated or donated components (plasma, platelets) within 4 weeks, and consented to prohibit blood donation from 30 days after the last administration of investigational product.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05816759",
    "statement": "Those who have continuously consumed more than 21 units/week (1 unit of alcohol = 10 g = 12.5 mL) within 6 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05816759",
    "statement": "Those who have More than 10 smokers a day within 6 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05816759",
    "statement": "Those who cannot use clinically acceptable contraceptive methods (e.g., infertility surgery between themselves and partners, intrauterine contraceptive devices, use of diaphragms or condoms) from the time the drug is administered to the last visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05816759",
    "statement": "Those who cannot inhibit the diet (especially grapefruit juice, caffeine) that can affect the absorption, distribution, metabolism, and excretion of the drug from 3 days before the last administration of the investigational product to the last visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05816759",
    "statement": "Those who have genetic problems such as galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05816759",
    "statement": "Those who receive intravenous administration of radioactive iodine contrast agents (for intravenous urography, venous cholangiography, angiography, computed tomography using contrast agents, etc.) within 48 hours before the first administration of investigational product.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05816759",
    "statement": "Those who are pregnant or breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05816759",
    "statement": "Those who are deemed inappropriate to participate in clinical trial by investigators.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "Ability to understand the trial procedures and possible adverse events, be able and willing to provide a written informed consent;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "Age 18-65 years on the date of signing informed consent (inclusive);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "Body mass index (BMI) within the range of 19.0-40.0 kg/m2 (inclusive);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "Renal function, assessed by estimated glomerular filtration rate at screening (eGFR):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "Normal renal function: 90-129 mL/min (inclusive);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "Mild impairment: 60-89 mL/min (inclusive);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "Moderate impairment: 30-59 mL/min (inclusive);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "Severe impairment: 15-29 mL/min (inclusive);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "Females of childbearing potential should have negative baseline blood pregnancy test, and must use highly effective contraception from signing the informed consent form to 2 months after the last dose of trial drug; Male subjects must agree to either remain abstinent or use highly effective contraceptive measures during the trial and 2 months after last dose of the trial drug, or have been surgically sterilized;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "Stable renal function, assessed by two eGFR during screening (apart at least 3 days);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "Diagnosed as stable, chronic renal disease for at least 3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "Have any GI disease which impacts gastric emptying (eg, gastric bypass surgery, pyloric stenosis, with the exception of appendectomy);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "Have a personal or family history of medullary thyroid carcinoma or have multiple endocrine neoplasia syndrome type 2; Have a history or presence of pancreatitis;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "Had a severe trauma or major surgery within 6 months prior to screening, planned to undergo surgery during the trial period;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "Participants in clinical trials of any drug or medical device in the 3 months prior to screening;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "Blood donation history or blood loss ≥400 mL within 3 month or ≥200 mL within 1 month before screening, or received blood transfusion within 3 months;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "Allergic constitution includes severe drug allergy or history of drug allergy;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "Hepatitis B surface antigen (HBsAg), HIV antibody detection, hepatitis C virus antibody (HCVAb), treponema pallidum specific antibody detection, positive;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "Regularly use known drugs of abuse and/or show positive findings on urinary drug screen that are not otherwise explained by permitted concomitant medications;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "Have an average weekly alcohol intake that exceeds 14 units per week or average daily cigarettes consumption exceeds 5 per day, and are unwilling to stop alcohol or cigarettes consumption 24 hours prior to dosing until discharge from the study or completion of all study procedures (1 unit =12 oz or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "History use of GLP-1R（glucagon-like peptide-1 receptor） agonist, GLP-1R/GCGR（glucagon receptor）agonist, GIPR（glucose-dependent insulinotropic polypeptide receptor/GLP-1R agonist or GIPR/GLP-1R/GCGR agonist within 2 months prior to screening;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "Breast-feeding women;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "The use of alcohol- or caffeine-containing foods or beverages within 72 hours prior to Check-in (Day -1), unless deemed acceptable by the investigator;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "History of Vasovagal Syncope; Do not have venous access sufficient to allow blood sampling as per the protocol；",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "The need to follow a special diet and unable to follow the diet requirement of protocol;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "The investigator considers that the subject has any other factors that would make it inappropriate to participate in this study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "Healthy Participants:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "Systolic blood pressure <90 mmHg or ≥140 mmHg; Diastolic blood pressure <50 mmHg 或≥90 mmHg; Heart Rate < 50 beats/min or >100 beats/min;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "Have a significant history or presence of cardiovascular (eg, myocardial infarction, cerebrovascular accident, etc. within the past 6 months), respiratory, hepatic, renal, GI, endocrine (except T2DM), haematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "Use of medications determined to be unsuitable by the investigator (including over-the-counter medication, prescription medication and herbal preparations) within the 14 days prior to screening;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "Have clinical laboratory test results outside normal reference range for the population or investigator site and judged to be clinically significant by the investigator;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "Participants with Renal Impairment：",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "Systolic blood pressure <90 mmHg or≥160 mmHg; Diastolic blood pressure <50 mmHg 或 ≥100 mmHg; Heart Rate < 50 beats/min or >100 beats/min;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "Have a significant history or presence of cardiovascular (eg, myocardial infarction, cerebrovascular accident, decompensated heart failure (NYHA classification III or IV), etc. within the past 6 months), respiratory, hepatic, renal (obstructive urinary tract disease, except CKD), GI, endocrine (except T2DM), haematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "History of Kidney Transplant;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "Subjects started new over-the-counter or prescription medications (eg, antihypertensive agents, aspirin, lipid-lowering agents) for treatment of concurrent medical conditions or on their treatment regimen for less than 1 month;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "Have following clinically relevant abnormal laboratory test results:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "Hemoglobin <85 grams per liter (g/L);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3× the upper limit of normal (ULN) or total bilirubin (TBL) >1.5× ULN;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "Serum triglyceride > 5.64 mmol/L（500 mg/dl）;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "Clinical relevant elevation in serum amylase or lipase；",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "QTcF > 450 msec;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06246175",
    "statement": "Other abnormal lab results, as determined by the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Males or females aged 18 or older.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Subjects diagnosed with type 2 diabetes mellitus according to the American Diabetes Association (ADA) criteria.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Subjects treated with stable doses of insulin and/or other hypoglycemic agent(s) for type 2 diabetes mellitus for at least 2 months prior to randomization.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Subjects whose fasting blood glucose levels are reasonably stable for at least 2 months prior to randomization and during the 2-week screening period.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Subjects who have Hemoglobin A1c levels of 7.5 to 10.0 % at Screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Subjects whose BMI is 30 or above.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Subjects who can give written informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Subjects who have any DM-related end-organ damages.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Subjects who have a history of diabetic ketoacidosis or hyperosmolar non-ketotic coma.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Subjects who have any disease likely to limit life span and/or increase risks of interventions such as:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Carotid B-mode ultrasound test results indicating clinically significant stenosis in the common carotid arteries requiring intervention by angioplasty or resection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Cancer treatment in the past 5 years, with the exception of cancers which have been cured, and carry a good prognosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Infectious disease: HIV positivity, active tuberculosis, or pneumonia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Subjects who have any of the following conditions related to cardiovascular disease:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Hospitalization for the treatment of heart disease in the past 12 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "New York Heart Association Functional Class > 2.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Left Bundle branch block on ECG at Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Third degree atrioventricular block on ECG at Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Uncontrolled hypertension with average systolic blood pressure of > 160 mmHg or diastolic blood pressure > 95 mmHg at Screening and Baseline.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Pulse rate > 95 beats per minute at Screening and Baseline.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Stroke or transient ischemic attack in the past 12 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Subjects who have any of the following conditions related to gastrointestinal disease:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Chronic hepatitis or cirrhosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Episode of alcoholic hepatitis or alcoholic pancreatitis in the past 2 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Inflammatory bowel disease requiring treatment in the past 12 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Significant abdominal surgery (e.g., gastrectomy, gastric bypass) in the past 2 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Subjects who have serum creatinine > 1.5 mg/dL for male or > 1.4 mg/dL for female.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Subjects who have chronic obstructive airway disease or asthma requiring daily therapy or home use oxygen.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Subjects who have hematocrit < 36.0% for male or < 33.0% for female.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Subjects who have any of the following conditions or behaviors likely to affect the conduct of the study:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Weight loss of > 10% in the past 6 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Unable to walk without assisted device.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Major psychiatric disorder which would impede conduct of the research.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Excessive alcohol intake (i.e., more than 2 drinks/day).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Subjects who take any of the following medications:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Psychoactive agents such as monoamine oxidase inhibitors and antidepressants (e.g., lithium, Prozac, Zoloft, Serzone, Paxil, Effexor).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Any other medications that may pose harm to the subject.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Female subjects who have a positive serum pregnancy test at Screening, plan a pregnancy during study period, or are breast feeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Female subjects who don't meet any of the following criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Surgically sterile (i.e., have had bilateral tubal ligation, hysterectomy, or bilateral oophorectomy) at least 6 months before randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "Post-menopausal for at least 12 months prior to Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02784275",
    "statement": "If sexually active, they should use oral contraceptives, double barrier contraception (e.g., condom with spermicide), intrauterine device, or other methods approved by the Sponsor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "Have been diagnosed with Type 2 diabetes according to the World Health Organization (WHO) criteria treated with basal insulin",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "Are receiving ≥10 units of basal insulin per day and ≤110 units per day at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "Have HbA1c value of 6.5% - 10% inclusive, at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "Have a Body mass index (BMI) less than or equal to 45 kilogram/square meter (kg/m²)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "Have been treated with one of the following stable insulin regimens at least 90 days prior to screening:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "once daily U100 or U200 of insulin degludec",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "once daily U100 or U300 of insulin glargine",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "once or twice daily U100 of insulin detemir, or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "once or twice daily human insulin NPH",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "acceptable non insulin glucose lowering therapies may include 0 to up to 3 of the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "dipeptidyl peptidase (DPP-4) IV inhibitors",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "SGLT2 inhibitors",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "metformin",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "alphaglucosidase inhibitors or,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "Glucagon-Like Peptide-1 (GLP-1) receptor agonists",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "Participants must be willing to stay on stable dose throughout the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "Have Type 1 diabetes mellitus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "Have acute or chronic hepatitis, cirrhosis, or obvious clinical signs or symptoms of any other liver disease, except Nonalcoholic Fatty Liver Disease (NAFLD)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "Estimated glomerular filtration rate (eGFR) <20 milliliters/minute/1.73 square meter (m²)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "Have active or untreated malignancy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "Are pregnant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "Have a significant weight gain or loss the past 3 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "Have received anytime in the past 6 months, any of the following insulin therapies:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "prandial insulin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "insulin mixtures",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "inhaled insulin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "U-500 insulin, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "continuous subcutaneous insulin infusion therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "Have had any of New York Heart Association Class IV heart failure or any of the following CV conditions in the past 3 months:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "acute myocardial infarctions",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "cerebrovascular accident (stroke), or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "coronary bypass surgery",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05275400",
    "statement": "Gastrointestinal: have undergone gastric bypass (bariatric) surgery, restrictive bariatric surgery (Lap-Band) or sleeve gastrectomy within 1 year prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524770",
    "statement": "Are overtly healthy males or females, as determined by medical history and physical examination",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524770",
    "statement": "Male participants with female partners of child-bearing potential or partners who are pregnant or breastfeeding agree to use a reliable method of contraception from the time of the first dose until 3 months after the last dose of investigational product, as determined by the investigator",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524770",
    "statement": "The method may be one of the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524770",
    "statement": "condom with spermicidal agent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524770",
    "statement": "male participant sterilization",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524770",
    "statement": "true abstinence (which is in line with the participant's usual lifestyle choice; withdrawal or calendar methods are not considered acceptable)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524770",
    "statement": "Female participants not of child-bearing potential (that is, are postmenopausal or permanently sterilized [such as, tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy]). Such participants will not be required to use contraception but must test negative for pregnancy at the time of enrollment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524770",
    "statement": "Postmenopausal is defined as at least 1 year post cessation of menses (without an alternative medical cause) or spontaneous amenorrhea for 6 to 12 months, with follicle stimulating hormone (FSH) ≥40 milli-international units per milliliters (mIU/mL)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524770",
    "statement": "Female participants who have undergone sterilization by tubal ligation agree to use a condom in conjunction with spermicidal gel, foam, cream, film or suppository from the time of screening until 3 months after the last dose of investigational product. Such participants must also test negative for pregnancy at the time of enrollment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524770",
    "statement": "Have a body mass index (BMI) of 18.5 to 32.0 kilograms per meters squared (kg/m^2), inclusive, at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524770",
    "statement": "Have clinical laboratory test results within the normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not clinically significant by the investigator",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524770",
    "statement": "Have venous access sufficient to allow for blood sampling as per the protocol",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524770",
    "statement": "Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures and are willing to follow study restrictions",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524770",
    "statement": "Have given written informed consent approved by Lilly and the ethical review board (ERB) governing the site",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524770",
    "statement": "Are currently enrolled in or have completed or discontinued within the last 30 days from a clinical trial involving an investigational product, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524770",
    "statement": "Have known allergies to Glucagon-like peptide 1 (GLP-1) -related compounds including dulaglutide, or any components of the formulation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524770",
    "statement": "Are persons who have previously completed or withdrawn from this study or any other study investigating dulaglutide in the 3 months prior to screening or have received glucagon-like peptides or incretin mimetics in the 3 months prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524770",
    "statement": "Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524770",
    "statement": "Have an abnormal blood pressure (after at least 5 minutes sitting) that, in the opinion of the investigator, increases the risks associated with participating in the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524770",
    "statement": "Have a history or presence of cardiovascular, respiratory, hepatic, renal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524770",
    "statement": "Have a history or presence of pancreatitis (history of chronic pancreatitis or idiopathic acute pancreatitis) or gastrointestinal disorder, for example relevant esophageal reflux or gall bladder disease, or any gastrointestinal disease which impacts gastric emptying (such as, gastric bypass surgery, pyloric stenosis, with the exception of appendectomy) or could be aggravated by GLP-1 analogs. Participants with dyslipidemia, and participants who had cholecystolithiasis (removal of gall stones) and/or cholecystectomy (removal of gall bladder) in the past, with no further sequelae, may be included in the study at the discretion of the screening physician",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524770",
    "statement": "Show evidence of significant active neuropsychiatric disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524770",
    "statement": "Have family history of medullary thyroid cancer (MTC) or a genetic condition that predisposes to MTC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524770",
    "statement": "Regularly use known drugs of abuse and/or show positive findings on urinary drug screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524770",
    "statement": "Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524770",
    "statement": "Show evidence of hepatitis C and/or positive hepatitis C antibody",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524770",
    "statement": "Show evidence of hepatitis B and/or positive hepatitis B surface antigen",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524770",
    "statement": "Are women with a positive pregnancy test or women who are lactating",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524770",
    "statement": "Have used or intend to use over-the-counter medication other than acetaminophen within 7 days prior to dosing or prescription medication (with the exception of vitamin/mineral supplements and/or hormone replacement therapy [HRT]) within 14 days prior to dosing",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524770",
    "statement": "Have donated blood of more than 500 milliliters (mL) within the last month",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524770",
    "statement": "Have an average weekly alcohol intake that exceeds 21 units per week (males up to age 65) and 14 units per week (males over 65 and females), or are unwilling to adhere to the alcohol restrictions (1 unit = 12 ounces [oz] or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524770",
    "statement": "Smoke more than 10 cigarettes (or equivalent in nicotine) per day, and are unwilling to refrain from smoking on the day of dulaglutide administration or are unable to abide by clinical research unit (CRU) restrictions",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01524770",
    "statement": "In the opinion of the investigator or sponsor, are unsuitable for inclusion in the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "American Diabetes Association (ADA) diagnostic criteria for Type 2 Diabetes (T2D)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "HbA1c >7.0% and ≤ 10%",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Current T2D duration > 3 months at Screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "T2D and other diseases must be stable. Stable disease is defined as disease which did not require a change in medication or dosing level on 4 or more consecutive days or 7 days in total within 28 days prior to Day 0.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Age ≥ 18 and ≤ 70 at Screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "BMI ≥ 23 and ≤ 40 kg/m2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "For female patients of child-bearing age, a negative serum pregnancy test. For patients with reproductive potential, a willingness to utilize adequate contraception (oral contraception plus a mechanical barrier) and not become pregnant (or have their partner[s] become pregnant) during the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Agrees not to change diet and exercise regimen during the trial",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Signed and dated Ethics Committee (EC) approved informed consent before any protocol-specific screening procedures are performed",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Use of the following medications:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Daily use of steroids or aspirin ≥ 700 mg per week",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Immunosuppressive treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Thiazolidinediones",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Concomitant treatment with any other therapeutic antibody, or treatment with any biologic agent that blocks the IL-1 or TNFα signaling pathway",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Change in medication for diabetes within 28 days prior to Day 0, defined as a change in dosing level on 4 or more consecutive days or 7 days in total",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Hemoglobin <10.0 g/dL, WBC <3.0 x 103/mm3 , platelet count <125 x 103/mm3, creatinine > 1.5mg/dL, AST/ALT >2 x ULN, alkaline phosphatase >2 x ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Abnormal, untreated T3, T4, thyroglobulin, or TSH levels or history of Grave's disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Known HIV antibody, hepatitis B surface antigen and/or hepatitis C antibody",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "History of malignancy within 5 years prior to study entry other than carcinoma in situ of the cervix, or adequately treated, nonmetastatic squamous or basal cell carcinoma of the skin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "History of tuberculosis, positive PPD test, active atopic disease requiring medication, or asthma",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Infectious disease:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "CRP >30 mg/L, fever, or infection requiring treatment with antibiotics within 3 weeks prior to Screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "History of recurrent infection or predisposition to infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Active leg or foot ulcer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Immunodeficiency",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Female patients who are pregnant, planning to become pregnant during the course of the study, or breast-feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Receipt of a live (attenuated) vaccine within 3 months prior to Screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Major surgery within 28 days prior to Day 0",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Participation in an investigational drug or device trial within 30 days prior to Screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871415",
    "statement": "Adult patient, >/= 18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871415",
    "statement": "Type 2 diabetes mellitus treated with stable metformin monotherapy for at least 12 weeks prior to screening; metformin dose should be >/= 1500 mg/day (or individual maximum tolerated dose), but no more than the maximum dose specified in the label",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871415",
    "statement": "HbA1c >/= 7% and </= 9.5% at screening or within 4 weeks prior to screening and at pre-randomization visit",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871415",
    "statement": "Fasting plasma glucose </= 13.3 mmol/L (</= 240 mg/dL) at pre-randomization visit",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871415",
    "statement": "Agreement to maintain diet and exercise habits implemented during the run-in phase during the full course of the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871415",
    "statement": "Pregnant women, women intending to become pregnant during the study period, currently lactating women, or women of child-bearing potential not using highly effective, medically approved birth control methods",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871415",
    "statement": "Diagnosis or history of:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871415",
    "statement": "Type 1 diabetes mellitus, diabetes resulting from pancreatic injury, or secondary forms of diabetes",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871415",
    "statement": "Acute metabolic diabetic complications such as ketoacidosis or hyperosmolar coma within the past 6 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871415",
    "statement": "Any previous treatment with thiazolidinedione or with a dual PPAR agonist",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871415",
    "statement": "Any body weight lowering or lipoprotein-modifying therapy (e.g. fibrates) within 12 weeks prior to screening with the exception of stable (>= 1 month) statin therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871415",
    "statement": "Prior intolerance to fibrate",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871415",
    "statement": "Treatment with anti-diabetic medication other than metformin in the last 12 weeks prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871415",
    "statement": "Triglycerides (fasting) > 4.5 mmol/L (> 400 mg/dL) at screening or within 4 weeks prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871415",
    "statement": "Clinically apparent liver disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871415",
    "statement": "Anemia at or within 4 weeks prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871415",
    "statement": "Inadequate renal function",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871415",
    "statement": "Symptomatic congestive heart failure NYHA Class II-IV at screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871415",
    "statement": "Myocardial infarction, acute coronary syndrome or transient ischemic attack/stroke within 6 months prior to screening visit",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871415",
    "statement": "Known macular edema at screening or prior to screening visit",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871415",
    "statement": "Diagnosed and/or treated malignancy (except for basal cell skin cancer, in situ carcinoma of the cervix, or in situ prostate cancer) within the past 5 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871415",
    "statement": "Uncontrolled hypertension",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871415",
    "statement": "History of active substance abuse (including alcohol) within the past 2 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05054842",
    "statement": "Voluntarily signed the informed consent, understood the procedures and methods of the study, and was willing to complete the study strictly in accordance with the clinical trial protocol;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05054842",
    "statement": "The screening age should be 18-75 years old (including both ends), male or female;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05054842",
    "statement": "Diagnosed with type 2 diabetes, 7.5%≤HbA1c≤11%;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05054842",
    "statement": "At least 8 weeks prior to screening, in addition to regular diet control and exercise, a steady dose of metformin ≥1500mg/d;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05054842",
    "statement": "Fasting glucose ≤13.3mmol/L; 6、19.0 < BMI 35.0 kg/m2 or less.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05054842",
    "statement": "General situation:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05054842",
    "statement": "1) Known or suspected allergy to DPP4i drugs or investigational drug excipients;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05054842",
    "statement": "2) Pregnant or lactating women, fertile men or women were unwilling to use contraception during the study period;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05054842",
    "statement": "History or evidence of any of the following diseases at the time of screening:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05054842",
    "statement": "1) Type 1 diabetes, single-gene mutation diabetes, diabetes due to pancreatic damage, or other secondary diabetes (e.g., diabetes due to Cushing's syndrome or acromegaly);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05054842",
    "statement": "2) Acute metabolic complications (such as ketoacidosis, lactic acidosis or hypertonic coma) occurred within 6 months prior to screening; Or have serious chronic complications of diabetes in the past (such as severe macrovascular or microvascular complications as judged by the investigator) and the investigator considers that they are not suitable to participate in this study;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05054842",
    "statement": "3) There is a history of severe hypoglycemia (such as drowsiness, disturbance of consciousness, delirium, or even coma caused by hypoglycemia, which requires the assistance of others for treatment), or repeated hypoglycemia (≥3 symptomatic hypoglycemia within a week, or blood glucose <3.0 mmol/L detected at least 3 times within a week);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05054842",
    "statement": "4) Patients with poorly controlled hypertension at screening were defined as systolic blood pressure (SBP) ≥160 mmHg and/or diastolic blood pressure (DBP) ≥100 mmHg;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05054842",
    "statement": "5) Had myocardial infarction, unstable angina, stroke (except lacunar infarction without attack symptoms) or transient ischemic attack, or had undergone coronary angioplasty, percutaneous coronary stent implantation or coronary artery bypass grafting within 6 months prior to screening; Or had congestive heart failure (NYHA grades III and IV), unstable or acute congestive heart failure, or persistent arrhythmias that the investigator determined significantly affected the subjects' safety within the 6 months prior to screening;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05054842",
    "statement": "6) History of acute and chronic pancreatitis, or risk factors that may lead to pancreatitis, such as history of symptomatic gallbladder, history of pancreatic injury, etc. (except cholecystectomy);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05054842",
    "statement": "7) A history of malignant tumor within 5 years prior to screening, excluding treated local basal cell carcinoma of the skin;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05054842",
    "statement": "8) have obvious diseases of the blood system (such as aplastic anemia, myelodysplastic syndrome, hemolytic anemia) or any diseases causing hemolysis or red blood cell instability (such as malaria);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05054842",
    "statement": "9) Clinically significant gastric emptying abnormalities (e.g., gastric outlet obstruction), severe chronic gastrointestinal diseases (e.g., active ulcers within 6 months prior to screening);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05054842",
    "statement": "10) There is a history of drug or alcohol abuse within 3 months prior to screening, which may affect the subject's compliance to participate in the test according to the investigator's judgment;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05054842",
    "statement": "Received any of the following pharmacological or non-pharmacological treatments or procedures prior to screening:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05054842",
    "statement": "1) Any hypoglycemic drug treatment other than metformin within 2 months prior to screening, including Chinese herbal therapy for hypoglycemic purposes (except cumulative use ≤7 days);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05054842",
    "statement": "2) received systemic steroid hormone therapy (including intravenous and oral administration) and intraarticular administration for more than 7 days within 2 months prior to screening;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05054842",
    "statement": "3) Bariatric surgery or procedures (e.g. gastric banding surgery) within 12 months prior to screening, or use of weight-loss medications within 3 months prior to screening, or weight fluctuation ≥10% within 3 months prior to screening;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05054842",
    "statement": "4) Have received other gastrointestinal surgery that may lead to malabsorption before screening, or long-term use of drugs that directly affect gastrointestinal motility;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05054842",
    "statement": "5) Have received blood transfusion, blood donation or blood loss ≥400 mL within 3 months before screening;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05054842",
    "statement": "6) Participated in clinical trials of any drug or medical device within 3 months prior to screening (subject to entering into randomised procedures);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05054842",
    "statement": "Any of the laboratory test indicators during screening meet the following standards (those who meet the criteria can be retested once within one week if there is a clear reason for retesting) :",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05054842",
    "statement": "1) Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≥3.0×ULN and/or total bilirubin ≥2.0×ULN;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05054842",
    "statement": "2) patients with renal function injury were defined as eGFR <60ml/min/1.73 m2 (calculated according to the simplified formula of dietary adjustment for renal disease (MDRD));",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05054842",
    "statement": "3) Thyroid function test: abnormal thyroid stimulating hormone (TSH), serum free triiodothyronine (FT3), serum free thyroxine (FT4);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05054842",
    "statement": "4) Fasting triglyceride ≥5.64 mmol/L (500 mg/ dL);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05054842",
    "statement": "5) Blood amylase or lipase exceeded the upper limit of the normal range and was clinically significant as judged by researchers",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05054842",
    "statement": "Significant abnormal 12-lead electrocardiogram (ECG) results during screening, which the investigator considered might affect the safety of the subjects and are not suitable for this study;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05054842",
    "statement": "Any other conditions (such as affecting the safety or efficacy evaluation of the subjects) that the investigator deemed inappropriate for the subjects to participate in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183415",
    "statement": "Male Patients:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183415",
    "statement": "Female patients:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183415",
    "statement": "Male and female postmenopausal patients with proven diagnose of type 2 diabetes mellitus treated with diet and exercise only or with one (or two) oral hypoglycaemic agents besides glitazones",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183415",
    "statement": "Glycosylated haemoglobin A1 (HbA1c)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183415",
    "statement": "≤ 8.5 % at screening for patients treated with diet and exercise and/or one oral hypoglycaemic agent or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183415",
    "statement": "≤ 8.0 % at screening for patients treated with two oral hypoglycaemic agents",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183415",
    "statement": "Male patients: Age ≥21 and Age ≤70 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183415",
    "statement": "Female patients: Age ≥60 and Age ≤70 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183415",
    "statement": "BMI ≥18.5 and BMI ≤35 kg/m2 (Body Mass Index)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183415",
    "statement": "Caucasian ethnicity",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183415",
    "statement": "Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice and the local legislation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183415",
    "statement": "Any finding of the medical examination (including Blood Pressure, Pulse Rate and Electrocardiogram) deviating from normal and of not acceptable clinical relevance",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183415",
    "statement": "Clinically relevant concomitant diseases like renal insufficiency, cardiac insufficiency NYHA (New York Heart Association) II-IV, known cardiovascular diseases including hypertension > 150/95mmHg, stroke and TIA (transient ischemic attack)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183415",
    "statement": "Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders besides type 2 diabetes, hyperlipidaemia and medically treated hypertension",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183415",
    "statement": "Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or relevant neurological disorders besides polyneuropathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183415",
    "statement": "Chronic or relevant acute infections (e.g. HIV, Hepatitis)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183415",
    "statement": "History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183415",
    "statement": "Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial except allowed co-medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183415",
    "statement": "Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183415",
    "statement": "Participation in another trial with an investigational drug within two months prior to administration or during the trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183415",
    "statement": "Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183415",
    "statement": "Inability to refrain from smoking on trial days",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183415",
    "statement": "Alcohol abuse (more than 40 g/day = 5 units/day)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183415",
    "statement": "Drug abuse",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183415",
    "statement": "Blood donation (more than 100 mL within four weeks prior to administration or during the trial)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183415",
    "statement": "Excessive physical activities (within one week prior to administration or during the trial)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183415",
    "statement": "Any laboratory value outside the reference range and the clinical relevance is not acceptable (or the value is more than three times higher than the upper limit of the normal range e.g. liver enzymes)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183415",
    "statement": "Change of drug dosing of allowed co-medication (anti-hypertensive agents, acetylic salicylic acid and statins) within the last 3 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183415",
    "statement": "Fasted blood glucose > 240 mg/dl (=13.3 mmol/L) on two consecutive days during washout",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183415",
    "statement": "Serum creatinine above upper limit of normal at screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183415",
    "statement": "Not willing to use adequate contraception (condom use plus another form of contraception e.g. spermicide, oral contraceptive taken by female partner, sterilisation, intrauterine device) during the whole study period from the time of the first intake of study drug until one month after the last intake",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02183415",
    "statement": "Positive pregnancy test",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "iv. Vasectomy with one of the following: diaphragm with spermicide; cervical cap; contraceptive sponge; condom; IUD; or hormonal contraception (see above).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "†Abstinence can be used as the sole method of contraception if it is in line with the subject's preferred and usual lifestyle and if considered acceptable by local regulatory agencies and ethics committees.\nPeriodic abstinence (e.g., calendar, ovulation, sympto-thermal, post-ovulation methods, etc.) and withdrawal are not acceptable methods of contraception.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Male and female subjects aged 18 and older.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Body mass index (BMI) of 19-30 kg/m2 at Screening and stable weight, with no more than 5 kg gain or loss in the 3 months prior to Screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "T1D subjects must have:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "A documented history of type 1 diabetes for at least 6 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Should be on an MDI regimen",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "C peptide levels of ˂ 0.7 ng/mL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "HbA1C ≥ 6.5% to ≤10%",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Females of childbearing potential must have a negative serum pregnancy test result at Screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Females who are not of childbearing potential are defined as:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "post-menopausal (defined as at least 12 months with no menses in women ≥45 years of age) or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "has had a hysterectomy and/or bilateral oophorectomy, or had bilateral tubal ligation or occlusion at least 6 weeks prior to Screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Subjects who are of childbearing potential must: a. agree to remain abstinent from heterosexual activity† or agree to use (or have their partner use) acceptable contraception to prevent pregnancy within the projected duration of the trial and for 14 days after the last dose of blinded investigational product. Two methods of contraception will be used to avoid pregnancy. Acceptable combinations of methods include: i. Use of one of the following double-barrier methods: diaphragm with spermicide and a condom; cervical cap and a condom; or a contraceptive sponge and condom ii. Use of hormonal contraception (any registered and marketed contraceptive agent that contains an estrogen and/or a progestational agent [including oral, subcutaneous, intrauterine and intramuscular agents, and cutaneous patch]) with one of the following: diaphragm with spermicide; cervical cap; contraceptive sponge; condom; vasectomy; or IUD. iii. Use of an IUD with one of the following: condom; diaphragm with spermicide; contraceptive sponge; vasectomy; or hormonal contraception (see above).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Clinical diagnosis of type 2 diabetes;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Evidence of unawareness of hypoglycemia unawareness, a documented plasma glucose ≤50 mg/dL in the absence of symptoms of hypoglycemia at Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "FPG >300 mg/dL at Screening; a single repeat test is allowable.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Use of the following medications:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Administration of thyroid preparations or thyroxine (except in subjects on stable replacement therapy) within 6 weeks prior to Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Administration of systemic long-acting corticosteroids within two months or prolonged use (more than one week) of other systemic corticosteroids or inhaled corticosteroids (if daily dosage is > 1,000 μg equivalent beclomethasone) within 30 days prior to Screening. Intra-articular and/or topical corticosteroids are not considered systemic.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Laboratory abnormalities at Screening including:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Abnormal serum thyrotropin (TSH) levels below the lower limit of normal or >1.5X the upper limit of normal",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Elevated liver enzymes (alanine transaminase (ALT), alanine aminotransferase (AST), alkaline phosphatase) >2X the upper limit of normal.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Very high triglyceride levels (>600 mg/dL); a single repeat test is allowable.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Any relevant abnormality that would interfere with the efficacy or the safety assessments during study treatment administration.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Subject has a Screening systolic blood pressure ≥165 mmHg or diastolic blood pressure ≥100 mmHg. Subjects will be allowed to take a BP rescue medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Any clinically significant ECG abnormality at Screening or cardiovascular disease. Clinically significant cardiovascular disease will include: a. History of stroke, transient ischemic attack, or myocardial infarction within 6 months prior to Screening,",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "History of or currently have New York Heart Associate Class II-IV heart failure prior to Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Presence of any clinically significant endocrine disease according to the Investigator (euthyroid subjects on replacement therapy will be included if the dosage of thyroxine is stable for at least six weeks prior to Screening).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Presence of any clinically significant condition (in the opinion of the Investigator) that might interfere with the evaluation of study medication, such as significant renal, hepatic, gastrointestinal (GI), cardiovascular (CV), immune disease, blood dyscrasias or any disorders causing hemolysis or unstable red blood cells, or clinically important hematological disorders (i.e. aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia) at Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "History of gastrointestinal disorders (e.g. hypochlorhydria) with the potential to interfere with drug absorption.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Presence or history of cancer within the past 5 years of Screening, with the exception of adequately-treated localized basal cell skin cancer or in situ uterine cervical cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "A subject with a history of malignancy >5 years prior to Screening should have no evidence of residual or recurrent disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "A subject with a history of melanoma, leukemia, lymphoma, or renal carcinoma is excluded.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Positive history of active liver disease (other than non-alcoholic hepatic steatosis), including chronic hepatitis B or C, primary biliary cirrhosis, or active symptomatic gallbladder disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Positive history of HIV.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Known allergy to soy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Subject is on a weight loss program and is not in the maintenance phase, or subject has started weight loss medication (e.g., orlistat or liraglutide), within 8 weeks prior to Screening. Subjects who have had bariatric surgery are also excluded.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "S ubject is pregnant or breast-feeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "Subject is a user of recreational or illicit drugs or has had a recent history (within 1 year of Screening) of drug or alcohol abuse or dependence. (Note: Alcohol abuse includes heavy alcohol intake as defined by >3 drinks per day or >14 drinks per week, or binge drinking) at Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04150107",
    "statement": "At the Principal Investigator's discretion, any condition or other factor that is deemed unsuitable for subject enrollment into the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03368807",
    "statement": "Have a Type 1 Diabetes Mellitus (T1D) or a Type 2 Diabetes Mellitus (T2D) diagnosis",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03368807",
    "statement": "Must be taking a mealtime bolus dose insulin, greater than or equal to (≥) 3 doses",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03368807",
    "statement": "Each individual bolus insulin dose must be less than (<) 40 units",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03368807",
    "statement": "Must be taking a stable insulin dose regimen for the last 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03368807",
    "statement": "Must be taking a bolus insulin analog (for example insulin lispro [U-100]/[U-200], insulin aspart, or insulin glulisine). In addition, must be able to switch to insulin lispro U-100 for the duration of the trial",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03368807",
    "statement": "Must have a hemoglobin A1c (HbA1c) ≥8.0% in the last 6 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03368807",
    "statement": "Participants with T1D must be ≥21 to less than or equal to (≤) 65 years of age. Participants with T2D must be ≥35 to ≤65 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03368807",
    "statement": "Women of childbearing potential must meet the following: (Note: females of childbearing potential are defined as those who have experienced menarche and who are NOT permanently sterile or postmenopausal. Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03368807",
    "statement": "Must agree to use 1 highly effective method of contraception, or a combination of 2 effective methods of contraception for the entirety of the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03368807",
    "statement": "Must test negative for pregnancy as indicated by a negative serum or urine pregnancy test",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03368807",
    "statement": "Participants with prior CGM/flash glucose monitoring experience must have stopped CGM/flash glucose monitoring ≥3 months prior to enrollment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03368807",
    "statement": "Have known tape/adhesive allergies with CGM sensors",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03368807",
    "statement": "Medical conditions, visual, physical, psychiatric, or cognitive impairment(s) that may preclude the ability to participate in the trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03368807",
    "statement": "Have history of liver disease, acute or chronic hepatitis, or alanine aminotransferase or aspartate aminotransferase levels ≥3 times the upper limit of the reference range within the last 6 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03368807",
    "statement": "Have history of chronic kidney disease stage 4 and higher within the last 6 months, or history of renal transplantation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03368807",
    "statement": "Have active malignancy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03368807",
    "statement": "Are pregnant or planning to become pregnant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03368807",
    "statement": "Are on or are intending to begin a weight loss program",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03368807",
    "statement": "Participants with T1D who have taken off-label antihyperglycemic agents within last 3 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03368807",
    "statement": "Have received insulin by continuous subcutaneous insulin infusion in the last 3 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03368807",
    "statement": "Participants taking opioid medications for medically invalid reasons or at doses considered excessive",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03368807",
    "statement": "Participants on routine use of acetaminophen",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03368807",
    "statement": "Currently undergoing systemic treatment with:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03368807",
    "statement": "Immunosuppressive medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03368807",
    "statement": "Chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical and inhaled preparations) or have received such therapy within the prior 2 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03368807",
    "statement": "Are currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03368807",
    "statement": "Have participated, within the last 30 days, in a clinical study involving an investigational product",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03368807",
    "statement": "Are unwilling or unable to comply with the use of a data collection device to directly record data",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02152371",
    "statement": "Have type 2 diabetes (based on the World Health Organization's [WHO] diagnostic criteria)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02152371",
    "statement": "Have been treated with basal insulin glargine once daily with or without metformin for at least 3 months prior to screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02152371",
    "statement": "Doses of once daily insulin glargine and metformin (if taken) must be stable during the 3-month period prior to screening. Doses of metformin are considered stable if all prescribed doses during this period are in the range between the minimum required dose (≥1500 mg/day) and the maximum approved dose per the locally-approved label",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02152371",
    "statement": "Have an HbA1c value ≥7.0% and ≤10.5% as assessed by the central laboratory at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02152371",
    "statement": "Require further insulin glargine dose increase at week 3 per the treat-to-target (TTT) algorithm based on the SMPG data collected during the prior week",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02152371",
    "statement": "Have stable weight (±5%) ≥3 months prior to screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02152371",
    "statement": "Have body mass index (BMI) ≤45 kilograms per square meter (kg/m^2) at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02152371",
    "statement": "Are able and willing to administer once weekly randomized therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02152371",
    "statement": "Are females of childbearing potential who must:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02152371",
    "statement": "Test negative for pregnancy at screening, based on a serum pregnancy test",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02152371",
    "statement": "Agree to use a reliable method of birth control",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02152371",
    "statement": "Not be breastfeeding",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02152371",
    "statement": "Have been treated with ANY other antihyperglycemia regimen, other than basal insulin glargine once daily with or without metformin, within the 3 months prior to screening or between screening and week 3",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02152371",
    "statement": "Have a history of ≥1 episode of ketoacidosis or hyperosmolar state/coma",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02152371",
    "statement": "Have a history of hypoglycemia unawareness within the 6 months prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02152371",
    "statement": "Have been treated with drugs that promote weight loss within the 3 months prior to screening or between screening and week 3",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02152371",
    "statement": "Are receiving chronic (>14 days) systemic glucocorticoid therapy or have received such therapy within the 4 weeks prior to screening or between screening and week 3",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02152371",
    "statement": "Have had any of the following cardiovascular conditions within the 2 months prior to screening: acute myocardial infarction (MI), New York Heart Association (NYHA) Class III or Class IV heart failure, or cerebrovascular accident (stroke)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02152371",
    "statement": "Have a known clinically significant gastric emptying abnormality or have undergone gastric bypass surgery or restrictive bariatric surgery",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02152371",
    "statement": "Have acute or chronic hepatitis, signs and symptoms of any other liver disease, or alanine aminotransferase (ALT) level >2.5 times the upper limit of the reference range, as determined by the central laboratory",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02152371",
    "statement": "Have a history of chronic pancreatitis or acute idiopathic pancreatitis, or were diagnosed with any type of acute pancreatitis within the 3 months prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02152371",
    "statement": "Have an estimated glomerular filtration rate (eGFR) <30 milliliters/minute/1.73 square meter (mL/min/m^2), calculated by the Chronic Kidney Disease-Epidemiology (CKD-EPI) equation, as determined by the central laboratory; for participants on metformin, have renal disease or renal dysfunction (for example, a serum creatinine ≥1.5 mg/deciliter [dL] [male] or ≥1.4 mg/dL [female] or eGFR [CKD-EPI] <60 mL/min/1.73 m^2)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02152371",
    "statement": "Have evidence of a significant, uncontrolled endocrine abnormality",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02152371",
    "statement": "Have any self or family history of type 2A or type 2B multiple endocrine neoplasia (MEN 2A or 2B) in the absence of known C-cell hyperplasia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02152371",
    "statement": "Have any self or family history of medullary C-cell hyperplasia, focal hyperplasia, or carcinoma (including sporadic, familial, or part of MEN 2A or 2B syndrome)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02152371",
    "statement": "Have serum calcitonin ≥20 picograms/mL, as determined by the central laboratory",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02152371",
    "statement": "Have evidence of a significant, active autoimmune abnormality",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02152371",
    "statement": "Have any other condition not listed in this section that is a contraindication for use of insulin glargine, or, for participants using metformin, have a condition that is a contraindication for the use of metformin and would require metformin discontinuation per label",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02152371",
    "statement": "Have a history of transplanted organ",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02152371",
    "statement": "Have a history of active or untreated malignancy, or are in remission from a clinically significant malignancy during the 5 years prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02152371",
    "statement": "Have a history of any other condition which, in the opinion of the investigator, may preclude the participants from following and completing the protocol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02152371",
    "statement": "Have any hematologic condition that may interfere with HbA1c measurement (eg, hemolytic anemias, sickle-cell disease)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00385697",
    "statement": "Subjects must meet all of the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00385697",
    "statement": "Subjects must have none of the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00385697",
    "statement": "Enrollment (Segment #1) or randomization (Segment #2) on Study Day 0 within 12 weeks of first visit to any physician for symptoms or signs of diabetes. Study Day 0 is the first day of study drug dosing.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00385697",
    "statement": "Diagnosis of type 1 diabetes mellitus, according to the American Diabetes Association (ADA) criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00385697",
    "statement": "Requirement for injected insulin therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00385697",
    "statement": "Have a detectable fasting or stimulated C-peptide level (above the lower limit of detection of the assay)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00385697",
    "statement": "One positive result on testing for any of the following antibodies:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00385697",
    "statement": "islet-cell autoantibodies (ICA512/IA-2),",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00385697",
    "statement": "glutamic acid decarboxylase autoantibodies, or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00385697",
    "statement": "insulin autoantibodies (if present during first 2 weeks, but not beyond 2 weeks, of insulin treatment)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00385697",
    "statement": "Male or female",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00385697",
    "statement": "Subject must be in one of the following age groups:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00385697",
    "statement": "Age 18-35 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00385697",
    "statement": "Age 12-17 years pending approval by Data Monitoring Committee",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00385697",
    "statement": "Age 8-11 years pending approval by Data Monitoring Committee",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00385697",
    "statement": "Body weight ≥ 36 kg",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00385697",
    "statement": "Prior administration of a monoclonal antibody -- within the 1 year before enrollment or randomization at Study Day 0 -- that could potentially prevent or confound a therapeutic response to MGA031",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00385697",
    "statement": "Participation in any type of therapeutic drug or vaccine clinical trial within the 12 weeks before enrollment or randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00385697",
    "statement": "Any medical condition that, in the opinion of the investigator, would interfere with safe completion of the trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00385697",
    "statement": "Pregnant or lactating females",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00385697",
    "statement": "Prior murine OKT®3 treatment at any time before enrollment or randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00385697",
    "statement": "Current or planned therapy with exenatide or any other agents that stimulate pancreatic beta cell regeneration or insulin secretion",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00385697",
    "statement": "Current or planned therapy with inhaled insulin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00385697",
    "statement": "Uncompensated heart failure, fluid overload, myocardial infarction or evidence of ischemic heart disease, or other serious cardiac disease within the 12 weeks before enrollment or randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00385697",
    "statement": "History of epilepsy, cancer, cystic fibrosis, sickle cell anemia, neuropathy, peripheral vascular disease or cerebrovascular disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00385697",
    "statement": "Newly diagnosed hypothyroidism (not currently being treated but which, in the opinion of the investigator, should be treated) or active Graves' disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00385697",
    "statement": "Eczema, asthma or severe atopic disease requiring treatment within the 12 weeks before enrollment or randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00385697",
    "statement": "Evidence of active infection, such as fever ≥ 38.0 degrees Celsius (100.5 degrees Fahrenheit)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00385697",
    "statement": "Known or suspected infection with human immunodeficiency virus (HIV)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00385697",
    "statement": "Evidence of active hepatitis B (HBV) or hepatitis C virus (HCV)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00385697",
    "statement": "Evidence of active or latent tuberculosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00385697",
    "statement": "Vaccination with a live virus within the 8 weeks before enrollment or randomization or planned live virus vaccination continuing through week 52 of the study. Vaccination with an antigen or killed organism must not be given within 8 weeks before or planned within 8 weeks after each dosing cycle.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00385697",
    "statement": "Any infectious mononucleosis-like illness within the 6 months before enrollment or randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00385697",
    "statement": "Serologic and clinical evidence of acute infection with Epstein-Barr virus (EBV)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00385697",
    "statement": "Serologic evidence of acute infection with cytomegalovirus (CMV)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Subjects must meet all of the following criteria to be eligible for participation in the study:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Age ≥ 21 and ≤ 65 years at time of enrollment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Disease diagnosed 2.1 Diagnosed with T2DM with baseline: And / Or 2.2 Diagnosed hypertension with baseline:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Fasting plasma glucose ≥ 140 mg/dl (7.8 mmol/l) and ≤ 270 mg/dL (15 mmol/L)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "HbA1c levels ≥ 7.0% and ≤ 9.0% (53-75 mmol/mol)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Triglyceride level < 400 mg/dL (4.52 mmol/L)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "On oral anti-hyperglycemic drug regimen of metformin. Subjects may be on additional oral anti-hyperglycemic drug of a different drug class",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Years of T2DM ≤ 10 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Office blood pressure of SBP of ≥ 140 mmHg and ≤ 180 mmHg and DBP ≥ 90 mmHg",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Mean 24-hour ambulatory SBP of ≥ 130 mmHg and ≤ 170 mmHg with ≥ 75% valid readings",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "On stable oral anti-hypertension drug regimen consisting of up to a maximum of three drugs",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "BMI between 27.5 and 40 kg/m2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "C-peptide testing: non-fasting random or stimulated C-peptide ≥ 2 ng/mL (660 pmol/L)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Vessel diameter of 3 mm to 7 mm with a minimum arterial treatable length of 20 mm in one or more of the following arteries:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Renal",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Hepatic",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "T1DM or poorly controlled T2DM (defined as HbA1c > 9.0% or use insulin as medication to control glucose level).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Office diastolic blood pressure < 90 mmHg.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Current use of > 3 hypertension medications.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Currently on beta blockers.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "One or more documented hyperglycemia episodes requiring hospitalization in the 180-day prior to screening date.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Prior evidence of hypoglycemia unawareness or serious hypoglycemia with loss of consciousness or confusion sufficient to prevent self-treatment in last 6 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "BMI > 40 kg/m2.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Diagnosed proliferative retinopathy or evidence of peripheral neuropathy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Lack of appropriate treatment site or anatomy precluding the intervention of the target arteries (renal and hepatic artery).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "History of prior renal or hepatic artery intervention including balloon angioplasty, stenting, etc.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Arterial stenosis >50% of the normal diameter segment (diameter stenosis, compared to the angiographically normal proximal or distal segment).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Any abnormality or disease in one or more of the target arteries that, per the physician assessment, precludes the safe insertion of the guiding catheter (including, but not limited to, artery aneurysm, excessive tortuosity, calcification).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Occlusive peripheral vascular disease that would preclude percutaneous femoral access for the procedure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Known or suspected secondary hypertension, such as Cushing's disease or Cushing's Syndrome, hyperaldosteronism, pheochromocytoma, thyroid and parathyroid abnormalities, history of pre-eclampsia, onset of hypertension prior to the age of 18.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Use of nonsteroidal anti-inflammatory drugs (NSAIDs) for two or more days per week over the month prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Severe or unstable cardiovascular comorbidities, such as AMI or ACS, cardiac valve stenosis, pulmonary embolism, heart failure with NYHA Class III or IV, chronic atrial fibrillation, primary pulmonary hypertension, COPD.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Renal transplant, history of nephrectomy or single kidney, renal tumor/cancer, known non-functioning kidney, unequal renal size (>2 cm difference in renal length between kidneys associated with a chronic kidney disease or a deterioration of the kidney function), chronic renal deficiency with eGFR ≤ 60ml/min/1.73m2, or on chronic renal replacement therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Prior liver transplant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Any organ transplantation procedures are planned in the 365 days following Index Procedure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Gastrointestinal permanent anatomic alteration surgery.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Any surgical procedure within 30 days prior to Index Procedure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Currently taking the following medications within 90 days prior to screening and/or there is a need or anticipated need for these medications during the study:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Systemic Corticosteroids",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Anticonvulsants",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Centrally acting sympatholytics",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Bleeding disorders, such as bleeding diathesis, thrombocytopenia, and severe anemia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Use of anticoagulation therapy which cannot be discontinued from 7 days before or 14 days after the Index Procedure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Any other condition(s) that would compromise the safety of the Subject or compromise study quality as judged by the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Significant alcohol consumption, defined as more than 2 drink units per day (equivalent to 20 g) in women and 3 drink units per day (equivalent to 30 g) in men, or inability to reliably quantify alcohol intake.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Active substance abuse, based on Investigator judgement, including inhaled or injected drugs, within 1 year prior to the initial screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Significant weight loss within the last 6 months (e.g., > 10% total body weight loss).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Hepatic decompensation defined as the presence of any of the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Serum albumin less than 3.5 g/dL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "International normalization ratio (INR) greater than 1.4 (unless due to therapeutic anticoagulants)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Total bilirubin greater than 2 mg/dL with the exception of Gilbert syndrome",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "History of esophageal varices, ascites, or hepatic encephalopathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "ALT or AST greater than 200 U/L.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Diagnosis of liver cirrhosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Chronic liver or biliary disease of the following etiology:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "History or diagnosis of Hepatitis B",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "History or diagnosis of Hepatitis C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "History or diagnosis of current active autoimmune hepatitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "History or diagnosis of primary biliary cholangitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "History or diagnosis of primary sclerosing cholangitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "History or diagnosis of Wilson's disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "History or diagnosis of alpha-1-antitrypsin deficiency",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "History or diagnosis of hemochromatosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "History or diagnosis of drug-induced liver disease, as defined on the basis of typical exposure and history.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Known bile duct obstruction.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Suspected or proven liver cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "History of acute or chronic pancreatitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Human immunodeficiency virus (HIV).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Subjects with a history of adverse reaction to heparin or heparin induced thrombocytopenia (HIT).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Systemic infection that the investigator judges would pose unacceptable procedural risks to the subject.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Known hypersensitivity to contrast media, nickel and ethanol that cannot be adequately pre-medicated.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Subject is depressed or on antidepressants.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Pregnancy or breastfeeding or plan to get pregnant in next 12 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Life expectancy of less than 5 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Unwilling or unable to comply with the follow-up study requirements.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Subjects or their legally authorized representatives unable to provide informed consent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Concurrent medical condition that would affect the investigator's ability to evaluate the patient's condition or could compromise patient safety.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05363761",
    "statement": "Currently participation in another pre-market drug or medical device clinical study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871428",
    "statement": "Adult patient, >/= 18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871428",
    "statement": "Diagnosis of Type 2 diabetes mellitus within 12 months prior to screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871428",
    "statement": "Drug-naïve (defined as no anti-hyperglycemic medication for at least 12 weeks prior to screening and for not longer than 3 consecutive months at any time in the past)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871428",
    "statement": "HbA1c >/= 7% and </= 9.5% at screening or within 4 weeks prior to screening and at pre-randomization visit",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871428",
    "statement": "Fasting plasma glucose </= 13.3 mmol/L (</= 240 mg/dL) at pre-randomization visit",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871428",
    "statement": "Agreement to maintain diet and exercise habits implemented during the run-in phase during the full course of the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871428",
    "statement": "Pregnant women, women intending to become pregnant during the study period, currently lactating women, or women of child-bearing potential not using highly effective, medically approved birth control methods",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871428",
    "statement": "Diagnosis or history of:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871428",
    "statement": "Type 1 diabetes mellitus, diabetes resulting from pancreatic injury, or secondary forms of diabetes",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871428",
    "statement": "Acute metabolic diabetic complications such as ketoacidosis or hyperosmolar coma within the past 6 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871428",
    "statement": "Any previous treatment with thiazolidinedione or with a dual peroxisome proliferator activated receptor (PPAR) agonist",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871428",
    "statement": "Any body weight lowering or lipoprotein-modifying therapy (e.g. fibrates) within 12 weeks prior to screening with the exception of stable (>= 1 month) statin therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871428",
    "statement": "Prior intolerance to fibrate",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871428",
    "statement": "Triglycerides (fasting) > 4.5 mmol/L (> 400 mg/dL) at screening or within 4 weeks prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871428",
    "statement": "Clinically apparent liver disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871428",
    "statement": "Anemia at or within 4 weeks prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871428",
    "statement": "Inadequate renal function",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871428",
    "statement": "Symptomatic congestive heart failure New York Heart Association (NYHA) Class II-IV at screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871428",
    "statement": "Myocardial infarction, acute coronary syndrome or transient ischemic attack/stroke within 6 months prior to screening visit",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871428",
    "statement": "Known macular edema at screening or prior to screening visit",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871428",
    "statement": "Diagnosed and/or treated malignancy (except for basal cell skin cancer, in situ carcinoma of the cervix, or in situ prostate cancer) within the past 5 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871428",
    "statement": "Uncontrolled hypertension",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01871428",
    "statement": "History of active substance abuse (including alcohol) within the past 2 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06037252",
    "statement": "Have a Body Mass Index (BMI) ≥35 kilogram/square meter (kg/m²) at screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06037252",
    "statement": "Have had stable body weight (±5%) during the 90 days preceding screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06037252",
    "statement": "Have been diagnosed with Type 2 Diabetes (T2D).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06037252",
    "statement": "Have been on a stable treatment of metformin only at least 90 days preceding screening and between screening and randomization with the minimum effective dose of ≥1500 milligram (mg)/day.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06037252",
    "statement": "Have Type 1 Diabetes (T1D), history of ketoacidosis or hyperosmolar state/coma, or any other types of diabetes except T2D.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06037252",
    "statement": "Have had 1 or more episode of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 6 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06037252",
    "statement": "Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06037252",
    "statement": "Have a prior or planned surgical treatment for obesity.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06037252",
    "statement": "Use products intended for weight loss including prescription drugs, over the counter (OTC) drugs, and herbal preparations, within 3 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06037252",
    "statement": "Have renal impairment measured as estimated glomerular filtration rate (eGFR) <45 milliliter/min (mL/min)/1.73 m².",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06037252",
    "statement": "Have any of the following cardiovascular (CV) conditions within 2 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06037252",
    "statement": "acute myocardial infarction.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06037252",
    "statement": "cerebrovascular accident (stroke).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06037252",
    "statement": "unstable angina .",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06037252",
    "statement": "hospitalization due to congestive heart failure, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06037252",
    "statement": "coronary artery revascularization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06037252",
    "statement": "Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) syndrome Type 2.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06037252",
    "statement": "Have a history of chronic or acute pancreatitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05462756",
    "statement": "Have a diagnosis of T2D according to the world health organization (WHO) criteria, currently treated with basal insulin and at least 2 injections of prandial insulin per day.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05462756",
    "statement": "Are receiving ≥10 units of total basal insulin per day at screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05462756",
    "statement": "Are receiving ≤2 units/kilogram/day of total daily insulin at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05462756",
    "statement": "Have an HbA1c value of 7.0% to 10%, inclusive, as determined by the central laboratory at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05462756",
    "statement": "Have been treated with a stable regimen of one of the following basal insulins used according to local product label with or without noninsulin diabetes therapy for at least 90 days prior to screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05462756",
    "statement": "once daily U-100 or U-200 insulin degludec",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05462756",
    "statement": "once daily U-100 or U-300 insulin glargine",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05462756",
    "statement": "once or twice daily U-100 insulin detemir or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05462756",
    "statement": "once or twice daily human insulin Neutral Protamine Hagedorn",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05462756",
    "statement": "Have been treated with at least twice daily dosing of one of the following insulins used according to local product label for at least 90 days prior to screening. One dose of prandial insulin must occur at the evening meal.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05462756",
    "statement": "Insulin lispro-aabc",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05462756",
    "statement": "Insulin lispro (U-100 and U-200)s, IN], U-100 or U200)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05462756",
    "statement": "Insulin aspart (U-100)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05462756",
    "statement": "Insulin glulisine (U-100), or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05462756",
    "statement": "Regular insulin (U-100)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05462756",
    "statement": "Acceptable noninsulin diabetes therapies may include 0 to up to 3 of the following with a stable dose for at least 90 days prior to screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05462756",
    "statement": "dipeptidyl peptidase IV inhibitors",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05462756",
    "statement": "sodium-glucose co-transporter-2 inhibitors",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05462756",
    "statement": "biguanides (for example, metformin), or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05462756",
    "statement": "glucagon-like peptide-1 receptor agonists Note: All noninsulin diabetes therapies must be used in accordance with the corresponding local product label at the time of screening, and participants should be willing to continue stable dosing throughout the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05462756",
    "statement": "Have a body mass index ≤45 kilogram/square meter (kg/m²)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05462756",
    "statement": "Have a diagnosis of type 1 diabetes mellitus or latent autoimmune diabetes, or specific type of diabetes other than T2D (for example, monogenic diabetes, diseases of the exocrine pancreas, drug-induced or chemical-induced diabetes).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05462756",
    "statement": "Are currently receiving any of the following insulin therapies anytime in the past 90 days:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05462756",
    "statement": "insulin mixtures",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05462756",
    "statement": "insulin human, inhalation powder, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05462756",
    "statement": "continuous subcutaneous insulin infusion therapy, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05462756",
    "statement": "regular insulin U-500",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05462756",
    "statement": "Have a history of greater than 1 episode of ketoacidosis or hyperosmolar state/coma requiring hospitalization in the 6 months prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05462756",
    "statement": "Have had any episodes of severe hypoglycemia, defined as requiring assistance due to neurologically disabling hypoglycemia, within the 6 months prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05462756",
    "statement": "Have hypoglycemia unawareness in the opinion of the investigator",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05462756",
    "statement": "Anticipate making changes in personal CGM or flash glucose monitoring (FGM) use (for example, initiation, stopping, or changing device) during the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05462756",
    "statement": "Have had New York Heart Association Class IV heart failure or any of the following cardiovascular conditions in the past 3 months prior to screening: acute myocardial infarction, cerebrovascular accident (stroke), or coronary bypass surgery.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05462756",
    "statement": "Have undergone gastric bypass (bariatric) surgery, restrictive bariatric surgery, or sleeve gastrectomy within 1 year prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "The participant was given the diagnosis of grade I or II essential hypertension and was judged by the principal investigator or investigator that they can be appropriately treated with azilsartan 20 mg and telmisartan 40 mg.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Sitting systolic blood pressure of ≥ 130 mmHg and < 180 mmHg or sitting diastolic blood pressure of ≥ 80 mmHg and < 110 mmHg at the start of the treatment period (Week 0) Sitting blood pressure will be measured until 2 consecutive stable measurements are obtained (i.e., the difference between 2 measurements: diastolic blood pressure of <5 mmHg and systolic blood pressure of < 10 mmHg) after resting in a sitting position for at least 5 minutes. The average value of the last 2 measurements will be recorded (the first the decimal place is rounded off).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Type 2 diabetes mellitus",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "HbA1c (NGSP (National Glycohemoglobin Standardization Program) value) of < 8.4% during 3 months before informed consent, with a ≤ 0.3% change in HbA1c (peak minus nadir) during 3 months before informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "No change in diet/exercise therapy during the 3 months before the informed consent in a participant who has been on diet/exercise therapy and instructed to improve life style (e.g., diet and exercise)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Age ≥ 20 years at the time of consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Outpatients",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Capable of providing written consent before participation in this study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Grade III essential hypertension (i.e., sitting systolic blood pressure 180 mmHg or sitting diastolic blood pressure ≥ 110 mmHg), secondary hypertension, or malignant hypertension.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Grade II essential hypertension (i.e., sitting systolic blood pressure ≥ 160 mmHg or sitting diastolic blood pressure ≥ 100 mmHg) for which antihypertensive drug(s) are used",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Use of oral antihypertensive medication within 2 weeks before the start of the treatment period Participants who are on any antihypertensive agent at the time of informed consent can be enrolled in the study only after 2-week washout following informed consent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Use of RAS inhibitors or thiazolidines within 3 months before the start of the treatment period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Type 1 diabetes mellitus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Fasting blood glucose of < 180 mg/dL and HOMA-R of ≤ 1.6 at the start of the treatment period (Week 0)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Receiving or requiring any of the following at the time of informed consent:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Insulin, glucagon-like peptide-1 (GLP-1) receptor agonists, or other parenteral hypoglycemic agents",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Combination therapy with 3 or more oral hypoglycemic agents",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Change of antidiabetic medication (including dosage change) within 3 months before the start of the treatment period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Having diagnosed/treated any of the following cardiovascular diseases within 3 months before the start of the treatment period:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Cardiac disease/condition: myocardial infarction, coronary revascularization procedure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Cerebrovascular disease: cerebral infarction, cerebral haemorrhage, transient ischaemic attack",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Advanced hypertensive retinopathy (retinal bleeding or oozing, papilloedema)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Having diagnosed/treated for any of the following cardiovascular diseases more than 3 months before the start of the treatment period, and is now still in unstable condition.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Cardiac disease/condition: myocardial infarction, coronary revascularization procedure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Cerebrovascular disease: cerebral infarction, cerebral haemorrhage, transient ischaemic attack",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Past or current history of any of the following cardiovascular diseases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Cardiac valve stenosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Angina pectoris requiring medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Congestive cardiac failure requiring medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Arrhythmia requiring medication (e.g., paroxysmal atrial fibrillation, severe bradycardia, torsade de pointes, and ventricular fibrillation)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Arteriosclerosis obliterans with intermittent claudication or other symptoms",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Have severe ketosis, diabetic coma or precoma, severe infection, or serious trauma",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Clinically evident renal disorder (e.g., eGFR <30 mL/min/1.73 m2)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Markedly low bile secretion or severe hepatic disorder",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "History of hypersensitivity or allergy to azilsartan or telmisartan or to both.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Presence of hyperkalemia (potassium level ≥ 5.5 mEq/L on laboratory testing)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Currently participating in any other clinical study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Pregnant women, women with possible pregnancy, or breast-feeding women.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02079805",
    "statement": "Other participants who are inappropriate for participation in this study in the opinion of the principal investigator or investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00995345",
    "statement": "Patients meeting the following criteria at the screening visit (Visit 1) will be eligible to participate in the trial:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00995345",
    "statement": "Signed written informed consent;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00995345",
    "statement": "Males and females 18 to 75 years of age, inclusive;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00995345",
    "statement": "Females of childbearing potential must agree to use 2 adequate forms of barrier method contraception (eg, latex condom AND intrauterine device or a diaphragm) to avoid pregnancy while in the study;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00995345",
    "statement": "On a stable dose (Greater than or equal to 10 weeks at the same dose) of metformin monotherapy (Less than or equal to 1500 mg/day or maximum tolerated dose), have an HbA1c greater than or equal to 7.0% and less than or equal to 10.5%; or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00995345",
    "statement": "On metformin (less than or equal to 1500 mg/day) and 1 other antidiabetic agent (excluding TZD, insulin, or incretin therapies [DPP-4 inhibitors and GLP-1 analogues]) and have an HbA1c greater than or equal to 6.8% and less than or equal to 10.0%; or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00995345",
    "statement": "Not on antidiabetic therapy (for at least 3 months prior to Visit 1) or have not been on a stable dose of metformin monotherapy for 10 weeks and have an HbA1c greater than or equal to 8.0% and less than or equal to 11.0%.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00995345",
    "statement": "History of type 1 diabetes mellitus or history of diabetic ketoacidosis or persistent hypoglycemia;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00995345",
    "statement": "History or presence of alcoholism or drug abuse within the 2 years prior to dosing;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00995345",
    "statement": "Typical consumption of greater than or equal to 10 drinks of alcohol weekly;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00995345",
    "statement": "Presence of any of the following conditions:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00995345",
    "statement": "Significant renal impairment (glomerular filtration rate less than 60 mL/min);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00995345",
    "statement": "Diabetic gastroparesis;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00995345",
    "statement": "Active liver disease (other than asymptomatic nonalcoholic fatty liver disease), cirrhosis, or symptomatic gallbladder disease;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00995345",
    "statement": "Fasting plasma glucose/blood glucose greater than 240 mg/dL (13.3 mmol/L) at Visit 3 (Week -2) (1 laboratory retest permitted);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00995345",
    "statement": "Body mass index less than or equal to 20 kg/m2 and greater than or equal to 48 kg/m2;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00995345",
    "statement": "Systolic blood pressure <100 mmHg or >160 mmHg and diastolic blood pressure <50 mmHg or >100 mmHg at Visit 3 (Note: medication to control blood pressure is allowed and should be optimized and stabilized prior to Visit 3);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00995345",
    "statement": "Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2 X the upper limit of normal (ULN) (1 laboratory retest permitted);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00995345",
    "statement": "Creatine phosphokinase (CPK) greater than 2 X the ULN (if not explained by muscular trauma or exercise) (1 laboratory retest permitted);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00995345",
    "statement": "Serum creatinine >1.5 mg/dL for males (132.6 μmol/L) and 1.4 mg/dL for females (123.8 μmol/L);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00995345",
    "statement": "Fasting triglycerides (TG) >600 mg/dL (6.78 mmol/L) at Visit 3 (Week -2) (Note: diet/exercise and lipid-lowering medication to control elevated TG is allowed; medications should be optimized and stabilized prior to Visit 3);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00995345",
    "statement": "Treatment with pioglitazone or rosiglitazone within the previous 10 weeks (Visit 1); treatment with incretin therapy (DPP-4 inhibitors or GLP-1 analogues) within the previous 4 weeks (Visit 1);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00995345",
    "statement": "Treatment with any type of insulin (ie, injected or inhaled) within the previous 3 months;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00995345",
    "statement": "Must meet other laboratory and Medical History clinical criteria. Please contact recruitment center for referrals",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Men or women at least 40 years old with a diagnosis of type 2 diabetes",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Established cardiovascular disease, including at least 1 of the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Coronary artery disease (CAD) with any of the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Documented history of spontaneous myocardial infarction (MI)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "≥50% stenosis in 1 or more major coronary arteries, determined by invasive angiography",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "≥50% stenosis in 2 or more major coronary arteries, determined by computed tomography coronary angiography (CTCA)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "History of surgical or percutaneous coronary revascularization procedure",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Cerebrovascular disease - any of the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Documented history of ischemic stroke",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Carotid arterial disease with ≥50% stenosis, documented by carotid ultrasound, magnetic resonance imaging (MRI), or angiography",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Carotid stenting or surgical revascularization",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Peripheral arterial disease with either of the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Intermittent claudication and ankle-brachial index <0.9",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Prior nontraumatic amputation or peripheral vascular procedure (eg, stenting or surgical revascularization), due to peripheral arterial ischemia",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Note: Supporting medical documentation is required in all instances",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "HbA1c ≥7% (≥53 mmol/mol) and ≤10.5% (≤91.3 mmol/mol) based on central laboratory assessment at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Body mass index (BMI) ≥25 kg/m2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "At the time of signing the informed consent: Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical trials.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Male patients: Men, regardless of their fertility status, with nonpregnant women of childbearing potential (WOCBP) partners must agree to either remain abstinent (if this is their preferred and usual lifestyle) or use condoms, as well as 1 additional highly effective (less than 1% failure rate) method of contraception (such as combination oral contraceptives, implanted contraceptives, or intrauterine devices) or effective method of contraception (such as diaphragms with spermicide or cervical sponges) for the duration of the study and until their plasma concentrations are below the level that could result in a relevant potential exposure to a possible fetus, predicted to be 90 days following the last dose of study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Men and their partners may choose to use a double-barrier method of contraception. (Barrier protection methods without concomitant use of a spermicide are not an effective or acceptable method of contraception. Thus, each barrier method must include use of a spermicide. It should be noted, however, that the use of male and female condoms as a double barrier method is not considered acceptable due to the high failure rate when these barrier methods are combined).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Periodic abstinence (eg, calendar, ovulation, symptothermal, or postovulation methods), declaration of abstinence just for the duration of a trial, and withdrawal are not acceptable methods of contraception.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Men with pregnant partners should use condoms during intercourse for the duration of the study and until the end of the estimated relevant potential exposure in WOCBP (90 days). Men should refrain from sperm donation for the duration of the study and until their plasma concentrations are below the level that could result in a relevant potential exposure to a possible fetus, predicted to be 90 days following the last dose of study drug. Men who are in exclusively same-sex relationships (as their preferred and usual lifestyle) are not required to use contraception.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Female patients: Women of childbearing potential who are abstinent (if this is complete abstinence, as their preferred and usual lifestyle) or in a same-sex relationship (as part of their preferred and usual lifestyle) must agree to either remain abstinent or stay in a same-sex relationship without sexual relationships with males. Periodic abstinence (eg, calendar, ovulation, symptothermal, or postovulation methods), declaration of abstinence just for the duration of a trial, and withdrawal are not acceptable methods of contraception. Otherwise, WOCBP participating must agree to use 2 forms of effective contraception, where at least 1 form is highly effective (less than 1% failure rate), for the entirety of the study. Contraception must continue following completion of study drug administration for the entirety of the study and for 30 days thereafter.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "WOCBP participating must test negative for pregnancy prior to initiation of treatment as indicated by a negative serum pregnancy test at the screening visit followed by a negative urine pregnancy test within 24 hours prior to exposure.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Two forms of effective contraception, where at least 1 form is highly effective, (such as combination oral contraceptives, implanted contraceptives, or intrauterine devices) will be used. Effective contraception (such as male or female condoms with spermicide, diaphragms with spermicide, or cervical sponges) may be used as the second therapy. Barrier protection methods without concomitant use of a spermicide are not a reliable or acceptable method. Thus, each barrier method must include use of a spermicide (ie, condom with spermicide, diaphragm with spermicide, or female condom with spermicide). It should be noted that the use of male and female condoms as a double barrier method is not considered acceptable due to the high failure rate when these methods are combined.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Women not of childbearing potential may participate and include those who are:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation), congenital anomaly such as mullerian agenesis, or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "postmenopausal - defined as either: A woman at least 40 years of age with an intact uterus, not on hormone therapy, who has cessation of menses for at least 1 year without an alternative medical cause, AND a follicle-stimulating hormone >40 mIU/mL; or ii. A woman 55 or older not on hormone therapy, who has had at least 12 months of spontaneous amenorrhea; or A woman at least 55 years of age with a diagnosis of menopause prior to starting hormone replacement therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "In the investigator's opinion, are well motivated, capable, and willing to:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "learn how to self-inject treatment (tirzepatide or dulaglutide), as required for this protocol (visually impaired persons who are not able to perform the injections must have the assistance of a sighted individual trained to inject the study drug; persons with physical limitations who are not able to perform the injections must have the assistance of an individual trained to inject the study drug),",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "inject study drug weekly,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "have a sufficient understanding of 1 of the provided languages of the country such that they will be able to complete the patient questionnaires, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "make themselves available for the duration of the study, and who will comply with the required study visits.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Capable of giving signed informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Have type 1 diabetes mellitus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Have uncontrolled diabetes requiring immediate therapy (such as diabetic ketoacidosis) at screening or randomization, in the judgment of the physician",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Have had 1 or more events of severe hypoglycemia and/or 1 or more events of hypoglycemia unawareness within 6 months prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Are currently planning treatment for diabetic retinopathy and/or macular edema.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Have been hospitalized for congestive heart failure (CHF) within 2 months prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Have chronic New York Heart Association Functional Classification IV CHF",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Are currently planning a coronary, carotid, or peripheral artery revascularization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Had chronic or acute pancreatitis any time prior to screening, irrespective of etiology",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Have a known clinically significant gastric emptying abnormality such as severe gastroparesis or gastric outlet obstruction, or have undergone or currently planning any gastric bypass (bariatric) surgery or restrictive bariatric surgery",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Have acute or chronic hepatitis, signs or symptoms of any other liver disease, an alanine aminotransferase (ALT) level ≥3 times the upper limit of normal (ULN) for the reference range, as determined by the central laboratory (Note: Patients with nonalcoholic fatty liver disease are eligible to participate if their ALT level is <3 times the ULN for the reference range)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Have known chronic severe renal failure (defined as a known estimated glomerular filtration rate (eGFR) <15 mL/minute/1.73 m2) or are on chronic dialysis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Have evidence of a significant, uncontrolled endocrine abnormality (eg, thyrotoxicosis or adrenal crises)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Have a family or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma (MTC) or personal history of nonfamilial MTC",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Have a serum calcitonin level at screening of: (based on central laboratory results)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "≥20 ng/L at Visit 1, if eGFR ≥60 mL/min/1.73 m2, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "≥35 ng/L at Visit 1, if eGFR <60 mL/min/1.73 m2",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years. An exception for this criterion is basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Have a history of any other condition (such as known drug or alcohol abuse or psychiatric disorder) that, in the opinion of the investigator, may preclude the patient from following and completing the protocol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Have had a transplanted organ (corneal transplants [keratoplasty] allowed) or awaiting an organ transplant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Have any other condition (eg, hypersensitivity) that is a contraindication to any incretin or glucagon-like peptide-1 (GLP-1) receptor agonist (RA)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Have had an MI, percutaneous coronary revascularization procedure, ischemic stroke, carotid stenting or surgical revascularization, nontraumatic amputation, or peripheral vascular procedure (eg, stenting or surgical revascularization) less than 60 days prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Have had coronary artery bypass graft surgery less than 5 years prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Have had a blood transfusion or severe blood loss within 90 days prior to screening or have known hematological conditions that may interfere with HbA1c measurement",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Treatment with GLP-1 RA or pramlintide, in a period of 3 months prior to Visit 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Discontinuation of GLP-1 RA or pramlintide, due to intolerability any time prior to Visit 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Are currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Have participated within the last 30 days in a clinical trial involving an investigational product. If the previous investigational product has a long half-life, 3 months or 5 half-lives (whichever is longer) should have passed",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04255433",
    "statement": "Have previously completed or withdrawn from this study or randomized into any other study investigating tirzepatide",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770445",
    "statement": "Has Diabetes Mellitus type 2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770445",
    "statement": "A glycosylated hemoglobin level greater than or equal to 6.5% and less than 8.5%.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770445",
    "statement": "Treatment with the following insulins with or without Oral Antidiabetic Therapy since 3 months:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770445",
    "statement": "Long acting basal insulin analogs",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770445",
    "statement": "NPH insulin",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770445",
    "statement": "Combination insulin with 1-2 daily doses except intensified insulin therapies.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770445",
    "statement": "A body mass index greater than or equal to 25.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770445",
    "statement": "Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770445",
    "statement": "Has a history of type 1 diabetes mellitus.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770445",
    "statement": "Has uncontrolled hypertension (systolic blood pressure greater than 160mmHg and/or diastolic blood pressure greater than 95mmHg) or change of antihypertensive treatment within the last 2 weeks.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770445",
    "statement": "Has acute infections.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770445",
    "statement": "Has anamnestic history of hypersensitivity to the study drugs or to drugs with similar chemical structure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770445",
    "statement": "Has a history of severe or multiple allergies.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770445",
    "statement": "History of drug or alcohol abuse in the past 5 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770445",
    "statement": "A history of significant cardiovascular (New York Heart Association stage I - IV), respiratory, gastrointestinal, hepatic (Alanine Aminotransferase and/or Aspartate Aminotransferase greater than 2.5 times the upper limit of the normal reference range), renal (serum creatinine greater than 1.2 mg/dL in women and greater than 1.5 mg/dL in men, Glomerular Filtration Rate less than 60 ml/min as estimated by the Cockroft-Gault formula), neurological, psychiatric and/or hematological disease as judged by the investigator",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770445",
    "statement": "History of macular edema.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770445",
    "statement": "State after kidney transplantation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770445",
    "statement": "Serum potassium greater than 5.5 mmol/L.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770445",
    "statement": "History of primary hyperaldosteronism.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770445",
    "statement": "Acute myocardial infarction, open heart surgery or cerebral event (stroke/ Transitory Ischemic Attack) within the previous 12 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770445",
    "statement": "Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770445",
    "statement": "Pre-treatment with gemfibrozil within the last 12 weeks.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770445",
    "statement": "Pre-treatment with rifampicin within the last 12 weeks.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770445",
    "statement": "Treatment with thiazolidinediones within the past 3 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770445",
    "statement": "If statin therapy applicable: Change of medication within the last 4 weeks.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770445",
    "statement": "Has used non-steroidal anti-inflammatory agents including low dose ASA or Cox-2-inhibitors if therapy has been initiated within the last 4 weeks.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770445",
    "statement": "Treatment with any other investigational drug within 4 weeks before trial entry.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770445",
    "statement": "Any elective surgery during study participation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770445",
    "statement": "Have had more than one unexplained episode of severe hypoglycemia (defined as requiring assistance of another person due to disabling hypoglycemia) within 6 months prior to screening visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770445",
    "statement": "History of dehydration, precoma diabeticorum or shock or diabetic ketoacidosis within the past year prior to screening visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770445",
    "statement": "Acute or scheduled investigation with iodine containing radiopaque material.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770445",
    "statement": "Uncontrolled unstable angina pectoris.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00770445",
    "statement": "Medical history of acute and clinically relevant pericarditis, myocarditis, endocarditis, recent pulmonary embolism, hemodynamic relevant aortic stenosis, aortic aneurysm.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Age ≥22 and ≤70 years old",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Type 2 diabetes diagnosis meeting the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "HbA1c > 7.0% and ≤ 9.0% (53 mmol/mol - 75 mmol/mol), AND",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "On at least two anti-diabetic medications; one at the highest tolerated dose with no changes in medication dose in the 12 weeks prior to the first screening visit",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Waist circumference ≥102 cm (male) and ≥88cm (female)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Diagnosis of hypertension: SBP ≥140mmHg OR SBP ≥130mmHg on hypertension medication(s)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Documented status of stable lifestyle modifications",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Women of childbearing potential (WOCBP) must be using at least one acceptable method of contraception throughout the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "BMI >40 kg/m2",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Diagnosis of type 1 diabetes",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Use of insulin within 90 days of consent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Two or more self-reported or documented severe hypoglycemia events (severe hypoglycemia event defined as: hypoglycemia associated with severe cognitive impairment requiring external assistance for recovery) in the 180 days prior to Index Procedure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "One or more documented hyperglycemia episodes requiring hospitalization in the 180-days prior to Index Procedure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "During medication run in period, uncontrolled hyperglycemia noted by a fasting glucose value of >270mg/dL or >360mg/dL at any point that is then confirmed by a second measurement (not on the same day)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "A history of bariatric surgery, renal denervation, baroreflex activation therapy, or liver transplant, or these procedures are planned in the 365 days following Index Procedure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Any surgical procedure within 30 days prior to Index Procedure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "History of or current symptomatic gallstones (e.g., cholecystitis, bile duct dilatation) without a cholecystectomy being performed (Note: subjects who have had a cholecystectomy are not excluded)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Previous hepatobiliary surgery/intervention that in the opinion of the investigator could preclude the ability to perform denervation of the common hepatic artery",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Currently taking the following medications within 90 days prior to screening and/or there is a need or anticipated need for these medications during the study:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Systemic corticosteroids",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Anticonvulsants",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Centrally acting sympatholytics",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Use of anticoagulation therapy which cannot be discontinued from 7 days before to 14 days after the Index Procedure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Any other condition(s) that would compromise the safety of the Subject or compromise study quality as judged by the Investigator",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "eGFR <45 mL/min/1.73 m2",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "History or diagnosis of proliferative retinopathy or advanced autonomic neuropathy (e.g., orthostatic hypotension attributable to autonomic neuropathy, a diagnosis of gastroparesis, or a clinical history strongly suggestive of delayed gastric emptying)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Myocardial infarction, unstable angina within 1 year prior to consent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Widespread atherosclerosis with documented intravascular thrombosis or unstable plaques",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Documented history or concurrent signs of significant thyroid disease NOTE: If a subject is on chronic thyroid drug treatment, and has a serum TSH test result in normal range at Screening they may enter study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet count <100,000/microliter, or documented coagulopathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Significant alcohol consumption, defined as more than 2 drink units per day (equivalent to 20 g) in women and 3 drink units per day (equivalent to 30 g) in men, or inability to reliably quantify alcohol intake",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Active substance abuse, based on Investigator judgment, including inhaled or injected drugs, within 1 year prior to the initial screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Significant weight loss within the last 6 months (e.g., >10% total body weight loss)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Hepatic decompensation defined as the presence of any of the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Serum albumin less than 3.5 g/dL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "International normalized ratio (INR) greater than 1.4 (unless due to therapeutic anticoagulants)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Total bilirubin greater than 2 mg/dL with the exception of Gilbert syndrome",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "History of esophageal varices, ascites, or hepatic encephalopathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "ALT or AST greater than 200 U/L",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Diagnosis of liver cirrhosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Chronic liver or biliary disease of the following etiology:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "History or diagnosis of Hepatitis B",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "History or diagnosis of Hepatitis C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "History or diagnosis of current active autoimmune hepatitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "History or diagnosis of primary biliary cholangitis (PBC)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "History or diagnosis of primary sclerosing cholangitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "History or diagnosis of Wilson's disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "History or diagnosis of alpha-1-antitrypsin deficiency",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "History or diagnosis of hemochromatosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "History or evidence of drug-induced liver disease, as defined on the basis of typical exposure and history",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Known bile duct obstruction",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Suspected or proven liver cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "History of acute or chronic pancreatitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Subjects unable to undergo CT for any reason",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Currently enrolled in any other investigational trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "History of an acute neurologic event including epilepsy, seizures, stroke, and transient ischemic attack.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Iliac/femoral artery stenosis precluding insertion of the catheter",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Human immunodeficiency virus (HIV)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Subjects with a history of adverse reaction to heparin or heparin induced thrombocytopenia (HIT)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Subjects with conditions that can affect RBC turnover, those who have received a blood transfusion in the past 90 days, or expect to have an elective procedure during the course of the study that may require blood transfusion",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Not a candidate for surgery or general anesthesia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Unwilling to comply with study requirements, including medication run-in, SMBG, patient diary and follow-up visits",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Subjects with implantable pacemakers, implantable cardiac defibrillators or implantable neurostimulators Anatomic Exclusions from CT Angiogram",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Replaced or accessory LHA or RHA determined on CT angiogram.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Vessel tortuosity or variant vascular anatomy that could preclude the access or maneuvering of the device from the femoral artery to the target location",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "Evidence of CHA and/or portal vein intraluminal thrombus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "CHA vessel diameter <4.0mm or >7.0mm",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "CHA diameter stenosis >30%",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285554",
    "statement": "CHA vessel length <20mm",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527735",
    "statement": "Histologically or cytologically confirmed lung cancer (Stage IIIb/IV nonsmall-cell lung cancer or extensive stage small-cell lung cancer [SCLC])",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527735",
    "statement": "Measurable tumor lesion (as long as it is not located in a previously irradiated area) as defined by modified World Health Organization criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527735",
    "statement": "Eastern Cooperative Oncology Group performance status of ≤1 at study entry",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527735",
    "statement": "Accessible for treatment and follow-up",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527735",
    "statement": "Brain metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527735",
    "statement": "Malignant pleural effusion",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527735",
    "statement": "Autoimmune disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527735",
    "statement": "Motor neuropathy of autoimmune origin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527735",
    "statement": "SCLC-related paraneoplastic syndromes",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527735",
    "statement": "Any concurrent malignancy other than nonmelanoma skin cancer; carcinoma in situ of the cervix or breast; or prostate cancer treated with systemic therapy (participants with a previous malignancy but without evidence of disease for 5 years were allowed to enter the study)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527735",
    "statement": "Prior systemic therapy for lung cancer. Prior radiation therapy or locoregional surgeries performed later than at least 3 weeks prior to randomization date were allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527735",
    "statement": "Grade 2 peripheral neuropathy (motor or sensory)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527735",
    "statement": "Known HIV or hepatitis B or C infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527735",
    "statement": "Chronic use of immunosuppressants and/or systemic corticosteroids (used in the management of cancer or noncancer-related illnesses). However, use of corticosteroids was allowed if used as premedication for paclitaxel infusion or for treating immune-related adverse events or adrenal insufficiencies.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527735",
    "statement": "Inadequate hematologic function defined by an absolute neutrophil count <1,500/mm^3, a platelet count <100,000/mm^3, or hemoglobin level <9 g/dL.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527735",
    "statement": "Inadequate hepatic function defined by a total bilirubin level >2.0 times the upper limit of normal (ULN), or ≥2.5 times the ULN if liver metastases are present, aspartate aminotransferase and alanine aminotransferase levels ≥2.5 times the ULN or ≥5 times the ULN if liver metastases are present.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527735",
    "statement": "Inadequate renal function defined by a serum creatinine level ≥2.5 times the ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00527735",
    "statement": "Inadequate creatinine clearance defined as less than 50 mL/min.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Evidence of histologically or cytologically confirmed diagnosis of unresectable advanced and/or recurrent NSCLC that carries an ALK rearrangement, as detected by an appropriate test.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Disease progression or intolerance to 1 previous treatment with ALK TKI. Participants may have also had prior chemotherapy for their advanced and/or recurrent disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Participants with asymptomatic CNS metastases (including participants controlled with stable or decreasing steroid use within the last 2 weeks prior to study enrollment) will be eligible.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Age ≥18 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Adequate hematologic and renal function as defined as:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Absolute neutrophil count (ANC) ≥1,000/mm3;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Platelets ≥50,000/mm3;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Hemoglobin ≥8 g/dL;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Estimated creatinine clearance ≥30 mL/min as calculated using the method standard for the institution.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Adequate liver function, including:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Total serum bilirubin ≤1.5 × upper limit of normal (ULN);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN (≤5.0 × ULN in case of liver metastases).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Adequate pancreatic function, including:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Serum total amylase ≤1.5 × ULN.*",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Serum lipase <1.5 × ULN. *if total amylase >1.5 × ULN, but pancreatic amylase is within the ULN, the participant may be enrolled.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Acute effects of any prior therapy resolved to baseline severity or to CTCAE Grade <1 except for AEs that in the Investigator's judgment do not constitute a safety risk for the participant.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Systemic anticancer therapy completed within a minimum of 5 half-lives of study enrollment (unless clinically meaningful tumor flare per discretion of the Investigator, in which discussion with the Sponsor is warranted).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Evidence of a personally signed and dated informed consent document indicating that the participant (or a legally acceptable representative) has been informed of all pertinent aspects of the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Willingness and ability to comply with the study scheduled visits, treatment plans, laboratory tests and other procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Pregnancy test for females of childbearing potential negative at Screening or female participants who are not of childbearing potential. Male and female participants of childbearing potential and at risk for pregnancy must agree to use a highly effective method of contraception from the time of Screening, throughout the study and for 3 months after the last dose of assigned treatment, 6 months if female participants.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Radiation therapy (except palliative to relieve bone pain) within 2 weeks of study enrollment. Palliative radiation (<10 fractions) must have been completed at least 48 hours prior to study enrollment. Stereotactic or small field brain irradiation must have completed at least 2 weeks prior to study enrollment. Whole brain radiation must have completed at least 4 weeks prior to study enrollment. Prior irradiation to >25% of the bone marrow.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Major surgery within 4 weeks prior to enrollment. Minor surgical procedures (eg, port insertion) are not excluded, but sufficient time should have passed for adequate wound healing.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Known prior or suspected severe hypersensitivity to study drug or any component in its formulation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Active and clinically significant bacterial, fungal, or viral infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Clinically significant vascular (both arterial and venous) and non-vascular cardiac conditions (active or within 3 months prior to enrollment), which may include, but are not limited to:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Arterial disease such as cerebral vascular accident/stroke (including transient ischemic attack [TIA]), myocardial infarction, unstable angina;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Venous diseases such as cerebral venous thrombosis, symptomatic pulmonary embolism;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Non-vascular cardiac disease such as congestive heart failure (New York Heart Association Classification Class ≥II), second degree or third degree atrioventricular (AV) block (unless paced) or any AV block with PR interval >220 msec; or ongoing cardiac dysrhythmias of NCI CTCAE Grade ≥2, uncontrolled atrial fibrillation of any grade, bradycardia defined as <50 beats per minute (bpm) (unless participant is otherwise healthy such as long distance runners, etc.), machine read ECG with QT interval corrected for heart rate (QTc) >470 msec, or congenital long QT syndrome.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "History or known presence of interstitial fibrosis, interstitial lung disease (ILD), pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, obliterative bronchiolitis, and pulmonary fibrosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Other severe acute or chronic medical or psychiatric condition, including recent (within the past year) or active suicidal ideation or behavior, or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the participant inappropriate for enrollment in this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Evidence of active malignancy (other than current NSCLC, non-melanoma skin cancer, in situ cervical cancer, papillary thyroid cancer, ductal carcinoma in situ [DCIS] of the breast or localized and presumed cured prostate cancer) within the last 3 years prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Concurrent use of any of the following food or drugs (consult the Sponsor if in doubt whether a food or a drug falls into any of the categories described below) within 12 days prior to the first dose of lorlatinib:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Known strong cytochrome (CYP)3A inducers (eg, carbamazepine, enzalutamide, mitotane, rifampin, St. John's Wort).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Known strong CYP3A inhibitors (eg, grapefruit juice or grapefruit/grapefruit related citrus fruits [eg, Seville oranges, pomelos], boceprevir, cobicistat, clarithromycin, conivaptan, diltiazem, idelalisib, indinavir, itraconazole, ketoconazole, lopinavir, nelfinavir, paritaprevir, posaconazole, ritonavir alone and with elvitegravir or indinavir or lopinavir or paritaprevir or ombitasvir or dasabuvir or saquinavir or tipranavir, telaprevir and voriconazole). The topical use of these medications (if applicable), such as 2% ketoconazole cream, is allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Known CYP3A substrates with narrow therapeutic index, such as pimozide, quinidine, tacrolimus, cyclosporine, sirolimus, alfentanil, fentanyl (including transdermal patch) or ergot alkaloids (ergotamine, dihydroergotamine).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Known permeability glycoprotein (P-gp) substrates with a narrow therapeutic index (eg, digoxin).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Participants who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the Investigator, or participants who are Pfizer employees directly involved in the conduct of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Participation in other studies involving investigational drug(s) (Phases 1-4) during study participation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04541706",
    "statement": "Breastfeeding female participants.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00373425",
    "statement": "Primary tissue from patient's surgery must be epidermal growth factor receptor (EGFR)-positive by certain tests",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00373425",
    "statement": "Patients may have up to 4 cycles of chemotherapy after surgery",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00373425",
    "statement": "Complete removal of the tumor by surgery",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00373425",
    "statement": "Able to start drug under the following timelines:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00373425",
    "statement": "6 months from the day of surgery for patients who get chemotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00373425",
    "statement": "3 months from the day of surgery for those who do not get chemotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00373425",
    "statement": "Confirmed diagnosis of Stage IB-IIIA NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00373425",
    "statement": "Patients must be accessible for follow-up visits",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00373425",
    "statement": "History of prior radiotherapy for NSCLC either before or after surgery",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00373425",
    "statement": "History of heart disease or uncontrolled heart arrhythmias within the previous year",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00373425",
    "statement": "History of poorly controlled gastrointestinal (GI) disorders that could affect the absorption of study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00373425",
    "statement": "History of other cancer except certain skin or cervical cancers, patients who have had other cancer are eligible if they have remained disease free for at least 5 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00373425",
    "statement": "Patients who have received chemotherapy for NSCLC before surgery",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00373425",
    "statement": "Tumors with mixed histology of NSCLC and Small Cell Lung Cancer (SCLC). Patients with carcinoid tumors are not eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "The participant has Stage IV NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "Part A: NSCLC Stage IV (any type)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "Part B: NSCLC Stage IV (squamous and nonsquamous)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "Part C: NSCLC Stage IV in Japanese participants (squamous and nonsquamous)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "The participant must have progressed after 1 platinum-based chemotherapy regimen for Stage IV NSCLC. Prior therapy with VEGF/VEGFR targeting agents is permitted. Prior neoadjuvant/adjuvant therapy is permitted. Prior treatment with EGFR-TKI and ALK inhibitors is mandatory in participants with NSCLC whose tumor has EGFR-activating mutations or ALK translocations, respectively.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "Measurable disease at the time of study entry as defined by Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "The participant has evaluable tumor tissue available for biomarker analyses.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "The participant has adequate organ function.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0-1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "The participant is currently enrolled in a clinical trial involving an investigational product or non-approved use of a drug or device.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2 monoclonal antibody.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "Have a serious concomitant systemic disorder or significant cardiac disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "The participant has undergone major surgery or received anti-cancer monoclonal antibody therapy in the 30-days prior to study enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "The participant has undergone chest irradiation within 2 weeks prior to receiving study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "The participant has brain metastases that are symptomatic.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "The participant has a history of arterial thromboembolism event (ATE) or venous thromboembolism event (VTE) within 3 months prior to study enrollment. Participants with history of VTE beyond 3 months prior to study enrollment can be enrolled if they are appropriately treated with low molecular weight heparin.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "The participant has a known allergy / history of hypersensitivity reaction to any of the treatment components, including any ingredient used in the formulation of necitumumab or pembrolizumab, or any other contraindication to one of the administered treatments.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "The participant has a concurrent active malignancy. Previous history of malignancy is permitted, provided that the participant has been free of disease for ≥3 years, with the exception of adequately treated basal or squamous cell carcinoma of the skin, preinvasive carcinoma of the cervix, or any cancers that in the judgment of the investigator and sponsor may not affect the interpretation of results (for example, prostate, bladder).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "History of interstitial lung disease, pneumonitis, autoimmune disease or syndrome that requires steroids or immunosuppressive agents.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "The participant has active infection requiring systemic therapy, including active tuberculosis or known history of infection with the human immunodeficiency virus (HIV 1/2 antibodies), or hepatitis B (e.g., HBsAg reactive) and/or C virus (e.g., HCV RNA [qualitative] is detected).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "The participant has an active autoimmune disease or a documented history of autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02451930",
    "statement": "The participant has received a live vaccine within 30 days prior to the first dose of trial treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Note: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Part A: histologically or cytologically confirmed advanced malignant solid tumor that is refractory to or intolerant of standard therapy or for which no standard therapy is available",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Part B: Pancreatic Adenocarcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Presence of histologically confirmed inoperable locally advanced or metastatic pancreatic adenocarcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Part B: NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Stage IIIB with malignant pleural effusion/pleural seeding or stage IV histologically confirmed NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Absence of known epidermal growth factor receptor (EGFR) mutation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Absence of known translocation or inversion events involving the ALK gene locus (resulting in EML4-ALK fusion)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Part B: Esophagogastric Adenocarcinoma:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Histologically confirmed inoperable advanced gastric adenocarcinoma (including adenocarcinoma of the gastrooesophageal junction) or relapsed gastric adenocarcinoma",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Human epidermal growth factor receptor 2 (HER2)-negative tumor (primary tumor or metastatic lesion)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Part B: First-Line Colorectal Cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Histologically confirmed inoperable advanced adenocarcinoma of the colon or rectum",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Radiographically measureable disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "No prior cytotoxic chemotherapy to treat their metastatic disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Part B: Second-Line Colorectal Cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Histologically confirmed inoperable advanced adenocarcinoma of the colon or rectum",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Radiographically measureable disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Received first-line combination therapy containing oxaliplatin and fluoropyrimidine with or without bevacizumab for metastatic disease with documented evidence of disease progression during or after treatment completion",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Part B: Breast Cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Histologically or cytologically confirmed metastatic breast cancer",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Radiographically measureable disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Previous hormonal therapy for metastatic breast cancer or cytotoxic adjuvant chemotherapy is allowed",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Treatment with weekly single-agent paclitaxel is appropriate in the opinion of the treating physician",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "HER-2 negative tumor (primary tumor or metastatic lesion)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Pregnant or lactating",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Individuals with known central nervous system (CNS) metastases, unless metastases are treated and stable and the individual does not require systemic steroids",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Myocardial infarction, symptomatic congestive heart failure, unstable angina, or serious uncontrolled cardiac arrhythmia within the last 6 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01803282",
    "statement": "Anti-tumor therapy within 28 days of study drug dosing; concurrent use of hormone therapy for breast or prostate cancer is permitted",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03023423",
    "statement": "Inclusion Criteria for Crossover:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03023423",
    "statement": "Exclusion Criteria for Crossover:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03023423",
    "statement": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03023423",
    "statement": "Have histologically or cytologically confirmed advanced or metastatic non-small cell lung cancer (NSCLC) (Stage IIIb or greater)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03023423",
    "statement": "Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03023423",
    "statement": "Tumor cell programmed death-ligand 1 (PD-L1) score of tumor cells (TC)1-3 and immune cell PD-L1 score of tumor-infiltrating immune cells (IC)0-3 as determined by an immunohistochemistry (IHC) assay performed by the central laboratory on tissue obtained after the last line of therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03023423",
    "statement": "A woman of childbearing potential must have a negative highly sensitive serum (beta-human chorionic gonadotropin [beta- hCG]) at Screening within 14 days prior to study drug administration",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03023423",
    "statement": "Participants must have been randomized to Arm A of the study and had radiographic disease progression according to RECIST 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03023423",
    "statement": "Participants must have a mandatory biopsy at the time of disease progression according to RECIST 1.1 prior to crossing over. If not clinically feasible, discussion with Sponsor is required",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03023423",
    "statement": "The first dose of atezolizumab in the crossover arm should be within 42 days of last dose but no less than 21 days from the last dose prior to crossing over",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03023423",
    "statement": "Received any of the following prescribed medications or therapies in the past:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03023423",
    "statement": "Anti-cluster of differentiation(CD)38 therapy, including daratumumab",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03023423",
    "statement": "CD137 agonists, immune checkpoint inhibitors including but not limited to CTLA-4, anti-PD-1, and anti-PD-L1 therapies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03023423",
    "statement": "Known to be seropositive for human immunodeficiency virus (HIV)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03023423",
    "statement": "Prior allogeneic bone marrow transplantation or solid organ transplant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03023423",
    "statement": "History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03023423",
    "statement": "Active hepatitis B, defined by a positive test for hepatitis B surface antigen [HBsAg] or prior history of hepatitis B, defined by presence of antibodies to hepatitis B core antigen [anti-HBc], regardless of hepatitis B surface antibody [anti-HBs] status; active hepatitis C or prior history of hepatitis C (anti-HCV positive), except in the setting of a sustained virologic response (SVR), defined as aviremia 12 weeks after completion of antiviral therapy. If hepatitis C virus (HCV) antibodies are detected, an HCV RNA test for viral load by polymerase chain reaction (PCR) should be performed at least 12 weeks after completion of antiviral therapy to rule out active infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03023423",
    "statement": "Received any subsequent anti-cancer therapies from the time between the last dose of atezolizumab prior to the first administration of study drug after crossing over",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03023423",
    "statement": "Whole brain radiation within 28 days or other radiotherapy within 14 days prior to first administration of study drug after crossing over",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "Histologically or cytologically confirmed stage IIIB or IV non-small cell lung cancer (NSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "Male or non-pregnant and non-lactating female, and equal or greater than age 18",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "If a female patient is of child-bearing potential, as evidence by regular menstrual periods, she must have a negative serum pregnancy test (beta human chorionic gonadotropin [βhCG]) documented within 72 hours of the first administration of study drug",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "If sexually active, the patient must agree to utilize contraception considered adequate and appropriate by the investigator",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "No other current active malignancy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "Radiographically-documented measurable disease (defined by the presence of at least 1 radiographically documented measurable lesion)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "Patients must have received no prior chemotherapy for the treatment of metastatic disease. Adjuvant chemotherapy permitted providing cytotoxic chemotherapy was completed 12 months prior to starting the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "Patient has the following blood counts at baseline:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "Absolute neutrophil count (ANC) greater than or equal to 1.5x10^9/L",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "Platelets greater than or equal to 100x10^9/L",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "Hemoglobin (Hgb) greater than or equal to 9 g/dL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "Patient has the following blood chemistry levels at baseline:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "Aspartate aminotransferase (SGOT), alanine aminotransferase (SGPT) less than or equal to 2.5 x upper limit of normal range (ULN) or less than or equal to 5.0 x ULN if liver metastases;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "Total bilirubin less than or equal to ULN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "Creatinine less than or equal to 1.5 mg/dL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "Expected survival of greater than 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "Patient or his/her legally authorized representative or guardian has been informed about the nature of the study, and has agreed to participate in the study, and signed the Informed Consent form prior to participation in any study-related activities",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "Evidence of active brain metastases, including leptomeningeal involvement. Prior evidence of brain metastasis permitted only if treated and stable and off therapy for greater than or equal to 1 month",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "The only evidence of disease is non-measurable",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "Patient has pre-existing peripheral neuropathy of Grade 2, 3, or 4 (per Common Terminology Criteria for Adverse Events [CTCAE] Version 3).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "Patient received radiotherapy in the last 4 weeks, except if to a non-target lesion only. Prior radiation to a target lesion is permitted only if there has been clear progression of the lesion since radiation was completed",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "Patient has a clinically significant concurrent illness",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "Patient has received treatment with any investigational drug within the previous 4 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "Patient has a history of allergy or hypersensitivity to any of the study drugs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "Patient has serious medical risk factors involving any of the major organ systems such that the investigator considers it unsafe for the patient to receive an experimental research drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00540514",
    "statement": "Patient is enrolled in any other clinical protocol or investigational trial that involves administration of experimental therapy and/or therapeutic devices.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "Signed written informed consent before any trial related procedure",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "Male or female participants aged greater than or equal to (>=) 18 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "Availability of a formalin-fixed, paraffin-embedded block containing tumor tissue or 7 unstained tumor slides suitable for PD-L1 expression assessment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "Tumor determined to be evaluable for PD-L1 expression per the evaluation of a central laboratory",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "Participants with histologically confirmed Stage IIIb/IV or recurrent NSCLC who have experienced disease progression",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "Participants must have progressed after an acceptable therapy defined as follows:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "Participants must have progressed during or after a minimum of 2 cycles of 1 course of a platinum based combination therapy administered for the treatment of a metastatic disease. A history of continuation (use of a non platinum agent from initial combination) or switch (use of a different agent) maintenance therapy is permitted provided there was no progression after the initial combination. A switch of agents during treatment for the management of toxicities is also permitted provided there was no progression after the initial combination OR",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "Participants must have progressed within 6 months of completion of a platinum-based adjuvant, neoadjuvant, or definitive chemotherapy, or concomitant chemoradiation regimen for locally advanced disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "Participants with non-squamous cell NSCLC of unknown epidermal growth factor receptor (EGFR) mutation status will require testing (local laboratory, or central laboratory if local testing is not available). Participants with a tumor that harbors an activating EGFR mutation will not be eligible",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1 at trial entry",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "Estimated life expectancy of more than 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "Adequate hematological function defined by White Blood Cell (WBC) count >= 2.5 × 10^9/L with absolute neutrophil count (ANC) >= 1.5 × 10^9/L, lymphocyte count >=0.5 × 10^9/L, platelet count >= 100 × 10^9/L, and hemoglobin >= 9 gram per deciliter (g/dL) (may have been transfused)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "Adequate hepatic function defined by a total bilirubin level less than or equal to (<=) 1.5 × the upper limit of normal (ULN) range and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels <= 2.5 × ULN for all participants",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "Adequate renal function defined by an estimated creatinine clearance > 30 milliliter per minute (mL/min) according to the Cockcroft-Gault formula (or local institutional standard method).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "In the United States only, participants with a squamous cell histology will be excluded",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "Systemic anticancer therapy administered after disease progression during or following a platinum based combination",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "Participants with non-squamous cell NSCLC whose disease harbors EGFR mutation(s) and/or anaplastic lymphoma kinase (ALK) rearrangement will not be eligible for this trial. Participants of unknown ALK and/or EGFR mutation status will require testing at screening (local laboratory, or central laboratory if local testing is not available)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "Prior therapy with any antibody/drug targeting T cell coregulatory proteins (immune checkpoints) such as PD-1, PD L1, or cytotoxic T lymphocyte antigen-4 (CTLA-4).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "Concurrent anticancer treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "Major surgery for any reason, except diagnostic biopsy, within 4 weeks of randomization and/or if the participant has not fully recovered from the surgery within 4 weeks of randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "Participants receiving immunosuppressive agents (such as steroids) for any reason should be tapered off these drugs before initiation of the trial treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "All participants with brain metastases, except those meeting the following criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "Brain metastases have been treated locally, and",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "No ongoing neurological symptoms that are related to the brain localization of the disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "Participants with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "Participants requiring hormone replacement with corticosteroids are eligible if the steroids are administered only for the purpose of hormonal replacement and at doses less than or equal to (<=)10 milligram (mg) or equivalent prednisone per day",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "Administration of steroids through a route known to result in a minimal systemic exposure are acceptable",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02395172",
    "statement": "Previous or ongoing administration of systemic steroids for the management of an acute allergic phenomenon is acceptable as long as it is anticipated that the administration of steroids will be completed in 14 days, or that the daily dose after 14 days will be <=10 mg per day of equivalent prednisone",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Signed written informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Female or male ≥18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Documented histologic or cytologic diagnosis of American Joint Committee on Cancer (AJCC) Stage III or IV NSCLC. Stage III patient must have unresectable disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Body mass index < 20 kg/m2 with involuntary weight loss of >2% within 6 months prior to screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Ongoing problems with appetite/eating associated with the underlying cancer, as determined by having score of ≤ 17 points on the 5-item Anorexia Symptom Scale and ≤ 37 points on the 12-item FAACT A/CS",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Patient receiving or not receiving systemic anti-cancer treatment at the time of screening are eligible to participate. Systemic anti-cancer treatment includes first, second, third treatment line with chemotherapy/radiation therapy, immunotherapy or targeted therapy. Patient not receiving systemic anti-cancer treatment is eligible if:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Not planning to receive anti-cancer treatment and/or at least 14 days must be elapsed from the completion of prior treatment at the day of screening, in case underwent previous cycle OR",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Planning to receive anti-cancer treatment within 14 days from randomization and/or at least 14 days must be elapsed from the completion of prior treatment at the day of screening, in case underwent previous cycle OR",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Patient on palliative care treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "ECOG performance status 0,1 or 2 at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "AST (SGOT) and ALT (SGPT) ≤ 3 x ULN or if hepatic metastases are present ≤ 5 x ULN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Adequate renal function, defined as creatinine ≤2 ULN, or calculated creatinine clearance >30 ml/minute",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Female patient shall be: a) of non-childbearing potential or b) of childbearing potential using reliable contraceptive measures and having a negative urine pregnancy test within 24 hours prior to first dose of investigational product. Notes:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Female patient of non-childbearing potential are defined as being in post-menopausal state since at least 1 year; or having documented surgical sterilization or hysterectomy at least 3 months before study participation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Reliable contraceptive measures include implants, injectables, combined oral contraceptives, intrauterine devices, vasectomized partner or complete (long term) sexual abstinence.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "The patient must be willing and able to comply with the protocol tests and procedures All inclusion criteria will be checked at screening visit (Visit 1).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Patient with other forms of lung cancer (e.g., small cell, neuroendocrine tumors)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Woman who is pregnant or breast-feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Reversible causes of reduced food intake, as determined by the Investigator. These causes may include but are not limited to:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "NCI CTCAE Grade 3 or 4 oral mucositis,",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "NCI CTCAE Grade 3 or 4 GI disorders [nausea, vomiting, diarrhea, and constipation],",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "mechanical obstructions making patient unable to eat, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "severe depression",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Patient undergoing major surgery (central venous access placement and tumor biopsies are not considered major surgery) within 4 weeks prior to randomization. Patient must be well recovered from acute effects of surgery prior to screening. Patient should not have plans to undergo major surgical procedures during the treatment period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Patient currently taking androgenic compounds (including but not limited to testosterone, testosterone-like agents, oxandrolone, megestrol acetate, corticosteroids, olanzapine, mirtazapine (however, long-term use of mirtazapine for depression for at least four weeks prior to screening is allowed), dronabinol or marijuana (cannabis) or any other prescription medication or off-label products intended to increase appetite or treat unintentional weight loss",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Patient with pleural effusion requiring thoracentesis, pericardial effusion requiring drainage, edema or evidence of ascites",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Patient with uncontrolled or significant cardiovascular disease, including:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "History of myocardial infarction within the past 3 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "A-V block of second or third degree (may be eligible if currently have a pacemaker)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Unstable angina",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Congestive heart failure within the past 3 months, if defined as NYHA class III-IV",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, Wolff-Parkinson-White (WPW) syndrome, or torsade de pointes)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Uncontrolled hypertension (blood pressure >150 mm Hg systolic and >95 mm Hg diastolic)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Heart rate < 50 beats per minute on pre-entry electrocardiogram and patient is symptomatic",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Patient on drugs that may prolong the PR or QRS interval durations, such as any of the antiarrhythmic medications Class I (Fast sodium (Na) channel blockers)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Patient unable to readily swallow oral tablets",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Patient with severe gastrointestinal disease (including esophagitis, gastritis, malabsorption)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Patient with history of gastrectomy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Patient with uncontrolled diabetes mellitus or unmonitored diabetes mellitus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Patient with cachexia caused by other reasons, as determined by the investigator such as:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Severe COPD requiring use of home O2,",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "New York Heart Association (NYHA) class III-IV heart failure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "AIDS",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Uncontrolled thyroid disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Patient receiving strong CYP3A4 inhibitors within 14 days of randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Patient currently receiving tube feedings or parenteral nutrition (either total or partial).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Current excessive alcohol or illicit drug use",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Any condition, including the presence of laboratory abnormalities, which in the Investigator's opinion, places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Enrollment in a previous study with anamorelin HCl",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743064",
    "statement": "Patient actively receiving a concurrent investigational agent, or having received an investigational agent within 28 days of Day 1 All exclusion criteria will be checked at screening visit (Visit 1).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04416633",
    "statement": "Provision of signed, written and dated informed consent prior to any study specific Procedures",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04416633",
    "statement": "Male or female aged 18 years or older",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04416633",
    "statement": "As per local prescribing information and in view of positive benefit-risk assessment, patient prescribed Durvalumab treatment as per independent clinical judgment of treating physician for either",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04416633",
    "statement": "Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or the follow-up period of an interventional study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04416633",
    "statement": "Current or prior use of immunosuppressive medication within 14 days before the first dose of study drug, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid. Systemic steroid administration required to manage toxicities arising from radiation therapy delivered as part of the chemoradiation therapy for locally advanced NSCLC is allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04416633",
    "statement": "Prior exposure to any anti-PD-1 or anti-PD-L1 antibody including durvalumab.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04416633",
    "statement": "For NSCLC cohort only:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04416633",
    "statement": "Mixed small cell and non-small cell lung cancer histology",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04416633",
    "statement": "Any unresolved toxicity CTCAE >Grade 2 from the prior chemoradiation therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04416633",
    "statement": "Patients with ≥Grade 2 pneumonitis from prior chemoradiation therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04416633",
    "statement": "Active or prior documented autoimmune disease within the past 2 years, inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis), primary immunodeficiency, organ transplant that requires therapeutic immunosuppression, hypersensitivity to study drug or any excipient, leptomeningeal carcinomatosis, tuberculosis. NOTE: Patients with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04416633",
    "statement": "Female patients who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04416633",
    "statement": "Any condition that, in the opinion of the investigator, would interfere with evaluation of the study drug or interpretation of patient safety or study results.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Subjects with any of the following characteristics/conditions will not be included in the study:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Evidence of histologically or cytologically confirmed diagnosis of locally advanced or metastatic ALK positive NSCLC where ALK status has been previously established by the Ventana ALK (D5F3) CDx Assay (Roche Diagnostics), the Vysis ALK Break Apart FISH Probe Kit (Abbott Molecular), or the EML4 ALK Fusion Gene Detection Kit (AmoyDx).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Subject should have:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "(in Cohort 1) Disease progression after crizotinib as the only ALK inhibitor;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "(in Cohort 2) Disease progression after one ALK inhibitor other than crizotinib, with or without prior crizotinib.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Prior treatment with an ALK inhibitor must have completed 5 half lives prior to study entry.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "All Subjects must have at least 1 measurable extracranial target lesion according to RECIST v1.1 that has not been previously irradiated. CNS metastases are allowed if:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Asymptomatic: either not currently requiring corticosteroid treatment, or on a stable or decreasing dose of 10 mg QD prednisone or equivalent; or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Previously diagnosed and treatment has been completed with full recovery from the acute effects of radiation therapy or surgery prior to enrollment, and if corticosteroid treatment for these metastases has been withdrawn for at least 4 weeks with neurological stability.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Eastern Cooperative Oncology Group performance status (ECOG PS) 0, 1, or 2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Age 18 years (or 20 years as required by local regulation).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Adequate bone marrow functions:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Absolute Neutrophil Count (ANC) 1,500/mm3 or 1.5 x 109/L;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Platelets 100,000/mm3 or 100 x 109/L;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Hemoglobin 9 g/dL.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Adequate pancreatic function:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Serum total amylase 1.5 x upper limit of normal (ULN);*",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Serum lipase 1.5 x ULN. *if total amylase >1.5 x ULN, but pancreatic amylase is within the ULN, then subject may be enrolled.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Adequate renal function: a. Serum creatinine 1.5 x ULN or estimated creatinine clearance 60 mL/min as calculated using the method standard for the institution.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Adequate liver function:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Total serum bilirubin 1.5 x ULN;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) 2.5 x ULN (5.0 x ULN in case of liver metastases).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Acute effects of prior radiotherapy and chemotherapy resolved to baseline severity or to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 except for AEs that in the investigator's judgment do not constitute a safety risk for the subject.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Serum or urine pregnancy test (for females of childbearing potential) negative at screening. Female subjects of non childbearing potential must meet at least 1 of the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause (which may be confirmed with a serum follicle stimulating hormone (FSH) level confirming the postmenopausal state if appropriate;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Have undergone a documented hysterectomy and/or bilateral oophorectomy;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Have medically confirmed ovarian failure. All other female subjects (including female subjects with tubal ligations) are considered to be of childbearing potential.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Willing and able to comply with the study scheduled visits, treatment plans, laboratory tests, and other procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "More than 1 prior chemotherapy regimen prior to enrollment in advanced/metastatic setting. If disease recurred/relapsed within the adjuvant chemotherapy treatment or <=6 months after the completion of the adjuvant chemotherapy, then the adjuvant chemotherapy is considered as the first line systemic chemotherapy to the disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Systemic anti cancer therapy completed within a minimum of 5 half lives of study enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Prior therapy with an antibody or drug specifically targeting T cell co stimulation or immune checkpoint pathways, including, but not limited to, anti programmed cell death protein 1 (anti PD 1), anti programmed cell death protein ligand 1 (anti PD L1), anti PD L2, anti cluster of differentiation 137 (anti CD137), or anti cytotoxic T lymphocyte associated antigen 4 (anti CTLA 4) antibody.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Known epidermal growth factor receptor (EGFR) activating mutations; known prior therapy with EGFR TKI(s) (the prior treatment with brigatinib is allowed as an ALK TKI).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Major surgery within 4 weeks prior to enrollment. Minor surgical procedures (eg, port insertion) are not excluded, but sufficient time should have passed for adequate wound healing.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Radiation therapy within 2 weeks prior to enrollment. Palliative radiation must have been completed at least 48 hours prior to enrollment. Stereotactic or partial brain irradiation must have completed at least 2 weeks prior to enrollment. Whole brain irradiation must have completed at least 4 weeks prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Spinal cord compression unless the subject has good pain control attained through therapy, and there is complete recovery of neurological function for the 4 weeks prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Gastrointestinal abnormalities, including inability to take oral medication; requirement for intravenous alimentation; prior surgical procedures affecting absorption including total gastric resection or lap band; active inflammatory gastrointestinal disease, chronic diarrhea, symptomatic diverticular disease; treatment for active peptic ulcer disease in the past 6 months; malabsorption syndromes.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Known prior or suspected severe hypersensitivity to lorlatinib or any component in the formulation; known prior therapy with lorlatinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Active and clinically significant bacterial, fungal, or viral infection including hepatitis B virus (HBV), hepatitis C virus (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Clinically significant cardiovascular disease (both arterial and venous) and non vascular cardiac conditions, (active or within 3 months prior to enrollment, which may include, but not are limited to:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Arterial disease such as cerebral vascular accident/stroke (including transient ischemic attack -TIA), myocardial infarction, unstable angina;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Venous diseases such as cerebral venous thrombosis, symptomatic pulmonary embolism;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Nonvascular cardiac disease such as congestive heart failure (New York Heart Association Classification Class ≥ II), second degree or third degree atrioventricular block (unless paced) or any AV block with PR interval >220 msec; or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Ongoing cardiac dysrhythmias of CTCAE Grade ≥2, uncontrolled atrial fibrillation of any grade, bradycardia defined as <50 bpm (unless subject is otherwise healthy such as long distance runners, etc.), machine read electrocardiogram (ECG) with QTc >470 msec, or congenital long QT syndrome.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Subject with predisposing characteristics for acute pancreatitis according to investigator judgment, including but not limited to uncontrolled hyperglycemia, current gallstone disease, in the last month prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "History of extensive, disseminated, bilateral or presence of Grade 3 or 4 interstitial fibrosis or interstitial lung disease including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis and pulmonary fibrosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Evidence of active malignancy (other than NSCLC, non melanoma skin cancer, or localized and presumed cured prostate cancer or any in situ cancer which does not currently require treatment) within the last 3 years prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Concurrent use of any of the following food or drugs (consult the sponsor if in doubt whether a food or a drug falls into any of the above categories) within 12 days prior to the first dose of administration of lorlatinib:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Known strong CYP3A inhibitors (eg, strong CYP3A inhibitors: grapefruit juice or grapefruit/grapefruit related citrus fruits [eg, Seville oranges, pomelos], boceprevir, cobicistat, conivaptan, itraconazole, ketoconazole, posaconazole, ritonavir alone and with danoprevir or elvitegravir or indinavir or lopinavir or paritaprevir or ombitasvir or dasabuvir or saquinavir or tipranavir, telaprevir, troleandomycin, and voriconazole). The topical use of these medications (if applicable), such as 2% ketoconazole cream, is allowed;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Known CYP3A substrates with narrow therapeutic index, such as astemizole*, terfenadine*, cisapride*, pimozide, quinidine, tacrolimus, cyclosporine, sirolimus, alfentanil, fentanyl (including transdermal patch) or ergot alkaloids (ergotamine, dihydroergotamine) (*withdrawn from US market);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Known strong CYP3A inducers (eg, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John's Wort);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Known P glycoprotein (P gp) substrates with a narrow therapeutic index (eg, digoxin).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Other severe acute or chronic medical or psychiatric condition, including recent (within the past year) or active suicidal ideation or behavior, or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator and/or the sponsor, would make the subject inappropriate for entry into this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Subject who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are Pfizer employees, including their family members, directly involved in the conduct of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Participation in other studies involving investigational drug(s) within 2 weeks prior to study entry and/or during study participation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Pregnant female participants; breastfeeding female participants; fertile male participants and female participants of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 97 days if male or 35 days if female, after the last dose of investigational product.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Vaccination and re-vaccination exclusion criteria",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "1. Acute disease at the time of vaccination.\n(acute disease is defined as the presence of a moderate or severe illness with or without fever).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "The following adverse events associated with vaccine immunisation constitute absolute contraindications to further vaccine administration.\nIf any of these events occur during the study, the participant must be withdrawn and followed until the resolution of the event, as with any adverse event:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Exclusion criteria on the day of CHMI",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "The following constitute absolute contraindications to CHMI:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Healthy Thai adults aged 20 to 55 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Minimum educational level of high school or equivalent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Red blood cells positive for the Duffy antigen/chemokine receptor (DARC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Women only: Must practice continuous effective contraception for the duration of the study period until 3 months post-challenge.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Agreement to refrain from blood donation during the study and for 1 year after the initiation of antimalarial treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Willing to be admitted to the Hospital for Tropical Diseases for clinical monitoring as required by the protocol until antimalarial treatment is completed and their symptoms are settling, willing to take a curative antimalarial treatment following CHMI, and willing to reside in Bangkok and its vicinity for 2 months after malarial treatment initiation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Able to read and write in Thai.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Provide written informed consent to participate in the trial",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Answer all questions on the informed consent quiz correctly",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Completed COVID-19 vaccination with 2 doses of any WHO-approved vaccine",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Positive malaria qPCR OR malaria film prior to vaccination and challenge",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Presence of any medical condition (either physical or psychological) that, in the judgment of the investigator, would place the participant at undue risk (including the history of clinically significant contact dermatitis) or interfere with the results of the study (e.g., underlying cardiac, renal, hepatic or neurological disease; severe malnutrition; congenital defects or febrile condition)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Presence of chronic disease or chronic use of medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Prior receipt of other investigational vaccine which is likely to impact the interpretation of the trial data as assessed by the Investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection, asplenia, history of splenectomy, recurrent severe infections, and chronic infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Immunosuppressant medication within the past 6 months preceding enrolment (D0) or plan to use during the study (inhaled and topical steroids are allowed)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "History of allergic disease or reactions likely to be exacerbated by malaria infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Female participant who is pregnant as evidenced by positive beta-human chorionic gonadotropin (β-HCG) test, or who is lactating or planning pregnancy during the course of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Contraindications to the use of antimalarial treatment (e.g., chloroquine, atovaquone/proguanil, or dihydroartemisinin/piperaquine)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Use of medications known to have potentially clinically significant interaction with the antimalarial drugs that will be used in this study (chloroquine, atovaquone/proguanil, or dihydroartemisinin/piperaquine)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "History of cardiac arrhythmia, including clinically relevant bradycardia or Known existing positive family history in both 1st AND 2nd-degree relatives < 50 years old for cardiac disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Family history of congenital QT prolongation or sudden death",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Any clinical condition, including using medications known to prolong the QT interval or screening electrocardiogram (ECG), demonstrates a QTc interval ≥ 450 ms.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Suspected or known history of alcohol abuse or history of drug abuse.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Concurrently participating in another clinical study, at any time during the study period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Positive hepatitis B surface antigen or seropositive for hepatitis C virus, or HIV",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Finding on safety laboratory values as defined below:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Abnormal ALT [>upper normal range]",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Abnormal serum creatinine [>upper normal range]",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Clinically significant abnormalities in corrected calcium and magnesium blood levels",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Haemoglobin < 11 g/dL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Blood group Rhesus negative",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Blood incompatibility to the inoculum",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "History of allergic disease or reactions likely to be exacerbated by any component of the vaccine",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Any history of anaphylaxis in reaction to vaccinations",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Anaphylactic reaction following administration of the vaccine",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Pregnancy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Acute disease, defined as a moderate or severe illness with or without fever",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Pregnancy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05380388",
    "statement": "Use of systemic antibiotics with known antimalarial activity in the 30 days before challenge (e.g., trimethoprim-sulfamethoxazole, doxycycline, tetracycline, clindamycin, erythromycin, fluoroquinolones, and azithromycin)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "All inclusion criteria were to be checked at screening visit (Visit 1).\nInclusion criterion #10 was to be re-checked and verified at Day 1 (Visit 2).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "All exclusion criteria were to be checked at screening visit (Visit 1).\nExclusion Criteria #3, 5, 6, 7g, and 9 were to be re-checked and verified before study drug administration (Visit 2).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Signed written informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Female or male ≥18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Documented histologic or cytologic diagnosis of American Joint Committee on Cancer (AJCC) Stage III or IV NSCLC. Stage III patient must have unresectable disease",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Body mass index < 20 kg/m2 with involuntary weight loss of >2% within 6 months prior to screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Ongoing problems with appetite/eating associated with the underlying cancer, as determined by having score of ≤ 17 points on the 5-item Anorexia Symptom Scale and ≤ 37 points on the 12-item FAACT A/CS",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Patient receiving or not receiving systemic anti-cancer treatment at the time of screening are eligible to participate. Systemic anti-cancer treatment includes first, second, third treatment line with chemotherapy/radiation therapy, immunotherapy or targeted therapy. Patient not receiving systemic anti-cancer treatment is eligible if:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Not planning to receive anti-cancer treatment and/or at least 14 days must be elapsed from the completion of prior treatment at the day of screening, in case underwent previous cycle OR",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Planning to receive anti-cancer treatment within 14 days from randomization and/or at least 14 days must be elapsed from the completion of prior treatment at the day of screening, in case underwent previous cycle OR",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Patient on palliative care treatment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "ECOG performance status 0,1 or 2 at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "AST (SGOT) and ALT (SGPT) ≤ 3 x ULN or if hepatic metastases are present ≤ 5 x ULN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Adequate renal function, defined as creatinine ≤2 ULN, or calculated creatinine clearance >30 ml/minute",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Female patient shall be: a) of non-childbearing potential or b) of childbearing potential using reliable contraceptive measures and having a negative urine pregnancy test within 24 hours prior to first dose of investigational product. Notes:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Female patient of non-childbearing potential are defined as being in post-menopausal state since at least 1 year; or having documented surgical sterilization or hysterectomy at least 3 months before study participation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Reliable contraceptive measures include implants, injectables, combined oral contraceptives, intrauterine devices, vasectomized partner or complete (long term) sexual abstinence.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "The patient must be willing and able to comply with the protocol tests and procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Patient with other forms of lung cancer (e.g., small cell, neuroendocrine tumors)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Woman who is pregnant or breast-feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Reversible causes of reduced food intake, as determined by the Investigator. These causes may include but are not limited to:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "NCI CTCAE Grade 3 or 4 oral mucositis,",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "NCI CTCAE Grade 3 or 4 GI disorders [nausea, vomiting, diarrhea, and constipation],",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "mechanical obstructions making patient unable to eat, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "severe depression",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Patient undergoing major surgery (central venous access placement and tumor biopsies are not considered major surgery) within 4 weeks prior to randomization. Patient must be well recovered from acute effects of surgery prior to screening. Patient should not have plans to undergo major surgical procedures during the treatment period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Patient currently taking androgenic compounds including but not limited to testosterone, testosterone-like agents, oxandrolone; megestrol acetate; corticosteroids; olanzapine, mirtazapine (however, long-term use of mirtazapine for depression for at least four weeks prior to screening is allowed); dronabinol; marijuana (cannabis); or any other prescription medication or off-label products intended to increase appetite or treat unintentional weight loss",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Patient with pleural effusion requiring thoracentesis, pericardial effusion requiring drainage, edema or evidence of ascites",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Patient with uncontrolled or significant cardiovascular disease, including:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "History of myocardial infarction within the past 3 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "A-V block of second or third degree (may be eligible if currently have a pacemaker)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Unstable angina",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Congestive heart failure within the past 3 months, if defined as NYHA class III-IV",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, Wolff-Parkinson-White (WPW) syndrome, or torsade de pointes)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Uncontrolled hypertension (blood pressure >150 mm Hg systolic and >95 mm Hg diastolic)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Heart rate < 50 beats per minute on pre-entry electrocardiogram and patient is symptomatic",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Patient on drugs that may prolong the PR or QRS interval durations, such as any of the antiarrhythmic medications Class I (Fast sodium (Na) channel blockers)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Patient unable to readily swallow oral tablets",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Patient with severe gastrointestinal disease (including esophagitis, gastritis, malabsorption)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Patient with history of gastrectomy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Patient with uncontrolled diabetes mellitus or unmonitored diabetes mellitus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Patient with cachexia caused by other reasons, as determined by the investigator such as:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Severe COPD requiring use of home O2,",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "New York Heart Association (NYHA) class III-IV heart failure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "AIDS",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Uncontrolled thyroid disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Patient receiving strong CYP3A4 inhibitors within 14 days of randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Patient currently receiving tube feedings or parenteral nutrition (either total or partial).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Current excessive alcohol or illicit drug use",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Any condition, including the presence of laboratory abnormalities, which in the Investigator's opinion, places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Enrollment in a previous study with anamorelin HCl",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03743051",
    "statement": "Patient actively receiving a concurrent investigational agent, or having received an investigational agent within 28 days of Day 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Adults and children ≥ 20 kg",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Symptomatic of malaria infection, i.e. history of fever within 24 hours and/or presence of fever >37.5°c.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Microscopic confirmation of asexual stages of P. falciparum (P. falciparum and mixed infection in Pailin only)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Capability of taking an oral medication",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Written informed consent given to participate in the trial",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Willingness and ability to adhere to follow-up visit schedule",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Pregnancy or lactation (urine test for β HCG to be performed on any woman of child bearing age, that is 18 to 45 y/o)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Female aged 12-18y",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Parasitemia > 150 000/µL).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Signs or symptoms indicative of severe malaria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Impaired consciousness (Blantyre Coma Score <5)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Severe anaemia (Hct<15%)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Bleeding disorder -evidenced by epistaxis, bleeding gums, frank haematuria, bleeding from venepuncture sites",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Respiratory distress",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Severe jaundice",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Known hypersensitivity to artemisinins - defined as history of erythroderma/other severe cutaneous reaction, angioedema or to pyronaridine",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "History of splenectomy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Known history or evidence of clinically significant disorders, such as:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Known active Hepatitis A, e.g. by detection of anti HAV-IgM.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Known hepatitis B surface antigen (HBsAg) carrier.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Known hepatitis C antibody (HCV Ab).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02389439",
    "statement": "Liver function tests (AST/ALT levels) more than 2.5 times the upper limit of normal range.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Health status:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "For cohort 1 and 3 (treatment with DSM265):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Female participants of childbearing potential (WOCBP) may be enrolled in the DSM265 cohorts but must have adequate contraception in place for the duration of the study and up to 60 days (9 weeks) after the last dose of DSM265, with adequate contraception defined as:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Male participants to be dosed with DSM265 in cohort 1 or 3 must agree to use a double method of contraception including condom plus diaphragm or condom plus stable oral/transdermal/injectable hormonal contraceptive by female partner from at least 14 days prior to the time of the dose of the study drug through 120 days (17 weeks) after the last dose of DSM265.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Abstinent male participants must agree to start a double method if they start a sexual relationship during the study and for up to 120 days (17 weeks) weeks following the last dose of DSM265.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "For cohort 2 (treatment with OZ439):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Female subjects must be considered as women of not childbearing potential (WONCBP) to be eligible.\nWONCBP is defined as:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Male participants to be dosed with OZ439 in cohort 2 must agree to use a double method of contraception including condom plus diaphragm or condom plus stable oral/transdermal/injectable hormonal contraceptive by female partner from at least 14 days prior to the time of the dose of the study drug through 96 days (14 weeks) after the last dose of OZ439.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Abstinent male participants must agree to start a double method if they start a sexual relationship during the study and for up to 96 days (14 weeks) following the last dose of OZ439.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "For Part B only (cohort 2 and 3):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "- All subjects must be Duffy Blood group positive.\nFemale subjects of childbearing potential (Cohort 3 only) should be blood group Rh positive.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Regulations:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "- Having given written informed consent prior to undertaking any study-related procedure.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Medical history and clinical status:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Interfering substance:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "General conditions:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Biological status",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Specific to the study_",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Participants are requested to refrain from taking non-approved concomitant medication from recruitment until the conclusion of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Participants who are excluded from participation on study days for any of the above reasons may be eligible to participate on a postponed schedule if the Investigator considers this appropriate.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Normal vital signs after 5 minutes resting in supine position:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "90 mmHg < systolic blood pressure (SBP) <140 mmHg,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "50 mmHg < diastolic blood pressure (DBP) <90 mmHg,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "40 bpm< heart rate (HR) <100 bpm.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Normal standard 12-lead electrocardiogram (ECG) after 5 minutes resting in supine position, QTcF≤450 ms (males and females) with absence of second or third degree atrioventricular block or abnormal T wave morphology.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Laboratory parameters within the normal range, unless the Investigator considers an abnormality to be clinically irrelevant for healthy participants enrolled in this clinical investigation. More specifically for serum creatinine, hepatic transaminase enzymes (aspartate aminotransferase, alanine aminotransferase), and total bilirubin (unless the Participant has documented Gilbert syndrome) should not exceed the upper laboratory norm and haemoglobin must be equal or higher than the lower limit of the normal range",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "As there is the risk of adverse effects of the investigational drugs (DSM265 and OZ439), and standard curative treatment (Riamet and primaquine - cohort 1 only) in pregnancy, it is important that any participants involved in this study do not get pregnant or get their female partners pregnant (refer to Section 6.7).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Stable hormonal contraception (with an approved oral, transdermal or depot regimen) for at least 3 months prior to screening i.e. oral contraceptives, either combined or progestogen alone, hormonal implantable contraception, vaginal ring, contraceptive patches",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Intrauterine (IUD) device or system in place for at least 3 months prior to screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Male partner sterilization prior to the female participant's entry into the study, and this male is the sole partner for that participant Abstinent female participants must agree to start a double method if they start a sexual relationship during the study and for up to 60 days (9 weeks) following the last dose of DSM265.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Spontaneous amenorrhoea for at least 1 year or spontaneous amenorrhea for at least 6 months confirmed by an FSH result above the laboratory defined range for post-menopausal",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "or permanently sterilised (eg tubal occlusion, hysterectomy, bilateral salpingectomy) Female subjects with same sex partners (abstinence from penile-vaginal intercourse), are eligible when this is their preferred and usual lifestyle.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Any history of malaria or participation to a previous malaria challenge study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Must not have travelled to or lived in a malaria-endemic country during the past 12 months or planned travel to a malaria-endemic country during the course of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Has evidence of increased cardiovascular disease risk (defined as >10%, 5 year risk) as determined by the Australian Absolute Cardiovascular Disease Risk Calculator (http://www.cvdcheck.org.au/). Risk factors include sex, age, systolic blood pressure (mm/Hg), smoking status, total and HDL cholesterol (mmol/L), and reported diabetes status.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "History of splenectomy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Presence or history of drug hypersensitivity, or allergic disease diagnosed and treated by a physician or history of a severe allergic reaction, anaphylaxis or convulsions following any vaccination or infusion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Presence of current or suspected serious chronic diseases such as cardiac or autoimmune disease (HIV or other immunodeficiencies), insulin-dependent and non-insulin dependent diabetes, progressive neurological disease, severe malnutrition, acute or progressive hepatic disease, acute or progressive renal disease, psoriasis, rheumatoid arthritis, asthma, epilepsy or obsessive compulsive disorder",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer), treated or untreated, within 5 years of screening, regardless of whether there is evidence of local recurrence or metastases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Participants with history of schizophrenia, bi-polar disease, or other severe (disabling) chronic psychiatric diagnosis including depression or receiving psychiatric drugs or who has been hospitalized within the past 5 years prior to enrollment for psychiatric illness, history of suicide attempt or confinement for danger to self or others.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Frequent headaches and/or migraine, recurrent nausea, and/or vomiting (more than twice a month)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Presence of acute infectious disease or fever (e.g., sub-lingual temperature ≥ 38.5°C) within the five days prior to inoculation with malaria parasites.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Evidence of acute illness within the four weeks before trial prior to screening that the Investigator deems may compromise subject safety.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Significant inter-current disease of any type, in particular liver, renal, cardiac, pulmonary, neurologic, rheumatologic, or autoimmune disease by history, physical examination, and/or laboratory studies including urinalysis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Participant has a clinically significant disease or any condition or disease that might affect drug absorption, distribution or excretion, e.g. gastrectomy, diarrhoea.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Participation in any investigational product study within the 12 weeks preceding the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Blood donation, any volume, within 1 month before inclusion or participation in any research study involving blood sampling (more than 450 mL/ unit of blood), or blood donation to Red Cross (or other) blood bank during the 8 weeks preceding the reference drug dose in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Participant unwilling to defer blood donations to the Australian Red Cross Blood Service (ARCBS) for 6 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Medical requirement for intravenous immunoglobulin or blood transfusions.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Participant who has ever received a blood transfusion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Symptomatic postural hypotension at screening, irrespective of the decrease in blood pressure, or asymptomatic postural hypotension defined as a decrease in systolic blood pressure ≥20 mmHg within 2-3 minutes when changing from supine to standing position.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "History or presence of alcohol abuse (alcohol consumption more than 40 g per day) or drug habituation, or any prior intravenous usage of an illicit substance.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Smoking more than 5 cigarettes or equivalent per day and unable to stop smoking for the duration of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Ingestion of any poppy seeds within the 24 hours prior to the screening blood test (participants will be advised by phone not to consume any poppy seeds in this time period).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Excessive consumption of beverages containing xanthine bases, including Red Bull, chocolate etc. more than 400 mg caffeine per day (equivalent to more than 4 cups per day)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Any medication (including St John's Wort) within 14 days before inclusion or within 5 times the elimination half-life (whichever is longer) of the medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Any vaccination within the last 28 days.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Any corticosteroids, anti-inflammatory drugs, immunomodulators or anticoagulants. Any participant currently receiving or having previously received immunosuppressive therapy, including systemic steroids including adrenocorticotrophic hormone (ACTH) or inhaled steroids in dosages which are associated with hypothalamic-pituitary-adrenal axis suppression such as 1 mg/kg/day of prednisone or its equivalent or chronic use of inhaled high potency corticosteroids (budesonide 800 μg per day or fluticasone 750 μg).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Any recent (< 6 weeks) or current systemic therapy with an antibiotic or drug with potential anti-malarial activity (i.e. chloroquine, piperaquine, benzodiazepine, flunarizine, fluoxetine, tetracycline, azithromycin, clindamycin, hydroxychloroquine, etc.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Any participant who, in the judgment of the Investigator, is likely to be noncompliant during the study, or is unable to cooperate because of a language or mental deficit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Any participant in the exclusion period of a previous study according to applicable regulations.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Any participant who lives alone (from Day 0 until at least the end of the anti-malarial drug treatment).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Any participant who cannot be contacted in case of emergency for the duration of the trial and up to 2 weeks following end of study visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Any participant who is the Investigator or any sub-investigator, research assistant, pharmacist, study coordinator, or other staff thereof, directly involved in conducting the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Any participant without a good peripheral venous access.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Positive result on any of the following tests: hepatitis B surface (HBs Ag) antigen, anti-hepatitis B core antibodies (anti-HBc Ab), anti-hepatitis C virus (anti-HCV) antibodies, anti-hepatitis A or E virus (IgM) antibodies, anti-human immunodeficiency virus 1 and 2 antibodies (anti-HIV1 and anti HIV2 Ab)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Any drug listed in Table 2 (Drug Screening) in the urine drug screen unless there is an explanation acceptable to the medical investigator (e.g., the participant has stated in advance that they consumed a prescription or OTC product which contained the detected drug) and/or the Participant has a negative urine drug screen on retest by the pathology laboratory.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Cardiac/QT risk",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Family history of sudden death or of congenital prolongation of the QTc interval or known congenital prolongation of the QTc interval or any clinical condition known to prolong the QTc interval.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "History of symptomatic cardiac arrhythmias or with clinically relevant bradycardia. Electrolyte disturbances, particularly hypokalaemia, hypocalcaemia, or hypomagnesaemia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Electrocardiogram (ECG) abnormalities in the standard 12-lead ECG (at screening) which in the opinion of the Investigator is clinically relevant or will interfere with the ECG analyses on study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Known hypersensitivity to DSM265 or OZ439, or any of its excipients or 4-aminoquinolines, artemether or other artemisinin derivatives, lumefantrine, or other arylaminoalcohols.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Known severe reaction to mosquito bites other than local itching and redness.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Unwillingness to abstain from consumption of citrus (grapefruit, Seville orange, etc.) for ≥21 days prior to initiation of the study (inoculation; Day 0) and for the study duration.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Unwillingness to abstain from consumption of quinine containing foods/beverages such as tonic water, lemon bitter, from inoculation (Day 0) to the end of the malaria treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Any history or presence of lactose intolerance.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02573857",
    "statement": "Use of prescription drugs, herbal supplements, within four weeks prior to administration of the study drug, and/or over-the-counter (OTC) medication, dietary supplements (including vitamins) within two weeks prior to initial dosing (Note: diazepam interferes with the analysis of blood levels of DSM265 and thus should not have been used for at least 8 weeks prior to administration of the study drug). If needed (i.e. an incidental and limited need) paracetamol is acceptable up to 4 g/day.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "The participant is eligible to enter the study if all of the following apply:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "The following criteria should be checked at the time of study entry.\nIf ANY exclusion criterion applies, the subject must not be included in the study:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Exceptions:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "a Inhaled and topical steroids.\nb Participation in hepatitis C vaccine study with confirmed negative HCV antibodies prior to participation in that study, and negative HCV RNA PCR at screening for this study c The following vaccinations may be administered more than 7 days before or after a study vaccination: polio, diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, Bacillus Calmette-Guérin (BCG vaccine), measles, influenza, pneumococcal disease, COVID-19 or yellow fever",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Participant is a healthy adult, aged 18 to 55 years (inclusive), of Thai origin.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Participant is willing and able to give informed consent to participate in the trial",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Able, in the investigator's opinion, and willing to comply with the study requirements and follow-up.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Women of childbearing potential: must agree to practice continuous, effective contraception for the duration of the trial, and have a negative pregnancy test before each vaccination. (Costs for contraceptives will be reimbursed by the trial.)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Pregnancy or breastfeeding, or planned pregnancy during the course of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Presence of any medical condition (physical or mental) which, may place the participant at undue risk or interfere with the results of the study*. Including: serious cardiac, renal, hepatic or neurological disease, severe malnutrition",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Any confirmed or suspected immunosuppressive or immunodeficient condition. Including: history of splenectomy, human immunodeficiency virus (HIV) infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Chronic administration (>14 days in total) of immunosuppressants or other immune-modifying drugs within six months of enrollment. Including: oral corticosteroids equivalent to prednisone > 20 mg/day (a)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "History of an autoimmune disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody(b) detected in serum.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Screening electrocardiogram (ECG) demonstrating a QTc interval ≥ 450 ms",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Seropositivity for hepatitis C virus (antibodies to HCV) at screening (b)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Finding on safety laboratory values as defined below:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "AST > 2 x upper normal limit",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "ALT > 2 x upper normal limit",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Anaemia (Hb < 10 g/dL),",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Platelets < 150,000",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Total bilirubin > 2 x upper normal limit",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Abnormalities of examination or investigations at screening. Including: hepatomegaly, right upper quadrant abdominal pain or tenderness, abnormal blood tests (as defined in the protocol which are not listed above)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Positive malaria parasitaemia (RDT) at screening or baseline (Month 0, Day 0).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Receipt or planned receipt of an investigational medical product or participation in an interventional clinical trial during the study period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Contraindications to the use of artemisinins, piperaquine or primaquine*. Including: use of medications with known potential interactions, prior allergic reactions to one or more components of the drug regimen.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "History of allergic disease or reactions likely to be exacerbated by any component of the vaccine (e.g. egg products)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "History of clinically significant contact dermatitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Contraindication to intramuscular (IM) injection*",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Administration of a vaccine not included in the study protocol within 30 days of a study vaccine (c).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "History of anaphylaxis post-vaccination.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Administration of immunoglobulins and/or any blood products during the period starting three months before the first dose of study vaccine or planned administration during the study period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "subject to the investigator's judgement",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Malaria infection (either locally transmitted or imported) detected at a health facility via passive surveillance, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Resides in a study Enumeration Area (EA), and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Provides informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "RACD Intervention Inclusion Criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Provides informed consent, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Index case resides in study EA, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "All non-index cases that reside or spent at least one night in the Target Area in the past 4 weeks, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Residents of the six houses closest to the index case, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "If 25 people are not enrolled in the study at the first six houses, plus the index case household, after the second visit then additional houses can be approached on the third visit.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "rfMDA Intervention Inclusion Criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Provides informed consent, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Index case resides in study EA, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "All non-index cases that reside or spent at least one night in the Target Area in the past 4 weeks, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Residents of the six houses closest to the index case, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "If 25 people are not enrolled in the study at the first six houses, plus the index case household, after the second visit then additional houses can be approached on the third visit.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Artemether/Lumefantrine (A-L) (combination medication) Inclusion Criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Consent to take A-L medication",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Does not meet A-L Exclusion Criteria under item #4 below",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Pill count Inclusion Criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Provides consent, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "People who receive any number of RACD or rfMDA drug dose(s)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Reactive Vector Control Inclusion Criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Informed consent provided by head of household or person in otherwise in charge of household, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Index case resides in study EA, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Index household and 6 non-index households closest to index household",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Endline Survey, Individual, Inclusion Criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Provides informed consent, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Resides or spent at least 1 night in the EA in the preceding 4 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Acceptability Assessment: Individual Interviews with study participants, Inclusion Criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Provides informed consent, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Resident of index household or of neighbouring households",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Acceptability Assessment: Individual Interviews with key stakeholders, Inclusion Criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "In leadership position within Zambezi region, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Provides informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Acceptability Assessment: Individual Interview with refusers, Inclusion Criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Refused to participate in rfMDA, RACD, and/or RAVC, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Provides informed consent to take part in the anonymous survey",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Acceptability Assessment: Focus group discussions with study participants, Inclusion Criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Provides informed consent, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Was eligible to be enrolled in the study in participant's Target Area, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Either took part in RACD or rfMDA intervention (+/- RAVC), OR refused these interventions",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Malaria infection identified through active case detection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Refusal to participate",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "RACD Intervention Exclusion Criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Index case does not reside in study EA, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Refusal to participate in RACD, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Household received the intervention in the previous 5 weeks, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Household > 500 m from the index case, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Severe or complicated malaria as assessed by study nurse (this will lead to referral for further evaluation at health facility but not enrolment in study)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "rfMDA Intervention Exclusion Criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Index case does not reside in study EA, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Refusal to participate in rfMDA, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Household received the intervention in the previous 5 weeks, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Household > 500 m from the index case, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Severe or complicated malaria as assessed by study nurse (this will lead to referral for further evaluation at health facility but not enrolment in study)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Artemether/Lumefantrine (combination medication) Exclusion Criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Pregnancy in first trimester, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Previous regular menstruation, with no menstruation for most recent 4 weeks, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Weight < 5 kg*, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Severe malaria, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Known allergy to A-L, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Refusal of the offered A-L",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Note regarding A-L weight exclusion: Because of the pre-set required field at the top of the Eligibility section of this Application, the investigators have indicated a 6 month minimum age limit, primarily to note to the reader that there will be a lower age limit to infants enrolled. Yet during the actual conduct of this trial the investigators will utilize 5 kg weight as the cutoff, rather than using age. A lower weight cutoff of 5 kg is in accordance with A-L's manufacturer (Novartis)'s guidance on supporting pediatric data.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Pill count Exclusion Criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Refusal to participate in pill count, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Individuals who did not receive any drug doses through RACD or rfMDA",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Reactive Vector Control Exclusion Criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Refusal by head of household to participate in RAVC, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Already received RAVC during current transmission season, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Household is > 500 m from index case household (note: refusal to participate in RACD or rfMDA is not an exclusion criterion for RAVC)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Endline Survey, Individual, Exclusion Criteria: • Refusal to participate in Endline Survey (note: lack of participation in rfMDA or RACD is not an exclusion criterion)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Acceptability Assessment: Individual Interviews with study participants, Exclusion Criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Refusal to participate in Acceptability Assessment, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Speaks language not understood or able to be translated, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Key stakeholder [see below]",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Age < 15 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Acceptability Assessment: Individual Interviews with key stakeholders, Exclusion Criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Refusal to participate in Acceptability Assessment, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Speaks language not understood or able to be translated, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Not in leadership position",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Acceptability Assessment: Individual Interview with refusers, Exclusion Criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Refusal to participate in Acceptability Assessment, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Speaks language not understood or able to be translated, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Age < 15 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Acceptability Assessment: Focus group discussions with study participants, Exclusion Criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Refusal to participate in Acceptability Assessment, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Speaks language not understood or able to be translated, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Key stakeholder or in another leadership position, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Age < 15 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04230161",
    "statement": "Passive data collection: all suspected malaria cases (fevers) that self-present to the national health system and are counted in the district health surveillance systems.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04230161",
    "statement": "Cross sectional survey: Households in the district.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04230161",
    "statement": "Residents of the household visited.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04230161",
    "statement": "Questionnaire: any adult member of the household .",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04230161",
    "statement": "Malaria screening: all members aged 6 months or older from the above consenting household.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04230161",
    "statement": "Individuals of box sexes, not belonging to vulnerable categories (those with cognitive impairment or other person for whom full and open consent cannot be guaranteed) (Key informant interviews, focus group discussions, and participant observations).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04230161",
    "statement": "Individuals 18 years old and above (Key informant interviews, focus group discussions, and observations).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04230161",
    "statement": "Individuals of both sexes regardless of age (observations).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04230161",
    "statement": "District non-residents.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04230161",
    "statement": "Malaria screening: history of recent (within one month) malaria infection or treatment with anti-malarial medication (cross-sectional).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04230161",
    "statement": "Parents or guardians who have not yet reached age of consent (18 years) and their children will not be included in study activities requiring consent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04230161",
    "statement": "Individuals belonging to vulnerable categories (key informant interviews, focus group discussions, observations).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04230161",
    "statement": "Individuals unwilling and/or unable of giving consent (key informant interviews, focus group discussions, observations).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04230161",
    "statement": "Individuals below age of consent (20 years) (key informant interviews, focus group discussions, observations).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04230161",
    "statement": "Heads of households unwilling and/or unable of giving consent (observations).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04230161",
    "statement": "Individuals who do not wish to be included in observations will be excluded (observations).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "All of the following criteria must be fulfilled for a subject to participate in this trial:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "CATEGORY 1:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "IN ADDITION TO",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "CATEGORY 2:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "-a barrier method to be used at the time of potentially reproductive sexual activity (e.g.\n[male/female condom, 'cap,' or diaphragm] plus spermicide).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "A subject will be excluded from participating in this trial if any one of the following criteria is fulfilled:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Age greater than or equal to 18 and less than or equal to 50 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "In good general health and without clinically significant medical history",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Malaria comprehension exam completed, passed (a score of greater than or equal to 80% or per investigator s discretion) and reviewed prior to enrollment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Reliable access to the clinical trial center and availability to participate for duration of study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Females of childbearing potential must be willing to use reliable contraception (as defined below) from 21 days prior to study day -2 to 28 days following last Sanaria .",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Subject to the judgment and discretion of the PI, female participants who meet ANY ONE of the criteria listed immediately below, may not be required to take any additional measures to avoid pregnancy. Such participants will be counseled on risks at the time of consent and at appropriate points (e.g. when pregnancy testing occurs) during the study:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Females who have had their uterus, and/or BOTH ovaries removed",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Females who have had BOTH fallopian tubes surgically tied or removed",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Females who are above the age of 45 and have spontaneously had no menses at any point during the past 12 or more consecutive months (i.e. have reached menopause)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Females who, in the conservative and reasonable judgment of the PI (e.g. due to sexual orientation or serious life choice (such as being celibate clergy or transgender), during the entire trial will NOT participate in any potentially reproductive sexual contact",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Females who, in the conservative and reasonable judgment of the PI, are in a monogamous stable relationship with a male who has undergone vasectomy at least 4 months prior or another procedure/medical condition that deems the male sterile",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Subject to the judgment and discretion of the PI, female participants who DO NOT meet ANY of the criteria listed above, will be appropriately counseled on reproductive risks and pregnancy avoidance, and will be required to adhere to the following measures and agree to 2 methods of pregnancy prevention as noted below:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "a highly effective hormonal method to prevent pregnancy [e.g. CONSISTENT, CONTINUOUS use of contraceptive pill, patch, ring, implant or injection], and/or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "IUD or equivalent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Currently is breast-feeding (if female).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Pregnancy as determined by a positive urine or serum human choriogonadotropin (beta-hCG) test at any point during the study (if female).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Recent travel to a malaria endemic area within 5 years of enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Planned travel to a malaria endemic area during the study period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "History of confirmed malaria diagnosis on peripheral blood smear or by clinical history in the past 10 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Hemoglobin, WBC, platelets, ALT, and creatinine outside of local lab normal range (subjects may be included at the investigator s discretion for not clinically significant values outside of normal range)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Abnormal urinalysis as defined by positive urine glucose, protein, and hemoglobin. Subject can be included if investigator determine the abnormality is not clinically significant .",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Anticipated use during the study period, or use within the following periods prior to enrollment:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Investigational malaria vaccine within the last five years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Malaria chemoprophylaxis within 6 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Chronic systemic immunosuppressive medications (>14 days) within 6 months (e.g.cytotoxic medications, oral/parental corticosteroids >0.5 mg/kg/day prednisone or equivalent). Corticosteroid nasal spray for allergic rhinitis and topical corticosteroids for mild, uncomplicated dermatitis are allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Blood products or immunoglobulins within 6 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Systemic antibiotics with antimalarial effects within 30 days (such as clindamycin, doxycycline)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Investigational or non-registered product or vaccine within 30 days",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Receipt of a live vaccine within 28 days or a killed vaccine within the 14 days prior to Sanaria PfSPZ Challenge",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Medications known to interact with pyrimethamine, chloroquine, atovaquone, proguanil (during the study period only)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "History of:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Sickle cell disease, sickle cell trait, or other hemoglobinopathies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Splenectomy or functional asplenia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Systemic anaphylaxis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Any allergic reactions to study drugs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Documented history of chronic or active neurologic disease (including seizures, uncontrolled migraine headaches)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Psoriasis or porphyria",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Ocular diseases including retinopathy or visual field defects",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Clinically significant medical condition, physical examination findings, other clinically significant abnormal laboratory results, or past medical history that may have clinically significant implications for current health status and participation in the study in the opinion of the Investigator. A clinically significant condition or process includes but is not limited to:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "A process that would affect the immune response, or requires medication that affects the immune response",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Any contraindication to repeated phlebotomy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "A condition or process in which signs or symptoms could be confused with reactions to malaria challenge and/or infection, including dermatologic abnormalities at the site of sporozoite inoculation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "A chronic or subclinical condition which could be exacerbated by administration of any of the PfSPZ-CVac components or malaria infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Weight > 77.2 Kg at the time of screening (this will result in a minimum dose of pyrimethamine of approximately 0.7mg/Kg for a 50mg daily dose). (Note not required for Arm 4 CHMI controls)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "History of, or known active cardiac disease including: (1) prior myocardial infarction (heart attack); (2) angina pectoris; (3) congestive heart failure; (4) valvular heart disease; (5) cardiomyopathy; (6) pericarditis; (7) stroke or transient ischemic attack; (8) exertional chest pain or shortness of breath; or ( 9) other heart conditions under the care of a doctor",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Clinically significant ECG findings, as determined by the expert study cardiologist",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Moderate or high risk for coronary heart disease (CHD) based on NHANES I cardiovascular risk assessment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Acute illness at the time of enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Infection with HIV, Hepatitis B, Hepatitis C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Psychiatric condition that precludes compliance with the protocol including but not limited to:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Psychosis within the past 3 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Ongoing risk for suicide, or history of suicide attempt or gesture within the past 3 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Suspected or known current alcohol or drug abuse as defined by the American Psychiatric Association in the DSM V at the discretion of the PI",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Clinical trial staff and/or Sanaria employees with direct involvement in the conduct of the trial are excluded from participation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Participating in other clinical trials involving investigational interventions or off label medication use during the study period (excluding participation in the optional long term follow up visits). Participation in other trials such as observational or imaging studies will be discussed with the investigators.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02511054",
    "statement": "Any other finding that, in the judgment of the Investigator, would interfere with, or serve as a contraindication to, protocol adherence, assessment of safety or reactogenicity, or a subject s ability to give informed consent, or increase the risk of having an adverse outcome from participating in the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Completion of the written informed consent process.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Men or WNCBP age 18 to 55 years, in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Male subjects agree to use acceptable methods of contraception if the male subject's partner could become pregnant from the time of the first administration of study medication until 130 (90+40) days following administration of the investigational medicinal product. One of the following acceptable methods of contraception must be utilized:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Condom and occlusive cap (diaphragm or cervical/vault caps)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Surgical sterilization (vasectomy with documentation of azoospermia) and a barrier method (condom or occlusive cap [diaphragm or cervical/vault caps].",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "The subject's female partner uses oral contraceptives (combination estrogen/progesterone pills), injectable progesterone or subdermal implants and a barrier method (condom or occlusive cap [diaphragm or cervical/vault caps].",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "The subject's female partner uses medically prescribed topically-applied transdermal contraceptive patch and a barrier method (condom or occlusive cap [diaphragm or cervical/vault caps].",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "The subject's female partner has undergone documented tubal ligation (female sterilization). In addition, a barrier method (condom or occlusive cap [diaphragm or cervical/vault caps].",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "The subject's female partner has undergone documented placement of an intrauterine device or intrauterine system. In addition, a barrier method (condom or occlusive cap [diaphragm or cervical/vault caps].",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "True abstinence: when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. Abstinent subjects have to agree to use 1 of the above-mentioned contraceptive methods, if they start sexual relationships during the study and for up to 100 days after the last dose of study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Women subjects must be of non-childbearing potential (WNCBP) as per one of the following definitions:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Natural (spontaneous) post-menopausal defined as being amenorrhoeic for at least 12 months without an alternative medical cause with a screening follicle stimulating hormone level consistent with local laboratory levels for post-menopause.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Premenopausal with irreversible surgical sterilization by hysterectomy and/or bilateral oophorectomy or salpingectomy at least 6 months before screening (as determined by subject medical history).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Haematology, clinical chemistry and urinalysis results at screening that are within the local laboratory reference range or, if outside the range, not clinically significant as judged by the Investigator. More specifically, serum creatinine, hepatic transaminase enzymes (AST ALT), and total bilirubin (unless the subject has documented Gilbert syndrome) should not exceed the upper laboratory norm and haemoglobin must be equal to or higher than the lower limit of the normal range.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Total body weight greater than 50 kg and a body mass index (BMI) within the range of 18 to 32 kg/m2 (inclusive).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Non-smoker or ex-smoker for more than 90 days prior to screening, or smoke no more than 5 cigarettes per day as determined by history. Must be able to abstain from smoking during the inpatient stay.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Agree to stay in contact with the study site for the duration of the study and up to 2 weeks following the end of study visit, provide updated contact information as necessary, and have no current plans to move away from the study area for the duration of the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Male subjects with a female partner(s) who is (are) pregnant or lactating from the time of the administration of study medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Evidence or history of clinically significant haematological, renal, endocrine, pulmonary, gastrointestinal (including gallbladder), cardiovascular (including a family history of long QT syndrome or sudden death), hepatic, psychiatric, neurologic, or allergic disease (including drug or food allergies, anaphylaxis or other severe allergic reactions but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "History of malignancy of any organ system (other than localised basal cell carcinoma of the skin), treated or untreated, within the past five years, regardless of whether there is evidence of local recurrence or metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Any surgical or medical condition possibly affecting drug absorption (e.g. cholecystectomy, gastrectomy, bowel disease, etc.), distribution, metabolism or excretion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Previous splenectomy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "A history of photosensitivity.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Subject positive for any of the following",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Anti-human immunodeficiency virus 1 or 2 antibodies (anti-HIV1 or anti-HIV2 Ab) (ELISA)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Hepatitis B surface antigen (HBsAg)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Anti-hepatitis B core antibodies (anti-HBcAb)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Anti-hepatitis C antibodies (anti-HCV)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Resting vital signs (measured after 5 minutes in the supine position) at screening, pre-dose (Part A) or pre-inoculation (Part B) outside of the following study-specific normal ranges:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "tympanic body temperature < 38.0 °C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "90 < SBP < 140 mmHg",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "50 < DBP < 90 mmHg",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "40 < pulse rate < 100 bpm",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Symptomatic postural hypotension at screening, irrespective of the decrease in blood pressure, or asymptomatic postural hypotension defined as a decrease in systolic blood pressure ≥20 mmHg 2 minutes after changing from a supine to standing position.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "A history of clinically significant ECG abnormalities, or any of the following ECG abnormalities at screening, pre-dose (Part A and B) or pre-inoculation (Part B):",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "PR >210 ms",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "QRS complex >120 ms",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "QTcF >450 ms",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Second or third degree atrioventricular block",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Incomplete, complete or intermittent bundle branch block",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Abnormal T wave morphology",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Left ventricular hypertrophy with repolarisation abnormalities",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Right ventricular hypertrophy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Presence of acute infectious disease or fever (i.e. tympanic body temperature ≥38.5 ºC) within five days prior to the first dose of study medication (Part A) or the inoculation administration (Part B).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Use of prescription or non-prescription drugs, herbal and dietary supplements within 14 days or 5 half-lives (whichever is the longer) prior to the first dose of study medication (Part A) or the inoculation administration (Part B). [As an exception, paracetamol may be used at doses of up to 1 g/day (Part A) or 2 g/day (Part B), or ibuprofen up to 1.2 g/day (Part B). Limited use of other non-prescription medications not believed to affect subject safety or the overall results of the study, may be permitted on a case-by-case basis following approval by the sponsor.]",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Recipient of any vaccination within 28 days prior to the first dose of study medication (Part A) or the inoculation administration (Part B).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Urine drug screen at screening, pre-dose (Part A) or pre-inoculation (Part B) positive for any drug as listed in Section 9.2.4 unless there is an explanation acceptable to the medical Investigator (e.g. the subject has stated in advance that they consumed a prescription or over the counter product which contained the detected drug) and/or the subject has a negative urine drug screen on retest by the pathology laboratory.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Ingestion of any poppy seeds within the 24 hours prior to the screening blood test.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "A positive alcohol breath test at screening, pre-dose (Part A) or pre-inoculation (Part B).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "History of regular alcohol consumption exceeding a weekly intake of more than 21 units for males and more than 14 units for females (one unit is equivalent to 8-10 g of ethanol, 285 ml of beer or lager, one glass [125 ml] of wine, or 25 ml of spirits) within 6 months of screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "History of drug habituation, or any prior intravenous usage of an illicit substance.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Participation in any investigational product study within 12 weeks or five half-lives (whichever is longer) prior to the first dose of the study medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Intake of grapefruit, grapefruit juice or grapefruit-related citrus fruits (e.g. Seville oranges, pomelos) within 28 days prior to the first dose of the study medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Excessive consumption of beverages containing xanthine bases (e.g. more than 400 mg of caffeine per day, equivalent to approximately 4 cups of coffee).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Pregnant or nursing (lactating) women.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Participation in any research study involving blood sampling (more than 450 ml/ unit of blood), or blood donation to the Australian Red Cross Blood Service (ARCBS) or other blood bank during the 8 weeks prior to IMP administration (Part A) or inoculation (Part B).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Blood donation (excluding plasma donation) of any volume, within 1 month prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Medical requirement for intravenous immunoglobulin or blood transfusions.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Subject with poor peripheral venous access.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Subject unwilling or unable to comply with the restrictions described in this protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Any subject who, in the judgment of the Investigator, is likely to be noncompliant during the study, or unable to cooperate because of a language problem or poor mental development.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Any subject who is the Investigator or any sub-investigator, research assistant, pharmacist, study coordinator, or other staff thereof, directly involved in conducting the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Recent (within the last three years) and/or recurrent history of autonomic dysfunction (e.g. recurrent episodes of fainting, palpitations, etc.).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Any history of malaria.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Participation in a previous malaria challenge study or Part A of the current study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Participation in a malaria vaccine trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Has travelled to or lived (for more than 2 weeks) in a malaria-endemic country during the past 12 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Any plan to travel to a malaria-endemic country during the course of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Evidence of increased cardiovascular disease risk (defined as >10%, 5 year risk for those greater than 35 years of age, as determined by the Australian Absolute Cardiovascular Disease Risk Calculator.39 Risk factors include sex, age, systolic blood pressure (mm/Hg), smoking status, total and HDL cholesterol (mmol/L), and reported diabetes status.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Frequent headaches and/or migraine, recurrent nausea, and/or vomiting (more than twice a month).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Subject unwilling to defer blood donations to the ARCBS for 6 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Subject who has ever received a blood transfusion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Subject currently receiving, or having previously received, immunosuppressive therapy (including systemic steroids, adrenocorticotrophic hormone or inhaled steroids) at a dose or duration associated with hypothalamic-pituitary-adrenal axis suppression (e.g. 1 mg/kg/day of prednisone or its equivalent, or chronic use of inhaled high potency corticosteroids such as budesonide 800 μg per day or fluticasone 750 μg).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Any recent (<6 weeks) or current systemic therapy with drugs known to have potential antimalarial activity listed in Section 6.5.2.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Known allergy to one of the rescue medication proposed for the challenge study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Subject is unwilling to abstain from consumption of quinine containing foods/beverages such as tonic water, lemon bitter, from inoculation (Day In0) to the end of the antimalarial treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783833",
    "statement": "Subject lives alone (at any stage from Day In0 until at least the end of the antimalarial drug treatment).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02123290",
    "statement": "Body weight between 45kg and 90kg",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02123290",
    "statement": "Mono-infection of P. falciparum or P. vivax confirmed by:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02123290",
    "statement": "Fever, or history of fever in the previous 24 hours and,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02123290",
    "statement": "Microscopically confirmed parasite infection: 1,000 to 35,000 asexual parasite count/µL blood",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02123290",
    "statement": "Written informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02123290",
    "statement": "Able to swallow oral medication",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02123290",
    "statement": "Able and willing to participate and to comply with the study requirements",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02123290",
    "statement": "Agree to hospitalisation for at least 72 hours and until malarial parasites are not detected by microscopy on 2 consecutive occasions",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02123290",
    "statement": "Agree to return to clinic on Day 5 (in addition to the other study days), if by Day 3 malarial parasites have not fallen below level of detection on at least two consecutive occasions. If there are no longer any signs or symptoms of malaria then to be available every 3-4 days for blood sampling for microscopy and Quantitative Polymerase Chain Reaction, and re-hospitalisation for standard treatment in the event of levels being detectable",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02123290",
    "statement": "Signs and symptoms of severe / complicated malaria according to the World Health Organisation Criteria 2010",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02123290",
    "statement": "Mixed Plasmodium infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02123290",
    "statement": "Severe vomiting, (more than three times in the 24 hours prior to inclusion) or inability to tolerate oral treatment, or severe diarrhoea",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02123290",
    "statement": "Presence of other serious or chronic clinical condition requiring hospitalisation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02123290",
    "statement": "Severe malnutrition",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02123290",
    "statement": "Known history or evidence of clinically significant disorders such as cardiovascular (including arrhythmia, QTcB or QTcF interval greater than or equal to 450 msec, personal or family history of long QT syndrome, PR interval >200msec; any degree of heart block), respiratory (including active tuberculosis), history of jaundice, hepatic, renal, gastrointestinal, immunological, neurological (including auditory), endocrine including any type of diabetes mellitus (controlled or not), diabetes insipidus, uncontrolled hypo- or hyperthyroidism, endocrine reproductive disorders not requiring concurrent medication, disorders of adrenal function, infectious conditions other than minor skin or soft tissue infections or confirmed lower urinary tract infection, malignancy, psychiatric, history of convulsions or other neurological or psychiatric abnormality; any other disorder or condition that may render the patient unfit for participation or place him/her at increased risk",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02123290",
    "statement": "Known active Hepatitis A, Hepatitis B or Hepatitis C antibody",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02123290",
    "statement": "Any antimalarial treatment in the past:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02123290",
    "statement": "a piperaquine-based compound, mefloquine, naphthoquine or sulphadoxine / pyrimethamine in the previous 6 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02123290",
    "statement": "amodiaquine or chloroquine in the previous 4 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02123290",
    "statement": "quinine, halofantrine, lumefantrine-based compounds and any other anti-malarial treatment or antibiotics with antimalarial activity (including cotrimoxazole, tetracyclines, quinolones and fluoroquinolones, and azithromycin) in the past 14 days",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02123290",
    "statement": "any herbal products or traditional medicines, in the past 7 days",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02123290",
    "statement": "Have received antibacterial treatment with known antimalarial activity in the preceding 14 days",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02123290",
    "statement": "Have received an investigational drug in the 4 weeks prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02123290",
    "statement": "(a) Aspartate Aminotransferase / Alanine Aminotransferase at least twice the upper limit of normal range and total bilirubin is normal (b) Aspartate Aminotransferase / Alanine Aminotransferase more than 1.5 times the upper limit of normal range and total bilirubin is greater than 1 and less than or equal to 1.5 times the upper limit of normal range",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02123290",
    "statement": "Hemoglobin level less than or equal to 8g/dL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02123290",
    "statement": "Total bilirubin greater than 1.5 times the upper limit of normal range",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02123290",
    "statement": "Serum creatinine levels more than twice the upper limit of normal range",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02123290",
    "statement": "Female patients must be neither lactating nor pregnant as demonstrated by a negative pregnancy test at screening and pre-dose and must be willing to take measures not to become pregnant during the study period and safety follow-up period (abstinence or oral contraceptives or double barrier contraception, such as male condom, female condom or diaphragm)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02123290",
    "statement": "Any prohibited medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01976416",
    "statement": "Pediatric subjects with documented sickle cell anemia (HbSS supported by hemoglobin electrophoresis or by peripheral blood smear showing sickled red blood cells)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01976416",
    "statement": "Age range of 1.00-3.99 years, inclusive, at the time of enrollment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01976416",
    "statement": "Weight at least 5.0 kg at the time of enrollment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01976416",
    "statement": "Willingness to comply with all study-related treatments, evaluations, and follow up",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01976416",
    "statement": "Known chronic medical condition (e.g., HIV, malignancy, active clinical tuberculosis)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01976416",
    "statement": "Severe malnutrition determined by impaired growth parameters as defined by WHO (weight for length/height or weight-for-length/height > 3 z-scores below the median WHO growth standards)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01976416",
    "statement": "Pre-existing severe hematological toxicity:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01976416",
    "statement": "Hb <4.0 g/dL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01976416",
    "statement": "Hb <6.0 g/dL AND ARC <100 x 10E9/L",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01976416",
    "statement": "Hb <7.0 g/dL AND ARC <80 x 10E9/L",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01976416",
    "statement": "Platelets <80 x 10E9/L",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01976416",
    "statement": "ANC <1.0 x 10E9/L",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01976416",
    "statement": "Alanine transaminase (ALT) or creatinine >2 times the upper limit of normal for age",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01976416",
    "statement": "Blood transfusion within 30 days prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04280692",
    "statement": "Healthy adults aged 18 to 45 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04280692",
    "statement": "Able and willing (in the Investigator's opinion) to comply with all study requirements.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04280692",
    "statement": "Informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04280692",
    "statement": "Use of effective method of contraception for duration of study (women only). We will ask the female volunteers to come with their family planning records to verify. Effective contraception is defined as a contraceptive method with failure rate of less than 1% per year when used consistently and correctly, in accordance with the product label. Examples of these include: combined oral contraceptives; injectable progestogen; implants of etenogestrel or levonorgestrel; intrauterine device or intrauterine system; male partner sterilisation at least 6 months prior to the female subject's entry into the study, and the relationship is monogamous; male condom combined with a vaginal spermicide (foam, gel, film, cream or suppository); and male condom combined with a female diaphragm, either with or without a vaginal spermicide (foam, gel, film, cream, or suppository).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04280692",
    "statement": "Body weight of less than 50kg or body mass index (BMI) less than 18 or greater than 25 kg/m2 at screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04280692",
    "statement": "Use of systemic antibiotics with known antimalarial activity within 30 days of administration of PfSPZ Challenge (e.g. trimethoprim-sulfamethoxazole, doxycycline, tetracycline, clindamycin, erythromycin, fluoroquinolones and azithromycin).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04280692",
    "statement": "Receipt of an investigational product in the 30 days preceding enrolment, or planned receipt during the study period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04280692",
    "statement": "Current participation in another clinical trial or recent participation within 12 weeks of enrolment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04280692",
    "statement": "Prior receipt of an investigational malaria vaccine.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04280692",
    "statement": "Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed). This will also include Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) positivity.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04280692",
    "statement": "Use of immunoglobulins or blood products within 3 months prior to enrolment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04280692",
    "statement": "Any serious medical condition reported or identified during screening that increases the risk of CHMI.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04280692",
    "statement": "Any clinically significant abnormal finding on biochemistry or haematology blood tests, urinalysis or clinical examination.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04280692",
    "statement": "Women only; pregnancy, or an intention to become pregnant during the duration of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04280692",
    "statement": "Sickle cell trait or disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04280692",
    "statement": "History of drug or alcohol abuse.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04280692",
    "statement": "Known hypersensitivity to or contraindications for use of artemether-lumefantrine, chloroquine, piperaquine, primaquine, sulfadoxine-pyrimethamine, or history of severe (allergic) reactions to mosquito bites.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04280692",
    "statement": "Confirmed gametocyte positivity at screening and/or a day before challenge",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04280692",
    "statement": "Confirmed parasite positive by PCR a day before challenge i.e. at C-1. Exclusion Criterion on Day of Challenge",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04280692",
    "statement": "Acute disease, defined as moderate or severe illness with or without fever (temperature >37.5 degrees Celcius).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04300309",
    "statement": "Male or female neonates/infants",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04300309",
    "statement": "Body weight <5 kg but ≥ 2 kg",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04300309",
    "statement": "In Cohort 1, infants aged >28 days; in Cohort 2, neonates aged 1 to ≤28 days (3 subgroups: 1-7 days; 8-14 days; 15-28 days)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04300309",
    "statement": "Microscopically confirmed diagnosis of P. falciparum malaria (or mixed infections):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04300309",
    "statement": "in Cohort 1 of ≥500 and <100,000 parasites/µL asexual P. falciparum parasitemia",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04300309",
    "statement": "in Cohort 2 of ≥100 and <100,000 parasites/µL asexual P. falciparum parasitemia",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04300309",
    "statement": "either congenital or neonatal",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04300309",
    "statement": "either symptomatic or asymptomatic",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04300309",
    "statement": "Head circumference < - 2 SD z-score in cm following WHO age and sex-specific reference curves (suspicion of microcephaly)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04300309",
    "statement": "Presence of severe malaria (according to WHO 2015 definition)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04300309",
    "statement": "HIV status :",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04300309",
    "statement": "in Cohort 1, patient's or patient's mother's current treatment with ARV",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04300309",
    "statement": "in Cohort 2, mother's known HIV positive status at patient's birth or mother's current treatment with ARV",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04300309",
    "statement": "Presence of the following signs of a critical condition: apnea-bradycardia, sustained bradycardia, tachycardia, desaturation, hypotension, hypothermia; or other severely deteriorated general condition (based on IMCI criteria in sick infants) (WHO 2005)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04300309",
    "statement": "Presence of any clinically significant neurological condition:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04300309",
    "statement": "any episode of convulsion during the present illness (in keeping with the IMCI list of general danger signs)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04300309",
    "statement": "known neurological disorders (e.g. chronic seizure disorders, cerebral palsy)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04300309",
    "statement": "Presence of clinically significant abnormality of the hepatic and renal systems",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04300309",
    "statement": "Patients unable to swallow or whose drinking is impaired",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04300309",
    "statement": "Known hypersensitivity of the patient or either patient's parent to artemether, lumefantrine, any of the excipients of Coartem®/Riamet® Dispersible tablet, or to drugs of similar chemical classes",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04300309",
    "statement": "History of malabsorption or previous gastrointestinal surgery, or history of radiation therapy that could affect drug absorption or metabolism, or any other disorder or history of a condition that could interfere with drug absorption, distribution, metabolism, or excretion",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04300309",
    "statement": "Known family history of congenital prolongation of the QTc interval or sudden death or with any other clinical condition known to be associated with prolongation of the QTc interval such as history of symptomatic cardiac arrhythmias, with clinically relevant bradycardia or with severe cardiac disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04300309",
    "statement": "Disturbances of electrolyte balance (e.g. hypokalaemia or hypomagnesaemia)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04300309",
    "statement": "Presence of any age-adjusted clinically or hematologically relevant laboratory and blood chemistry abnormalities",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04300309",
    "statement": "Patients who received any antimalarial drug, including antibiotics with antimalarial activity, within 14 days of trial start, or any other prohibited drug (see Table 6-2)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04300309",
    "statement": "Patients who received an investigational drug within 5 half-lives of enrollment or participated in an investigational study or within 30 days, whichever is longer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02488902",
    "statement": "Willing subjects in good general health.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02488902",
    "statement": "Males aged 18 to 60; females aged 50 to 60.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02488902",
    "statement": "Subjects who planned to stay in the study area until the end of the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02488902",
    "statement": "Subjects with any cardiovascular, liver, neurologic, or renal function abnormality which, in the opinion of the clinical investigators, would have placed them at increased risk of an adverse event or confused the result.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02488902",
    "statement": "Subjects with a personal or family history of seizures or frank psychiatric disorder.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02488902",
    "statement": "Females who had not ceased menstruation; a urine β-human chorionic gonadotrophin (β-HCG) test was to be performed at screening females who had ceased menstruation to exclude pregnancy as a cause.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02488902",
    "statement": "Females who were lactating.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02488902",
    "statement": "Subjects given antimalarial drugs for treatment within two weeks of study drug initiation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02488902",
    "statement": "Subjects with clinically significant abnormalities (to include but not limited to abnormal hepatic or renal function) as determined by history, physical and routine blood chemistry and haematology values.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02488902",
    "statement": "Subjects with known hypersensitivity to any of the study drugs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02488902",
    "statement": "Subjects unwilling to remain in the area, report for drug administration or blood drawing during the 3-4 month duration of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02488902",
    "statement": "Subjects with G6PD deficiency (as determined by two separate qualitative tests per subject administered using distinct methods; methods used were visual dye and filter paper methods).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02488902",
    "statement": "Subjects with any of the following laboratory values: haemoglobin (Hb) <8g/dL, platelets <80,000/mm3, white blood cell count (WBC) <3000/mm3, creatinine >1.5mg/dL, alanine transaminase (ALT) >60IU or 1+ haematuria as detected by urine dipstick.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Completion of the written informed consent process.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Men or WNCBP age 18 to 55 years, in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Male subjects agree to use acceptable methods of contraception if the male subject's partner could become pregnant from the time of the first administration of study medication until 130 (90+40) days following administration of the investigational medicinal product. One of the following acceptable methods of contraception must be utilized:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Condom and occlusive cap (diaphragm or cervical/vault caps)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Surgical sterilization (vasectomy with documentation of azoospermia) and a barrier method (condom or occlusive cap [diaphragm or cervical/vault caps].",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "The subject's female partner uses oral contraceptives (combination estrogen/progesterone pills), injectable progesterone or subdermal implants and a barrier method (condom or occlusive cap [diaphragm or cervical/vault caps].",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "The subject's female partner uses medically prescribed topically-applied transdermal contraceptive patch and a barrier method (condom or occlusive cap [diaphragm or cervical/vault caps].",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "The subject's female partner has undergone documented tubal ligation (female sterilization). In addition, a barrier method (condom or occlusive cap [diaphragm or cervical/vault caps].",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "The subject's female partner has undergone documented placement of an intrauterine device or intrauterine system. In addition, a barrier method (condom or occlusive cap [diaphragm or cervical/vault caps].",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "True abstinence: when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. Abstinent subjects have to agree to use 1 of the above-mentioned contraceptive methods, if they start sexual relationships during the study and for up to 100 days after the last dose of study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Women subjects must be of non-childbearing potential (WNCBP) as per one of the following definitions:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Natural (spontaneous) post-menopausal defined as being amenorrhoeic for at least 12 months without an alternative medical cause with a screening follicle stimulating hormone level consistent with local laboratory levels for post-menopause.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Premenopausal with irreversible surgical sterilization by hysterectomy and/or bilateral oophorectomy or salpingectomy at least 6 months before screening (as determined by subject medical history).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Haematology, clinical chemistry and urinalysis results at screening that are within the local laboratory reference range or, if outside the range, not clinically significant as judged by the Investigator. More specifically, serum creatinine, hepatic transaminase enzymes (AST ALT), and total bilirubin (unless the subject has documented Gilbert syndrome) should not exceed the upper laboratory norm and haemoglobin must be equal to or higher than the lower limit of the normal range.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Total body weight greater than 50 kg and a body mass index (BMI) within the range of 18 to 32 kg/m2 (inclusive).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Non-smoker or ex-smoker for more than 90 days prior to screening, or smoke no more than 5 cigarettes per day as determined by history. Must be able to abstain from smoking during the inpatient stay.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Agree to stay in contact with the study site for the duration of the study and up to 2 weeks following the end of study visit, provide updated contact information as necessary, and have no current plans to move away from the study area for the duration of the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Male subjects with a female partner(s) who is (are) pregnant or lactating from the time of the administration of study medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Evidence or history of clinically significant haematological, renal, endocrine, pulmonary, gastrointestinal (including gallbladder), cardiovascular (including a family history of long QT syndrome or sudden death), hepatic, psychiatric, neurologic, or allergic disease (including drug or food allergies, anaphylaxis or other severe allergic reactions but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "History of malignancy of any organ system (other than localised basal cell carcinoma of the skin), treated or untreated, within the past five years, regardless of whether there is evidence of local recurrence or metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Any surgical or medical condition possibly affecting drug absorption (e.g. cholecystectomy, gastrectomy, bowel disease, etc.), distribution, metabolism or excretion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Previous splenectomy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "A history of photosensitivity.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Subject positive for any of the following",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Anti-human immunodeficiency virus 1 or 2 antibodies (anti-HIV1 or anti-HIV2 Ab) (ELISA)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Hepatitis B surface antigen (HBsAg)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Anti-hepatitis B core antibodies (anti-HBcAb)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Anti-hepatitis C antibodies (anti-HCV)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Resting vital signs (measured after 5 minutes in the supine position) at screening, pre-dose (Part A) or pre-inoculation (Part B) outside of the following study-specific normal ranges:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "tympanic body temperature < 38.0 °C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "90 < SBP < 140 mmHg",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "50 < DBP < 90 mmHg",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "40 < pulse rate < 100 bpm",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Symptomatic postural hypotension at screening, irrespective of the decrease in blood pressure, or asymptomatic postural hypotension defined as a decrease in systolic blood pressure ≥20 mmHg 2 minutes after changing from a supine to standing position.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "A history of clinically significant ECG abnormalities, or any of the following ECG abnormalities at screening, pre-dose (Part A and B) or pre-inoculation (Part B):",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "PR >210 ms",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "QRS complex >120 ms",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "QTcF >450 ms",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Second or third degree atrioventricular block",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Incomplete, complete or intermittent bundle branch block",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Abnormal T wave morphology",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Left ventricular hypertrophy with repolarisation abnormalities",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Right ventricular hypertrophy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Presence of acute infectious disease or fever (i.e. tympanic body temperature ≥38.5 ºC) within five days prior to the first dose of study medication (Part A) or the inoculation administration (Part B).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Use of prescription or non-prescription drugs, herbal and dietary supplements within 14 days or 5 half-lives (whichever is the longer) prior to the first dose of study medication (Part A) or the inoculation administration (Part B). [As an exception, paracetamol may be used at doses of up to 1 g/day (Part A) or 2 g/day (Part B), or ibuprofen up to 1.2 g/day (Part B). Limited use of other non-prescription medications not believed to affect subject safety or the overall results of the study, may be permitted on a case-by-case basis following approval by the sponsor.]",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Recipient of any vaccination within 28 days prior to the first dose of study medication (Part A) or the inoculation administration (Part B).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Urine drug screen at screening, pre-dose (Part A) or pre-inoculation (Part B) positive for any drug as listed in Section 9.2.4 unless there is an explanation acceptable to the medical Investigator (e.g. the subject has stated in advance that they consumed a prescription or over the counter product which contained the detected drug) and/or the subject has a negative urine drug screen on retest by the pathology laboratory.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Ingestion of any poppy seeds within the 24 hours prior to the screening blood test.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "A positive alcohol breath test at screening, pre-dose (Part A) or pre-inoculation (Part B).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "History of regular alcohol consumption exceeding a weekly intake of more than 21 units for males and more than 14 units for females (one unit is equivalent to 8-10 g of ethanol, 285 ml of beer or lager, one glass [125 ml] of wine, or 25 ml of spirits) within 6 months of screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "History of drug habituation, or any prior intravenous usage of an illicit substance.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Participation in any investigational product study within 12 weeks or five half-lives (whichever is longer) prior to the first dose of the study medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Intake of grapefruit, grapefruit juice or grapefruit-related citrus fruits (e.g. Seville oranges, pomelos) within 28 days prior to the first dose of the study medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Excessive consumption of beverages containing xanthine bases (e.g. more than 400 mg of caffeine per day, equivalent to approximately 4 cups of coffee).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Pregnant or nursing (lactating) women.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Participation in any research study involving blood sampling (more than 450 ml/ unit of blood), or blood donation to the Australian Red Cross Blood Service (ARCBS) or other blood bank during the 8 weeks prior to IMP administration (Part A) or inoculation (Part B).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Blood donation (excluding plasma donation) of any volume, within 1 month prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Medical requirement for intravenous immunoglobulin or blood transfusions.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Subject with poor peripheral venous access.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Subject unwilling or unable to comply with the restrictions described in this protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Any subject who, in the judgment of the Investigator, is likely to be noncompliant during the study, or unable to cooperate because of a language problem or poor mental development.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Any subject who is the Investigator or any sub-investigator, research assistant, pharmacist, study coordinator, or other staff thereof, directly involved in conducting the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02783820",
    "statement": "Recent (within the last three years) and/or recurrent history of autonomic dysfunction (e.g. recurrent episodes of fainting, palpitations, etc.).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Age greater than or equal to 18 and less than or equal to 50 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "In good general health and without clinically significant medical history",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Malaria comprehension exam completed, passed (a score of greater than or equal to 80% or per investigator s discretion) and reviewed prior to enrollment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Reliable access to the clinical trial center and availability to participate for duration of study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Females of childbearing potential must be willing to use reliable contraception (as defined below) from 21 days prior to study day -2 to 28 days following last Sanaria PfSPZ Challenge exposure",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Subject to the judgment and discretion of the PI, female participants who meet ANY ONE of the criteria listed immediately below, may not be required to take any additional measures to avoid pregnancy. Such participants will be counseled on risks at the time of consent and at appropriate points (e.g. when pregnancy testing occurs) during the study:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Females who have had their uterus, and/or BOTH ovaries removed",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Females who have had BOTH fallopian tubes surgically 'tied' or removed",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Females who are above the age of 45 and have spontaneously had no menses at any point during the past 12 or more consecutive months (i.e. have reached menopause)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Females who, in the conservative and reasonable judgment of the PI (e.g. due to sexual orientation or serious life choice (such as being celibate clergy or transgender), during the entire trial will NOT participate in any potentially reproductive sexual contact",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Females who, in the conservative and reasonable judgment of the PI, are in a monogamous stable relationship with a male who has undergone vasectomy at least 4 months prior or another procedure/medical condition that deems the male sterile",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Subject to the judgment and discretion of the PI, female participants who DO NOT meet ANY of the criteria listed above, will be appropriately counseled on reproductive risks and pregnancy avoidance, and will be required to adhere to the following measures and agree to 2 methods of pregnancy prevention as noted below:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "CATEGORY 1: a highly effective hormonal method to prevent pregnancy [e.g. CONSISTENT, CONTINUOUS use of contraceptive pill, patch, ring, implant or injection], and/or IUD or equivalent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "IN ADDITION TO CATEGORY 2: a barrier method to be used at the time of potentially reproductive sexual activity (e.g. [male/female condom, 'cap,' or diaphragm] + spermicide).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Currently is breast-feeding (if female).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Pregnancy as determined by a positive urine or serum human choriogonadotropin (beta- hCG) test at any point during the study (if female).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Recent travel to a malaria endemic area within 5 years of enrollment (Endemic areas are defined per the CDC website. Factors such as but not limited to use of antimalaria prophylaxis during travel, length of stay, activities during the travel, history of illnesses within 30 days of travel will be considered to determine the likelihood that the subject was exposed to malaria)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Planned travel to a malaria endemic area (as defined by the Center for Disease Control) during the study period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Reported history of confirmed malaria diagnosis on peripheral blood smear or by clinical history in the past 10 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Hemoglobin, WBC, platelets, ALT, and creatinine outside of local lab normal range (subjects may be included at the investigator s discretion for not clinically significant values outside of normal range)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Abnormal urinalysis as defined by positive urine glucose, protein, and red blood cells. Subject can be included if investigator determine the abnormality is not clinically significant .",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "BMI < 17 or BMI > 35",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Anticipated use during the study period, or use within the following periods prior to enrollment:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Investigational malaria vaccine within the last five years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Malaria chemoprophylaxis within 6 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Chronic systemic immunosuppressive medications (>14 days) within 6 months (e.g.cytotoxic medications, oral/parental corticosteroids >0.5 mg/kg/day prednisone or equivalent). Corticosteroid nasal spray for allergic rhinitis and topical corticosteroids for mild, uncomplicated dermatitis are allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Blood products or immunoglobulins within 6 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Systemic antibiotics with antimalarial effects within 30 days (such as clindamycin, doxycycline)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Investigational or non-registered product or vaccine within 30 days",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Receipt of a live vaccine within 28 days or a killed vaccine within the 14 days prior to Sanaria PfSPZ Challenge",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Medications known to interact with pyrimethamine and/or chloroquine (for the main and pilot study participants ONLY), atovaquone, proguanil (ALL participants)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Reported history of:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Sickle cell disease, sickle cell trait, or other hemoglobinopathies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Splenectomy or functional asplenia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Systemic anaphylaxis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Any allergic reactions to study drugs (pyrimethamine, chloroquine) or NSAIDs, atovaquone, proguanil",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Documented history of chronic or active neurologic disease (including seizures, uncontrolled migraine headaches)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Psoriasis or porphyria",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Ocular diseases including retinopathy or visual field defects",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Clinically significant medical condition, physical examination findings, other clinically significant abnormal laboratory results, or past medical history that may have clinically significant implications for current health status and participation in the study in the opinion of the Investigator. A clinically significant condition or process includes but is not limited to:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "A process that would affect the immune response, or requires medication that affects the immune response",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Any contraindication to repeated phlebotomy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "A condition or process in which signs or symptoms could be confused with reactions to malaria challenge and/or infection, including dermatologic abnormalities at the site of sporozoite inoculation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "A chronic or subclinical condition which could be exacerbated by administration of any of the PfSPZ-CVac components or malaria infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "History of, or known active cardiac disease including: (1) prior myocardial infarction (heart attack); (2) angina pectoris; (3) congestive heart failure; (4) valvular heart disease; (5) cardiomyopathy; (6) pericarditis; (7) stroke or transient ischemic attack; (8) exertional chest pain or shortness of breath; or ( 9) other heart conditions under the care of a doctor",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Clinically significant ECG findings, as determined by the expert study cardiologist",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Moderate or high risk for coronary heart disease (CHD) based on NHANES I cardiovascular risk assessment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Acute illness at the time of enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Infection with HIV, Hepatitis B, Hepatitis C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Psychiatric condition that precludes compliance with the protocol including but not limited to:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Psychosis within the past 3 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Ongoing risk for suicide, or history of suicide attempt or gesture within the past 3 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Suspected or known current alcohol or drug abuse as defined by the American Psychiatric Association in the DSM V at the discretion of the PI",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Clinical trial staff and/or Sanaria Inc. employees with direct involvement in the conduct of the trial are excluded from participation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Participating in other clinical trials involving investigational interventions or off label medication use during the study period (excluding participation in the optional long term follow up visits). Participation in other trials such as observational or imaging studies will be discussed with the investigators.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03083847",
    "statement": "Any other finding that, in the judgment of the Investigator, would interfere with, or serve as a contraindication to, protocol adherence, assessment of safety or reactogenicity, or a subject s ability to give informed consent, or increase the risk of having an adverse outcome from participating in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02639299",
    "statement": "All of the following criteria must be fulfilled for a subject to participate in this trial:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02639299",
    "statement": "A subject will be excluded from participating in this trial if any one of the following criteria is fulfilled:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02639299",
    "statement": "Age greater than or equal to 18 and less than or equal to 50 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02639299",
    "statement": "In good general health and without clinically significant medical history",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02639299",
    "statement": "Reliable access to the clinical trial center and available in the area for more than 1 year",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02639299",
    "statement": "Females of childbearing potential must be willing to undergo periodic pregnancy testing and use reliable contraception per protocol when enrolled into LMIV clinical trials (protocol-specific requirements)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02639299",
    "statement": "Pregnant, breastfeeding, or planned pregnancy in the upcoming year.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02639299",
    "statement": "Hemoglobin, white blood cell (WBC), platelets, alanine transaminase (ALT), and creatinine (Cr) outside of local lab normal range (subjects may be included at the investigator s discretion for not clinically significant values outside of normal range).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02639299",
    "statement": "Anticipated use during the study period, or use within the following periods prior to enrollment:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02639299",
    "statement": "Investigational malaria vaccine within the last five years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02639299",
    "statement": "Chronic systemic immunosuppressive medications (e.g., cytotoxic medications, oral/parental corticosteroids > 0.5 mg/kg/day prednisone or equivalent). Corticosteroid nasal spray for allergic rhinitis and topical corticosteroids for mild, uncomplicated dermatitis are allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02639299",
    "statement": "Recurrent receipt of blood products or immunoglobulins",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02639299",
    "statement": "History of:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02639299",
    "statement": "Sickle cell disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02639299",
    "statement": "Splenectomy or functional asplenia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02639299",
    "statement": "Systemic anaphylaxis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02639299",
    "statement": "Uncontrolled psoriasis or porphyria",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02639299",
    "statement": "Clinically significant medical condition, physical examination findings, other clinically significant abnormal laboratory results, or past medical history that may have clinically significant implications for current health status and participation in the study in the opinion of the Investigator. A clinically significant condition or process includes but is not limited to:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02639299",
    "statement": "A process that would affect the immune response, or requires medication that affects the immune response.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02639299",
    "statement": "Any contraindication to repeated phlebotomy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02639299",
    "statement": "History of or known active cardiac disease including:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02639299",
    "statement": "prior myocardial infarction (heart attack)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02639299",
    "statement": "angina pectoris",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02639299",
    "statement": "congestive heart failure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02639299",
    "statement": "valvular heart disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02639299",
    "statement": "cardiomyopathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02639299",
    "statement": "pericarditis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02639299",
    "statement": "stroke or transient ischemic attack",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02639299",
    "statement": "exertional chest pain or shortness of breath",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02639299",
    "statement": "other heart conditions under the care of a doctor",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02639299",
    "statement": "Infection with HIV, hepatitis B, and/or hepatitis C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02639299",
    "statement": "Psychiatric condition that precludes compliance with the protocol including but not limited to:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02639299",
    "statement": "Psychosis within the past 3 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02639299",
    "statement": "Ongoing risk for suicide, or history of suicide attempt or gesture within the past 3 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02639299",
    "statement": "Suspected or known current alcohol or drug abuse as defined by the American Psychiatric Association in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition at the discretion of the PI",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02639299",
    "statement": "Any other finding that, in the judgment of the Investigator, would interfere with, or serve as a contraindication to, protocol adherence, assessment of safety or reactogenicity, or a subject s ability to give informed consent, or increase the risk of having an adverse outcome from participating in the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320060",
    "statement": "Males and Females (non-pregnant and non-lactating) between 18 and 70 years of age with type 1 or type 2 diabetes",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320060",
    "statement": "Sitting blood pressure of <=170/100 mm Hg at weeks -2 and -1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320060",
    "statement": "Hemoglobin A1C <=12% at week -2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320060",
    "statement": "Patients with diagnosis of diabetic nephropathy as defined by",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320060",
    "statement": "Serum Creatinine <=2.0 mg/dL at weeks -2 and -1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320060",
    "statement": "Urinary albumin excretion >=300 mg/24 hours at week -2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320060",
    "statement": "Diagnosis of diabetic retinopathy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320060",
    "statement": "Creatinine clearance >=40 mL/min at weeks -2 and -1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320060",
    "statement": "Voluntary written consent to participate in this study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320060",
    "statement": "History of allergic or adverse response to any B vitamin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320060",
    "statement": "History of major cardiovascular or cerebrovascular events",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320060",
    "statement": "History of cancer except adequately treated basal or squamous cell carcinoma of the skin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00320060",
    "statement": "History of diabetic ketoacidosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05287893",
    "statement": "Demography",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05287893",
    "statement": "a. Highly effective birth control methods include: combined (oestrogen and progestogen containing) oral/intravaginal/transdermal/implantable hormonal contraception associated with inhibition of ovulation, progestogen-only oral/injectable/implantable hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomised partner, or sexual abstinence or same sex relationship.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05287893",
    "statement": "b. Female participants who are abstinent (from penile-vaginal intercourse) must agree to start a double method if they start a sexual relationship with a male during the study.\nFemale participants must not be planning in vitro fertilisation within the required contraception period.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05287893",
    "statement": "7. Women of non-childbearing potential (WONCBP) are defined as:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05287893",
    "statement": "Male or female (non-pregnant, non-lactating) aged 18 to 55 years inclusive who will be contactable and available for the duration of the trial and up to two weeks following the EOS visit.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05287893",
    "statement": "Total body weight greater than or equal to 50 kg, and a body mass index (BMI) within the range of 18 to 32 kg/m2 (inclusive). BMI is an estimate of body weight adjusted for height. It is calculated by dividing the weight in kilograms by the square of the height in metres. Health status",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05287893",
    "statement": "Certified as healthy by a comprehensive clinical assessment (detailed medical history and full physical examination).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05287893",
    "statement": "Vital signs at screening (measured after 5 min in the supine position):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05287893",
    "statement": "Systolic blood pressure (SBP) - 90-140 mmHg,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05287893",
    "statement": "Diastolic blood pressure (DBP) - 40-90 mmHg,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05287893",
    "statement": "Heart rate (HR) 40-100 bpm.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05287893",
    "statement": "At Screening and pre-inoculation with the malaria challenge agent: normal standard mean of triplicate 12-lead electrocardiogram (ECG) parameters after 5 minutes resting in supine position in the following ranges:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05287893",
    "statement": "QTcF ≤450 msec (male participants); QTcF ≤470 msec (female participants);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05287893",
    "statement": "QRS 50-120 msec",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05287893",
    "statement": "PR interval ≤ 210 msec for both males and females, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05287893",
    "statement": "Normal ECG tracing unless the PI or delegate considers an ECG tracing abnormality to be not clinically relevant.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05287893",
    "statement": "Women of childbearing potential (WOCBP) who anticipate being sexually active with a male during the trial must agree to the use of a highly effective method of birth control (see below) combined with a barrier contraceptive from the screening visit until 100 days after the last dose of pyronaridine (covering a full menstrual cycle of 30 days starting after 5 half-lives of last dose pyronaridine) and have a negative result on urine pregnancy test performed before inoculation with the malaria challenge agent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05287893",
    "statement": "Natural (spontaneous) post-menopausal defined as being amenorrhoeic for at least 12 months without an alternative medical cause with a screening follicle stimulating hormone level (FSH) >25 IU/L (or at the local laboratory levels for post-menopause)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05287893",
    "statement": "Premenopausal with irreversible surgical sterilization by hysterectomy and/or bilateral oophorectomy or salpingectomy at least 6 months before screening (as determined by participant medical history) 8. Males who have, or may have, female sexual partners of child bearing potential during the course of the study must agree to use a double method of contraception including condom plus diaphragm, or condom plus intrauterine device, or condom plus stable oral/transdermal/injectable/implantable hormonal contraceptive by the female partner, from the time of informed consent through to 70 days (covering a spermatogenesis cycle) after pyronaridine administration. Abstinent males must agree to start a double method if they begin sexual relationship with a female during the study and up to 70 days after the last dose of pyronaridine. Males with female partners of child-bearing potential that are surgically sterile, or males who have undergone sterilisation and have had testing to confirm the success of the sterilisation, may also be included and will not be required to use above described methods of contraception. Regulations 9. Completion of the written informed consent process prior to undertaking any trial-related procedure. 10. Must be willing and able to communicate and participate in the whole trial. 11. Agreement to adhere to Lifestyle Considerations (see Section 5.3) throughout trial duration 12. Agreement to provide current contact details (two telephone numbers including a mobile number and a responsible adult as an emergency contact) and a relevant email address. Exclusion Criteria: History of an episode of mild/moderate depression lasting more than 6 months that required pharmacological therapy and/or psychotherapy within the last 5 years; or any episode of major depression. The Beck Depression Inventory-II (BDI-II) will be used as a validated tool for the assessment of depression at screening. In addition to the conditions listed above, participants with a score of 20 or more on the BDI-II and/or a response of 1, 2 or 3 for item 9 of this inventory (related to suicidal ideation) will not be eligible for participation. These participants will be referred to a general practitioner or medical specialist as appropriate. Participants with a BDI-II score of 17 to 19 may be enrolled at the discretion of an Investigator if they do not have a history of the psychiatric conditions mentioned in this criterion and their mental state is not considered to pose additional risk to the health of the participant or to the execution of the trial and interpretation of the data gathered. 13. History of recurrent headache (e.g. tension-type, cluster, or migraine) with a frequency of ≥2 episodes per month on average and severe enough to require medical therapy, during the 2 years preceding screening. 14. Presence of clinically significant infectious disease or fever (e.g., sublingual temperature ≥38.5°C) within the five days prior to inoculation. 15. Blood product donation to any blood bank during the 8 weeks (whole blood) or 4 weeks (plasma and platelets) prior to admission in the clinical unit on Day 8. 16. History or presence of alcohol abuse (alcohol consumption more than 40 g/4 units/4 standard drinks per day), or drug habituation, or any prior intravenous usage of an illicit substance. 17. Any individual who currently (within 14 days prior to inoculation) smokes >5 cigarettes/day. 18. Breastfeeding or lactating; positive serum pregnancy test at screening, positive urine pregnancy test upon admission or at other time points as specified by schedule of activities tables. 19. Any COVID-19 vaccine within 14 days of inoculation, any other vaccination within 28 days of IMP intake, and any vaccination (including COVID-19 initial or second dose) planned up to the final follow-up visit. 20. Any corticosteroids, anti-inflammatory drugs (excluding commonly used over-the-counter anti-inflammatory drugs such as ibuprofen, acetylsalicylic acid, diclofenac), immunomodulators or anticoagulants within the past three months. Any individual currently receiving or having previously received immunosuppressive therapy (including systemic steroids, adrenocorticotrophic hormone or inhaled steroids) at a dose or duration potentially associated with hypothalamic-pituitary-adrenal axis suppression within the past year. 21. Use of prescription drugs (excluding contraceptives) or non-prescription drugs or herbal supplements (such as St John's Wort), within 14 days or five half-lives (whichever is longer) prior to inoculation. Limited use of other non-prescription medications or dietary supplements, not believed to affect participant safety or the overall results of the trial, may be permitted on a case-by-case basis following approval by the Sponsor in consultation with the PI. Participants are requested to refrain from taking non-approved concomitant medications from recruitment until the conclusion of the trial. 22. Cardiac/QT risk: Family history of sudden death or of congenital prolongation of the QTc interval or known congenital prolongation of the QTc interval or any clinical condition known to prolong the QTc interval. History of symptomatic cardiac arrhythmias or with clinically relevant bradycardia. 23. Any history of malaria or participation in a previous malaria challenge trial or malaria vaccine trial. 24. Must not have had malaria exposure that is considered by the PI or their delegate to be significant. This includes but is not limited to: history of having travelled to or lived (>2 weeks) in a malaria-endemic region during the past 12 months or planned travel to a malaria-endemic region during the course of the trial; history of having lived for >1 year in a malaria-endemic region in the past 10 years; history of having ever lived in a malaria-endemic region for more than 10 years inclusive. For endemic regions see https://malariaatlas.org/explorer/#/, Bali is not considered a malaria-endemic region. 25. Has evidence of increased cardiovascular disease risk (defined as >10%, 5-year risk for those greater than 35 years of age, as determined by the Australian Absolute Cardiovascular Disease Risk Calculator [http://www.cvdcheck.org.au/]). Risk factors include sex, age, systolic blood pressure (mm/Hg), smoking status, total and HDL cholesterol (mmol/L), and reported diabetes status. 26. History of splenectomy. 27. Individual unwilling to defer blood donations to the Blood Service for at least twelve months after the EOS visit. 28. Individual who has ever received a blood transfusion. 29. Any recent (<6 weeks) therapy with an antibiotic or drug with potential antimalarial activity (e.g. chloroquine, piperaquine phosphate, benzodiazepine, flunarizine, fluoxetine, tetracycline, azithromycin, clindamycin, doxycycline etc.). General conditions 30. Any individual who, in the judgement of an Investigator, is likely to be non-compliant during the trial, or is unable to cooperate because of a language problem or poor mental development. 31. Any individual in the exclusion period of a previous trial according to applicable regulations. 32. Any individual who is an Investigator, research assistant, pharmacist, trial coordinator, or other staff thereof, directly involved in conducting the trial. 33. Any individual without good peripheral venous access. Biological status 34. Positive result on any of the following tests: hepatitis B surface antigen (HBs Ag), anti-hepatitis B core antibodies (anti-HBc Ab), anti-hepatitis C virus (anti-HCV) antibodies, anti-human immunodeficiency virus 1 and 2 antibodies (anti-HIV1 and anti-HIV2 Ab). 35. Positive urine drug test. Any drug listed in the urine drug screen unless there is an explanation acceptable to an Investigator (e.g., the participant has stated in advance that they consumed a prescription or over-the-counter product that contained the detected drug) and the participant has a negative urine drug screen on retest by the pathology laboratory. 36. Severe G6PD deficiency. 37. Positive alcohol breath test. 38. Positive for SARS-CoV-2 by PCR. NPA testing is to occur between Day -3 to Day -1 but only in the event that there is community transmission in South East Queensland (see section 8.3.7) 39. Positive for red cell antibodies",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05287893",
    "statement": "Individual who lives alone, OR, does not satisfy the following criteria: Participants who live alone may be included on a case-by-case basis, following discussion with the Principal Investigator. Participants who live alone must identify and provide contact details of a support person who is aware of the participant's participation in the study and is available to provide assistance if required (for example with contacting the participant in the event that study staff are unable to, or with transporting the participant to and from the study site if required). 2. Known hypersensitivity to pyronaridine, artesunate or any of its derivatives, artemether, lumefantrine or other artemisinin derivatives, proguanil/atovaquone, primaquine, or 4-aminoquinolines. 3. Haematology, biochemistry or urinalysis results at screening or at the eligibility visit that are outside of Sponsor-approved clinically acceptable laboratory ranges (appendix) or are considered clinically significant by the PI or their delegate. 4. Participation in any investigational product trial within the 12 weeks preceding pyronaridine administration. 5. Symptomatic postural hypotension at screening (confirmed on two consecutive readings), irrespective of the decrease in blood pressure, or asymptomatic postural hypotension defined as a decrease in systolic blood pressure ≥20 mmHg within 2-3 min when changing from supine to standing position. 6. Any history of anaphylaxis or other severe allergic reactions including face, mouth, or throat swelling or any difficulty breathing, or other food or drug allergy that the Investigator considers may impact on participant safety. Participants with seasonal allergies/hay fever or allergy to animals or house dust mite that are untreated and asymptomatic at the time of dosing can be enrolled in the trial. 7. History of convulsion (including drug or vaccine-induced episodes). A medical history of a single febrile convulsion during childhood (< 5 years) is not an exclusion criterion. 8. Presence of current or suspected serious chronic diseases such as cardiac or autoimmune disease, diabetes, progressive neurological disease, severe malnutrition, hepatic or renal disease. Acute or progressive hepatic or renal disease, porphyria, psoriasis, rheumatoid arthritis, asthma (excluding childhood asthma, or mild asthma with preventative asthma medication required less than monthly), or epilepsy. 9. History of malignancy of any organ system (other than localised basal cell carcinoma of the skin or in situ cervical cancer), treated or untreated, within five years of screening, regardless of whether there is evidence of local recurrence or metastases. 10. Individuals with history of schizophrenia, bipolar disorder psychoses, disorders requiring lithium, attempted or planned suicide, or any other severe (disabling) chronic psychiatric diagnosis including generalised anxiety disorder. 11. Individuals who have been hospitalised within five years prior to enrolment for either a psychiatric illness or due to danger to self or others.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01499082",
    "statement": "The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01499082",
    "statement": "Participants with type 2 diabetes mellitus",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01499082",
    "statement": "Substudy inclusion criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01499082",
    "statement": "Completion of the 6-month study period in main study (Visit 10)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01499082",
    "statement": "Randomized and treated with insulin glargine new formulation during the 6-month treatment period (Baseline - month 6)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01499082",
    "statement": "Age less than (<) 18 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01499082",
    "statement": "HbA1c <7.0% or greater than (>) 10% at screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01499082",
    "statement": "Diabetes other than type 2 diabetes mellitus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01499082",
    "statement": "Less than 1 year on basal plus mealtime insulin and self-monitoring of blood glucose",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01499082",
    "statement": "Any contraindication to use of insulin glargine as defined in the national product label",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01499082",
    "statement": "Participants using human regular insulin as mealtime insulin in the last 3 months before screening visit",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01499082",
    "statement": "Use of an insulin pump in the last 6 months before screening visit",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01499082",
    "statement": "Initiation of new glucose-lowering agents and/or weight loss drugs in the last 3 months before screening visit",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01499082",
    "statement": "History or presence of significant diabetic retinopathy or macular edema likely to require laser or injectable drugs or surgical treatment during the study period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01499082",
    "statement": "Pregnant or breast-feeding women or women who intend to become pregnant during the study period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01499082",
    "statement": "Substudy exclusion criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01499082",
    "statement": "Participant not willing to use the adaptable injection intervals on at least two days per week",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870194",
    "statement": "Present with type 2 diabetes",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870194",
    "statement": "Patients have been treated with a stable dose of the following for at least 3 months prior to screening:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870194",
    "statement": "100 mg/day sitagliptin and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870194",
    "statement": "≥1500 mg/day metformin, or maximum tolerated dose (extended release or immediate-release).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870194",
    "statement": "Have inadequate glycemic control as evidenced by an HbA1c between 7.1% and 9%, inclusive.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870194",
    "statement": "Have a body mass index (BMI) ≥20 kg/m2 and <45 kg/m2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870194",
    "statement": "Are currently enrolled in, or discontinued within the last 30 days (or longer, if local guidelines require) from, a clinical trial involving an off-label use of an investigational drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870194",
    "statement": "Have previously completed or withdrawn from this study or any other study investigating exenatide.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870194",
    "statement": "Have a known allergy or hypersensitivity to exenatide, sitagliptin or excipients contained in exenatide or sitagliptin.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870194",
    "statement": "Used drugs for weight loss (for example, orlistat, sibutramine, phenylpropanolamine, or similar over-the-counter medications) within 1 month of screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870194",
    "statement": "Are currently treated with any of the following excluded medications:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870194",
    "statement": "Thiazolidinediones (TZD) within 3 months of screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870194",
    "statement": "Sulfonylurea (SU) within 3 months of screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870194",
    "statement": "Dipeptidyl peptidase-4 [DPP-4] inhibitors, with the exception of sitagliptin, within 3 months of screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870194",
    "statement": "Meglitinide derivatives (for example, repaglinide or nateglinide) within 3 months of screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870194",
    "statement": "Alpha-glucosidase inhibitors (for example, miglitol or acarbose) within 3 months of screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870194",
    "statement": "Exogenous insulin within the 3 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870194",
    "statement": "Drugs that directly affect gastrointestinal motility, including, but not limited to: metoclopramide, cisapride, and chronic macrolide antibiotics.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870194",
    "statement": "Systemic corticosteroids (excluding topical and inhaled preparations) by oral, intravenous (IV), or intramuscular (IM) route used regularly (for longer than 1 month) or used within 1 month immediately prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00870194",
    "statement": "Any other oral antidiabetic (OAD) agent, other than sitagliptin or metformin, within 3 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00832624",
    "statement": "Patients Who Are 18 Years Of Age With Type 2 Diabetes Mellitus Who Are Either:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00832624",
    "statement": "Not On Antihyperglycemic (AHa) Medication (Off For At Least 2 Months)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00832624",
    "statement": "Or On A Single AHa",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01499095",
    "statement": "The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01499095",
    "statement": "Participants with type 2 diabetes mellitus",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01499095",
    "statement": "Substudy inclusion criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01499095",
    "statement": "Completion of the 6-month study period in main study (Visit 10)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01499095",
    "statement": "Randomized and treated with insulin glargine new formulation during the 6- month treatment period (Baseline - Month 6)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01499095",
    "statement": "Age less than (<) 18 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01499095",
    "statement": "HbA1c <7.0% or greater than (>) 10% at screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01499095",
    "statement": "Diabetes other than type 2 diabetes mellitus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01499095",
    "statement": "Less than 6 months on basal insulin treatment together with oral antihyperglycemic drug(s) and self-monitoring of blood glucose",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01499095",
    "statement": "Participants using sulfonylurea in the last 2 months before screening visit",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01499095",
    "statement": "Any contraindication to use of insulin glargine as defined in the national product label",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01499095",
    "statement": "Use of insulin pump in the last 6 months before screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01499095",
    "statement": "Initiation of new glucose-lowering medications in the last 3 months before screening visit",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01499095",
    "statement": "History or presence of significant diabetic retinopathy or macular edema likely to require laser or injectable drugs or surgical treatment during the study period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01499095",
    "statement": "Pregnant or breast-feeding women or women who intend to become pregnant during the study period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01499095",
    "statement": "Substudy exclusion criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01499095",
    "statement": "Participant not willing to use the adaptable injection intervals on at least two days per week",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05689099",
    "statement": "Male or female",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05689099",
    "statement": "Aged 18-55 years (both inclusive) at the time of signing informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05689099",
    "statement": "Body mass index (BMI) between 20.0 and 29.9 kilograms per meter square (kg/m^2) (both inclusive)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05689099",
    "statement": "Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using highly effective contraceptive method",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05689099",
    "statement": "Any disorder which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05689099",
    "statement": "Use of prescription medicinal products or non-prescription drugs, except routine vitamins, topical medications, highly effective contraceptives and occasional use of paracetamol, ibuprofen and acetylsalicylic acid, within 14 days prior to the day of screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05689099",
    "statement": "Abuse or intake of alcohol, defined as any of the below:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05689099",
    "statement": "Known or suspected alcohol abuse within 1 year before screening (defined as regular intake of more than an average intake of 24 grams (g) alcohol daily for men and 12 g alcohol daily for women - 12 g of alcohol equals about 300 milliliters (mL) of beer or lager, 100 mL of wine, or 25 mL spirits)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05689099",
    "statement": "Positive alcohol test at screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05689099",
    "statement": "Abuse or intake of drugs, defined as any of the below:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05689099",
    "statement": "Known or suspected drug or chemical substance abuse within 1 year before screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05689099",
    "statement": "Positive drug of abuse test at screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05232708",
    "statement": "Male or female",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05232708",
    "statement": "Aged 20-55 years (both inclusive) at the time of signing informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05232708",
    "statement": "Body mass index (BMI) between 25.0 and 34.9 kilogram per meter square (kg/m^2) (both inclusive)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05232708",
    "statement": "Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05232708",
    "statement": "Any disorder which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05232708",
    "statement": "Use of prescription medicinal products or non-prescription drugs, except routine vitamins, topical medications, highly effective contraceptives and occasional use of paracetamol and acetylsalicylic acid, within 14 days prior to the day of screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05232708",
    "statement": "Abuse or intake of alcohol, defined as any of the below:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05232708",
    "statement": "Known or suspected alcohol abuse within 1 year before screening (defined as regular intake of more than an average intake of 24 grams (g) alcohol daily for men and 12 g alcohol daily for women - 12 g of alcohol equals about 300 milliliters (mL) of beer or lager, 100 mL of wine, or 25 mL spirits).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05232708",
    "statement": "Positive alcohol test at screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05232708",
    "statement": "Abuse or intake of drugs, defined as any of the below:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05232708",
    "statement": "Known or suspected drug or chemical substance abuse within 1 year before screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05232708",
    "statement": "Positive drug of abuse test at screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157859",
    "statement": "-Male and female patients at least one 1year of age and weighing more than 10kg.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157859",
    "statement": "-Microscopic confirmation of P. falciparum and /or P.vivax infection (any parasitaemia).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157859",
    "statement": "-Fever (axillary temperature >37.5oC) or history of fever in the last 48 hours.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157859",
    "statement": "-Able to participate in the trial and comply with the clinical trial protocol",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157859",
    "statement": "-Written informed consent to participate in trial; verbal consent in presence of literate witness is required for illiterate patients, and written consent from parents/guardian for children below age of consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157859",
    "statement": "Pregnancy or lactation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157859",
    "statement": "-Inability to tolerate oral treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157859",
    "statement": "-Signs/symptoms indicative of severe/complicated malaria or warning signs requiring parenteral treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157859",
    "statement": "-Known hypersensitivity or allergy to artemisinin derivatives",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157859",
    "statement": "-Serious underlying disease (cardiac, renal or hepatic)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00157859",
    "statement": "-Parasitaemia >4%",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03604198",
    "statement": "Have completed a Corcept-sponsored study of relacorilant in endogenous Cushing syndrome with at least 80% compliance with the dosing schedule.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03604198",
    "statement": "According to the Investigator's opinion will benefit from continuing treatment with relacorilant",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03604198",
    "statement": "Premature discontinuation from a relacorilant parent study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03604198",
    "statement": "Has uncontrolled, clinically significant hypothyroidism or hyperthyroidism",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03604198",
    "statement": "Has poorly controlled hypertension",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03604198",
    "statement": "Has Stage ≥ 4 renal failure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04221399",
    "statement": "Aged ≥ 19 years at the time of screening test",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04221399",
    "statement": "Body weight of ≥ 50.0 kg to ≤ 90.0 with a body mass index (BMI) of ≥ 20.0 to ≤ 45.0",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04221399",
    "statement": "Have been diagnosed with type 2 diabetes",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04221399",
    "statement": "Have clinically uncontrolled or unstable hepatic, neurological, immune system, respiratory, hemato-oncology, cardiovascular, or psychiatric disorder (subject with chronic disease such as hypertension, diabetes, and hyperlipidemia that is well controlled or stable is eligible to participate in the study based on investigator's judgement)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04221399",
    "statement": "History of gastrointestinal diseases, dialysis, kidney transplantation, HIV, hepatitis B or C, acute or chronic infection, recent diabetic ketoacidosis, or gastrointestinal surgery that may affect the absorption of the study drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04221399",
    "statement": "Received SGLT2 inhibitors or drugs of thiazolidinedione class within 6 weeks of scheduled IP administration day",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04221399",
    "statement": "Clinical laboratory test values are outside the accepted normal range at screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04221399",
    "statement": "AST (SGOT), ALT (SGPT) > 2 x the upper limit of normal",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04221399",
    "statement": "Repeatedly confirmed QTc interval > 450 ms",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04221399",
    "statement": "Sitting systolic blood pressure < 80 mmHg or > 180 mmHg or sitting diastolic blood pressure < 60 mmHg or > 110 mmHg after resting for more than 3 minutes",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04221399",
    "statement": "Other exclusive inclusion criteria, as defined in the protocol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06010004",
    "statement": "Have Type 2 Diabetes (T2D)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06010004",
    "statement": "Have HbA1c ≥7.0% (≥53 mmol/mol) to ≤10.5% (≤91 mmol/mol) as determined by the central laboratory at screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06010004",
    "statement": "Are of stable weight (±5%) for at least 90 days prior to screening and agree to not initiate an intensive diet or exercise program during the study with the intent of reducing body weight other than the lifestyle and/or dietary measures for diabetes treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06010004",
    "statement": "Have a BMI ≥23.0 kilogram/square meter (kg/m²) at screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06010004",
    "statement": "Have Type 1 Diabetes (T1D).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06010004",
    "statement": "Have a history of severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to screening, or between screening and randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06010004",
    "statement": "Have New York Heart Association functional classification IV congestive heart failure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06010004",
    "statement": "Have had any of the following cardiovascular (CV) conditions within 60 days prior to screening, or between screening and randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06010004",
    "statement": "acute myocardial infarction",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06010004",
    "statement": "cerebrovascular accident (stroke), or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06010004",
    "statement": "hospitalization for congestive heart failure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06010004",
    "statement": "Have acute or chronic hepatitis and pancreatitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03214380",
    "statement": "Have been diagnosed (clinically) with T2D, based on the World Health Organization (WHO) classification for at least 1 year prior to screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03214380",
    "statement": "Have been treated for at least 90 days prior to screening with:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03214380",
    "statement": "Basal insulin (insulin glargine U-100 [Basaglar/Abasaglar or LANTUS] or U-300, insulin detemir, insulin degludec U-100 or U-200, or neutral protamine Hagedorn [NPH] insulin) in combination with at least 1 prandial injection of bolus insulin (insulin lispro U-100 or U-200, insulin aspart, insulin glulisine, or regular insulin) Or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03214380",
    "statement": "Premixed analog or human insulin regimens with any basal and bolus insulin combination injected at least twice daily",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03214380",
    "statement": "Participants may be treated with up to 3 of the following oral antihyperglycemic medications (OAMs) in accordance with local regulations:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03214380",
    "statement": "Metformin",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03214380",
    "statement": "Dipeptidyl peptidase-4 (DPP-4) inhibitor",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03214380",
    "statement": "Sodium glucose cotransporter 2 (SGLT2) inhibitor",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03214380",
    "statement": "Sulfonylurea",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03214380",
    "statement": "Meglitinide",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03214380",
    "statement": "Alpha-glucoside inhibitor",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03214380",
    "statement": "Have an HbA1c value between ≥7.0 and ≤10.0%, according to the central laboratory at the time of screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03214380",
    "statement": "Have a body mass index (BMI) of ≤45.0 kilograms per meter squared at screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03214380",
    "statement": "Have been diagnosed, at any time, with type 1 diabetes (T1D) or Latent Autoimmune Diabetes in Adults.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03214380",
    "statement": "Have hypoglycemia unawareness as judged by the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03214380",
    "statement": "Have had any episode of severe hypoglycemia within the 6 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03214380",
    "statement": "Have had 1 or more episodes of diabetic ketoacidosis or hyperglycemic hyperosmolar state within the 6 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03214380",
    "statement": "Have used thiazolidinediones, Glucagon-Like Peptide 1 (GLP-1) receptor agonist, or pramlintide within 90 days prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285983",
    "statement": "1. Participants must be type 2 diabetes mellitus patients meeting the following conditions: Have severe renal impairment or end-stage renal disease, with serum creatinine (mg/dL) or creatinine clearance (Ccr; mL/min) meeting the following criteria within 3 months before the start of treatment with this product",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285983",
    "statement": "1. Participants with any of the following contraindications for trelagliptin will be excluded:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285983",
    "statement": "Serum creatinine (mg/dL)*: male: > 2.4, female: > 2.0",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285983",
    "statement": "Ccr (mL/min): < 30 In patients with end-stage renal disease, this product may be administered irrespective of the time of hemodialysis.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285983",
    "statement": "Estimated values corresponding to the Ccr (for persons aged 60 years weighing 65 kg)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285983",
    "statement": "Patient with severe ketosis, diabetic coma or pre-coma, or type 1 diabetes mellitus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285983",
    "statement": "Patient with severe infection, perioperative status, or serious trauma",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04285983",
    "statement": "Patient with a history of hypersensitivity to any ingredients of trelagliptin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02223065",
    "statement": "Signed Informed Consent Form",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02223065",
    "statement": "Signed written informed consent must be obtained from the subjects in accordance with requirements of the study center's IRB or IEC before the initiation of any protocol-required procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02223065",
    "statement": "Target Population",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02223065",
    "statement": "Healthy subjects as determined by no clinically significant deviation from normal in medical history, psychiatric history, physical examination findings, vital sign measurements, 12-lead ECG measurements, physical measurements, and clinical laboratory test results.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02223065",
    "statement": "Age and Reproductive Status Exclusion Criteria: Physical and Laboratory Test Findings e) Abnormal liver function tests (alanine or aspartate aminotransferase [ALT or AST, respectively], or total bilirubin). f) Any of the following on 12-lead ECG prior to study drug administration, confirmed by repeat. i) PR ≥ 210 ms ii) QRS ≥ 120 ms iii) QT ≥ 500 ms iv) QTcF ≥ 450 ms g) Positive urine screen for drugs of abuse. h) Positive urine alcohol test. i) Positive blood screen for hepatitis C virus (HCV) antibody, hepatitis B surface antigen (HBsAg), or human immunodeficiency virus (HIV)-1 or HIV-2 antibodies at screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02223065",
    "statement": "Males and females, ages 19 to 55 years, inclusive. To extent possible, the distribution of men and women between the sequences will be balanced",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02223065",
    "statement": "Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02223065",
    "statement": "Women must not be breastfeeding. d) WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drugs saxagliptin and dapagliflozin plus 5 half lives of study drug dapagliflozin (the longer half life between the 2 drugs; 3 days) for a total of 3 days following treatment completion. e) Men who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drugs saxagliptin and dapagliflozin plus 5 half lives of dapagliflozin (the longer half life between the 2 drugs; 3 days) for a total of 3 days following treatment completion. f) Azoospermic males and WOCBP who are continuously not heterosexually active are exempt from contraceptive requirements. However, they must still undergo pregnancy testing as described in this section",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02223065",
    "statement": "Any significant acute or chronic medical illness.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02223065",
    "statement": "Current or recent (within 3 months of study drug administration) gastrointestinal disease that could impact upon the absorption of study drug",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02223065",
    "statement": "Any other sound medical, psychiatric, and/or social reason as determined by the investigator",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02223065",
    "statement": "Any major surgery within 4 weeks of study drug administration.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02223065",
    "statement": "Any prior GI surgery including cholecystectomy (remote history of appendectomy will not be exclusionary).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02223065",
    "statement": "Current, recent (within 3 months of study drug administration), or remote history of pancreatitis.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02223065",
    "statement": "Donation of blood or plasma to a blood bank or in a clinical study (except at screening visit) within 4 weeks before study drug administration.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02223065",
    "statement": "Blood transfusion within 4 weeks of study drug administration. h) Inability to tolerate oral medication.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02223065",
    "statement": "Inability to be venipunctured performed and/or tolerate venous access.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02223065",
    "statement": "Use of tobacco- or nicotine-containing products (including, but not limited to, cigarettes, pipes, e-cigarettes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months before check-in.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02223065",
    "statement": "Drug or alcohol abuse (within 2 years of study drug administration) as defined in the Diagnostic and Statistical Manual of Mental Disorders - 4th Edition, Diagnostic Criteria for Drug and Alcohol Abuse History of glucose intolerance or diabetes mellitus.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02223065",
    "statement": "For females, history of chronic or recurrent urinary tract infection (UTI) (defined as 3 occurrences per year) or UTI in the past 3 months. For males, any UTI within the previous 5 years that has not been thoroughly evaluated and for which an explanation is not clear.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02223065",
    "statement": "History of recurrent (defined as 3 occurrences per year) or recent vulvovaginal mycotic infections.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02223065",
    "statement": "Any other sound medical, psychiatric, and/or social reason as determined by the investigator.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02223065",
    "statement": "Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECGs, or clinical laboratory determinations beyond what is consistent with the target population.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02223065",
    "statement": "Abnormal urinalysis at screening (may repeat once). If the urinalysis is abnormal on Day -1 of Period 1, continuation in the study is up to the investigator's discretion. The CRO medical monitor should be consulted.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02223065",
    "statement": "Glucosuria or hematoria at screening or Day -1 of Period 1, repeat is not permitted. d) A positive nicotine test (ie, cotinine).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02223065",
    "statement": "Allergies and Adverse Drug Reaction",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02223065",
    "statement": "History of allergy or adverse reactions to DPP4 or SGLT inhibitors or related compounds.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02223065",
    "statement": "History of any significant drug allergy (such as anaphylaxis or hepatotoxicity).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02223065",
    "statement": "Other Exclusion Criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02223065",
    "statement": "Prisoners or subjects who are involuntarily incarcerated.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02223065",
    "statement": "Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02223065",
    "statement": "Inability to comply with restrictions and prohibited activities/treatments",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04573920",
    "statement": "Age 18 years and older for patients in the IgAN, FSGS, and Alport Syndrome cohorts",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04573920",
    "statement": "Age 18-70 years for patients in the DKD cohort",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04573920",
    "statement": "Receiving a maximally tolerated dose of RAS inhibitor therapy (ACEi or ARB) that has been stable for at least 12 weeks.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04573920",
    "statement": "For patients enrolling in IgAN Cohort:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04573920",
    "statement": "Biopsy-proven IgA nephropathy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04573920",
    "statement": "UPCR between 0.5 to less than 1.0 g/g",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04573920",
    "statement": "Screening eGFR ≥ 30 mL/min/1.73 m2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04573920",
    "statement": "For patients enrolling in FSGS Cohort:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04573920",
    "statement": "Biopsy-proven FSGS or documented genetic mutation in a podocyte protein associated with FSGS",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04573920",
    "statement": "UPCR > 1.0 g/g",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04573920",
    "statement": "Screening eGFR ≥ 30 mL/min/1.73 m2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04573920",
    "statement": "Subjects receiving systemic corticosteroids or other immunosuppressants must be on a stable dose for at least 12 weeks.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04573920",
    "statement": "BMI ≤ 40 kg/m2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04573920",
    "statement": "For patients enrolling in Alport syndrome Cohort:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04573920",
    "statement": "Diagnosis of Alport syndrome by genetic testing",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04573920",
    "statement": "UPCR > 0.5 g/g",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04573920",
    "statement": "Screening eGFR ≥ 30 mL/min/1.73 m2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04573920",
    "statement": "For patients enrolling in DKD Cohort:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04573920",
    "statement": "Diagnosis of type 2 diabetes mellitus",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04573920",
    "statement": "UACR ≥ 0.5 g/g",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04573920",
    "statement": "Screening eGFR ≥ 45 mL/min/1.73 m2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04573920",
    "statement": "Receiving a stable dose of SGLT2 inhibitor for at least 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04573920",
    "statement": "Willing and able to provide informed consent and comply with all study requirements",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04573920",
    "statement": "Current diagnosis of another cause of chronic kidney disease or another primary glomerulopathy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04573920",
    "statement": "History of kidney transplantation or other organ transplantation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04573920",
    "statement": "Except for FSGS patients, use of systemic immunosuppressant medications, such as steroids, for more than 2 weeks in the past 3 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04573920",
    "statement": "Blood pressure above 150 mmHg systolic or 95 mmHg diastolic as evaluated by the Investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04573920",
    "statement": "History of heart failure or a previous hospital admission for fluid overload.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04573920",
    "statement": "Clinically significant history of liver disease as assessed by the Investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04573920",
    "statement": "Hemoglobin below 9 g/dL as measured by the Investigator or blood transfusion for anemia within the past 3 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04573920",
    "statement": "Clinical diagnosis of nephrotic syndrome",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04573920",
    "statement": "Malignancy within the past 5 years. Exception to the criteria include nonmelanoma skin cancer and curatively treated cervical carcinoma in situ.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04573920",
    "statement": "For women, pregnant, breastfeeding, or intent to become pregnant during the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04573920",
    "statement": "For men, intent to father a child or donate sperm during the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04573920",
    "statement": "Recently received an investigational agent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04573920",
    "statement": "Clinically significant unstable or uncontrolled medical condition as assessed by the Investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153023",
    "statement": "Exclusion Criteria: None",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153023",
    "statement": "Type 2 diabetes mellitus",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153023",
    "statement": "Aged 30-70 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153023",
    "statement": "Hypertension at screening defined as:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153023",
    "statement": "an average cuff systolic blood pressure > 130 mmHg and/or diastolic blood pressure >80 mmHg in untreated patients OR",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153023",
    "statement": "patients receiving antihypertensive therapy (i.e., medications specifically prescribed to treat hypertension)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153023",
    "statement": "Overt nephropathy defined by 24 hour proteinuria >= 900 mg and by serum creatinine below 265 mol/l (3.0 mg/dl)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "NOTE: Availability of lab results within the 30 days of Screening is acceptable.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Provide written informed consent, which will consist of reading, signing, and dating the informed consent document after the Investigator, sub-Investigator or other designated study staff member has explained the study procedures, risks, and contact information.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Eighteen (18) years of age or older, of either sex, and of any race or skin type.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Willing and able to make all required study visits.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Able to follow instructions and perform the dressing changes at home or have a caregiver who can perform the dressing changes according to the protocol.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Subject is currently being treated in an in-patient acute care setting.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Willing to use an appropriate off-loading device to keep weight off of foot ulcers; currently receiving adequate pressure redistribution according to local protocol in the affected area for pressure ulcers.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "For DFU: An ulcer present on any part of the plantar surface of the foot or plantar surface of the hallux which is 0.5 cm2 - 10 cm2 inclusive (as measured at the Screening Visit using the ARANZ Silhouette imaging device). For PU: Stage II-IV ulcer that is 1 cm2 to 64 cm2 inclusive (as measured at the Screening Visit using the ARANZ Silhouette imaging device). - Subjects may have more than one ulcer without limitation on the ulcer burden, but only one qualifying ulcer per subject will be selected for the study (selection based on greatest clinical need, as determined by the Investigator).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "For lower extremity ulcers: Adequate arterial blood flow as evidenced by an ankle brachial index (ABI) of > 0.70 and ≤ 1.2. If ABI > 1.2, perfusion at or near the site of the ulcer must be confirmed: i.e., the foot is warm to the touch and has palpable pulses. Availability of an ABI completed within the 90 days of Screening is acceptable.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Separation of at least 5 cm (closest ulcer edge to other closest ulcer edge) as measured using the ARANZ Silhouette imaging device if ≥ 2 ulcers are present.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Target ulcer is not infected based on clinical assessment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Contraindications or hypersensitivity to the use of clostridial collagenase.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Participation in another clinical trial within thirty (30) days of Screening, or planned participation overlapping with this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Bleeding disorder that would preclude sharp debridement during the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Active cellulitis of the target ulcer, lymphangitic streaking, deep tissue abscess, or infection of muscle, tendon, joint or bone.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Co-morbidities leading to systemic organ dysfunction or severe single- or multi-organ failure that in the opinion of the Investigator would preclude safe subject participation in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "A target ulcer which involves the underlying tissues of tendon.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Diagnosis of chronic granulomatous disease, leukocyte adhesion defects, or severe neutropenia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Current treatment (at the time of the Screening Visit) with any of the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Systemic corticosteroids. If corticosteroid treatment was for ≥ 10 days, there must be a 1 week interval between discontinuation and screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Immunosuppressive agents",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Chemotherapeutic agents",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Antiviral agents",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Systemic antibiotic therapy for acute wound-related infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Topical antibiotic treatment of the target ulcer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Treatment of target ulcer with bioactive therapies within 1 month of screening:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Platelet-derived growth factor (e.g., Regranex)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Cellular or Tissue-based Products (e.g., Apligraf, Dermagraft, Integra, Oasis, etc.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Amniotic membrane products (e.g., EpiFix, Grafix, etc.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Prior treatment of target ulcer for any length of time with CCO (SANTYL) within 30 days of screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Any prior radiation therapy to the affected area",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Medical or physical condition that, in the opinion of the Investigator, would preclude safe subject participation in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Blood counts and blood chemistry values as follows:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Alanine aminotransferase (ALT) > 3x upper limit of normal",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Aspartate aminotransferase (AST) > 3x upper limit of normal",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Gamma Glutamyl Transferase (GGT) > 2.5x upper limit of normal",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Serum albumin < 2.0 g/dL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Pre-albumin levels of < 10 mg/dL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Alkaline phosphatase > 500 U/L",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Serum total bilirubin > 3.0 mg/dL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Serum BUN > 75 mg/dL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Serum creatinine > 4.5 mg/dL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "HbA1c > 12%",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Hemoglobin (Hgb) < 8.0 g/dL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "WBC < 2.0 x 109/L",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Absolute neutrophil count < 1.0 x 109/L",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02716519",
    "statement": "Platelet count < 50 x 109/L",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "Body weight between 50 and 95 kg, inclusive, body mass index between 18.5 and 29 kg/m², inclusive.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "Fasting serum C-peptide <0.3 nmol/L.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "Glycohemoglobin (HbA1c) ≤75 mmol/mol (≤9%).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "Stable insulin regimen for at least 2 months prior to study (with respect to safety of the patient and scientific integrity of the study).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "Certified as otherwise healthy for T1DM patient by assessment of medical history and physical examination (cardiovascular system, chest and lungs, thyroid, abdomen, nervous system, skin and mucosae, and musculoskeletal system), unless the Investigator considers any abnormality to be clinically irrelevant and not interfering with the conduct of the study (with respect to safety of the subject and scientific integrity of the study).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "Normal vital signs after at least 10 minutes resting in supine position:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "95 mmHg <systolic blood pressure (SBP) <150 mmHg.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "45 mmHg <diastolic blood pressure (DBP) <95 mmHg.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "50 bpm <heart rate (HR) <90 bpm.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "Normal standard 12-lead electrocardiogram (ECG) after at least 10 minutes resting in supine position; 120 ms <PR <220 ms, QRS <120 ms, QTc ≤450 ms if male, ≤470 ms if female.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "Laboratory parameters within the normal range (or defined screening threshold for the Investigator site), unless the Investigator considers an abnormality to be clinically irrelevant for diabetes patients; however serum creatinine should be strictly below the upper laboratory norm; alkaline phosphatase, hepatic enzymes (aspartate aminotransferase, alanine aminotransferase), and total bilirubin (unless the patient has documented Gilbert syndrome) should not be above 1.5 x upper limit of normal (ULN).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "Women of childbearing potential (less than 2 years postmenopausal or not surgically sterile for more than 3 months), must have a negative serum beta-human chorionic gonadotropin (β-HCG) pregnancy test at screening and a negative urine β-HCG pregnancy test at Day 1 in all treatment periods (TPs) and must use a highly effective method of birth control, which is defined as those which result in a low failure rate (ie, less than 1% per year) according to the Note for guidance on nonclinical safety studies for the conduct of human clinical trials for pharmaceuticals (CPMP/ICH/286/95, modifications). During the entire study female subjects of childbearing potential must use 2 independent methods of contraception, eg, diaphragm and spermicide-coated condom. The use of a condom and spermicidal creams is not sufficiently reliable. For postmenopausal women with presence of less than 2 years post menopausal, and not surgically sterile for more than 3 months, the hormonal status will be determined (follicle-stimulating hormone [FSH] >30 IU/L).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "Having given written informed consent prior to undertaking any study-related procedure.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "Covered by a health insurance system where applicable, and/or in compliance with the recommendations of the national (German) laws in force relating to biomedical research.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "Not under any administrative or legal supervision.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "Nonsmoking at least for the last 6 months before screening (to be confirmed by serum cotinine <25 µg/L or urine <500 µg/L).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "Pulmonary function test at screening: forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) greater than or equal to 70% of the individual prediction according to the equation of the Third National Health and Nutrition Examination Survey (NHANES III).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic (apart from T1DM), hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynecologic (if female), or infectious disease, or signs of acute illness.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "Severe hypoglycemia resulting in coma/seizures or requiring assistance of another person, and/or hospitalization for diabetic ketoacidosis in the last 6 months before screening visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "Frequent headaches and/or migraine, recurrent nausea and/or vomiting (more than twice a month).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "Blood donation, any volume, within 3 months before inclusion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "Symptomatic postural hypotension, irrespective of the decrease in blood pressure, or asymptomatic postural hypotension defined as a decrease in systolic blood pressure ≥20 mmHg within 3 minutes when changing from supine to standing position.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "Presence or history of drug hypersensitivity, or allergic disease diagnosed and treated by a physician.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "History or presence of drug or alcohol abuse (alcohol consumption more than 40 g per day).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "Excessive consumption of beverages containing xanthine bases (more than 4 cups or glasses per day).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "If female, pregnancy (defined as positive β-HCG blood test), breastfeeding at screening and before any treatment periods (defined as positive β-HCG urine test).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "Any medication (including St John's Wort) within 14 days before inclusion or within 5 times the elimination half-life or PD half-life of the medication, with the exception of insulin, stable treatment (at least 2 months) with thyroid hormones, lipid-lowering and antihypertensive drugs and if female with the exception of hormonal contraception or menopausal hormone replacement therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "Any vaccination within the last 28 days.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "Any patient who, in the judgment of the Investigator, is likely to be noncompliant during the study, or unable to cooperate because of a language problem or poor mental development.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "Any patient in the exclusion period of a previous study according to applicable regulations.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "Any patient who cannot be contacted in case of emergency.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "Any patient who is the Investigator or any sub-Investigator, research assistant, pharmacist, study coordinator, or other staff thereof, directly involved in conducting the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "Positive result on any of the following tests: hepatitis B surface antigen (HBs Ag), antihepatitis C virus (anti-HCV) antibodies, anti-human immunodeficiency virus 1 and 2 antibodies (anti-HIV1 and anti HIV2 Ab).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "Positive result on urine drug screen (amphetamines/methamphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates, and cotinine).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "Positive alcohol test.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "Presence or history of any acute or chronic obstructive bronchopulmonary disease (COPD) including asthma, cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "Upper respiratory tract infection within 8 weeks before screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "Known hypersensitivity to Afrezza TI and excipients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "Inability, in the opinion of the Principal Investigator or a designee, to adequately inhale Afrezza powder.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02485327",
    "statement": "Any history or presence of deep leg vein thrombosis or a frequent appearance of deep leg vein thrombosis in first-degree relatives (parents, siblings, or children).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Body mass index (BMI) ≥ 27 and ≤ 40 kg/m2 (inclusive) at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Glycated haemoglobin (HbA1c) ≤ 8.0% at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Diagnosed with T2DM with glucose control managed with metformin monotherapy where no significant dose change (increase or decrease ≥ 500 mg/day) has occurred in the 3 months prior to screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Any subject who has received another investigational product as part of a clinical study or a GLP-1 analogue-containing preparation within the last 30 days or 5 half-lives of the drug (whichever is longer) at the time of screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Any subject who has received any of the following medications prior to the start of the study:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Herbal preparations or drugs licensed for control of body weight or appetite (eg, orlistat, bupropion naltrexone, phentermine-topiramate, phentermine, lorcaserin)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Opiates, domperidone, metoclopramide or other drugs known to alter gastric emptying",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Glucagon",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Warfarin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Any contraindication to magnetic resonance imaging/MRS scanning including claustrophobia or dislike of confined spaces",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Symptoms of acutely decompensated blood glucose control (eg, thirst, polyuria, weight loss), a history of type 1 diabetes mellitus (T1DM) or diabetic ketoacidosis, or if the subject has been treated with daily SC insulin within 90 days prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Recurrent unexplained hypoglycaemic episodes (defined as glucose < 3.0 mmol/L or < 54 mg/dL on more than 2 occasions in 6 months prior to screening)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Significant inflammatory bowel disease, gastroparesis, or other severe disease or surgery affecting the upper GI tract (including weightreducing surgery and procedures) which may affect gastric emptying or could affect the interpretation of safety and tolerability data",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Acute or chronic pancreatitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Significant hepatic disease (except for NASH or nonalcoholic fatty liver disease without portal hypertension or cirrhosis) and/or subjects with any of the following results at screening:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Aspartate transaminase (AST) ≥ 3 × upper limit of normal (ULN)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Alanine transaminase (ALT) ≥ 3 × ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Total bilirubin ≥ 2 × ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Impaired renal function defined as estimated glomerular filtration rate (eGFR) < 30 mL/minute/1.73m2 at screening (glomerular filtration rate estimated according to Modification of Diet in Renal Disease (MDRD) using MDRD Study Equation IDMS-traceable (International System of Units [SI] units)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Poorly controlled hypertension defined as:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Systolic blood pressure (BP) > 180 mm Hg",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Diastolic BP > 105 mm Hg After 10 minutes of supine rest and confirmed by repeated measurement at screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Unstable angina pectoris, myocardial infarction, transient ischemic attack or stroke within 3 months prior to screening, or subjects who have undergone percutaneous coronary intervention or a coronary artery bypass graft within the past 6 months or who are due to undergo these procedures at the time of screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Severe congestive heart failure (New York Heart Association Class III or IV)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Basal calcitonin level > 50 ng/L at screening or history/family history of medullary thyroid carcinoma or multiple endocrine neoplasia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "History of neoplastic disease within 5 years prior to screening, except for adequately treated basal cell, squamous cell skin cancer, or in situ cervical cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Any positive results for serum hepatitis B surface antigen (HBsAg), hepatitis C antibody and human immunodeficiency virus (HIV) antibody",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03555994",
    "statement": "Substance dependence or history of alcohol abuse and/or excess alcohol intake (defined as > 21 units per week for a male subject, and >14 units per week for a female subject). Subjects must have a negative alcohol test result at screening and prior to randomisation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "Japanese male or female patients with T2DM treated with diet and exercise alone or with one hypoglycaemic drug other than glitazones.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "Hemoglobin A1c (HbA1c) at screening (Visit 1)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "For patients treated with 1 other oral antidiabetic drug: HbA1c between 6.5% and 9.0%.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "For patients not treated with any antidiabetic drug: HbA1c between 7.0% and 10.0%.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "Age between 20 and 70 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "Body mass index (BMI) between18.0 and 40.0 kg/m2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "Signed and dated written informed consent before admission to the trial in accordance with the Good Clinical Practice (GCP) and the local legislation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "Antidiabetic treatment with insulin or glitazones within 3 months before obtaining informed consent or with more than 1 oral hypoglycaemic agent at the time of informed consent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "Fasted blood glucose of >240 mg/dL (>13.3 mmol/L) or a randomly determined blood glucose level of >400 mg/dL (22.2 mmol/L) on 2 consecutive days during wash-out period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "Myocardial infarction, stroke, or transient ischaemic attack within 6 months before informed consent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "Clinically relevant concomitant diseases other than T2DM, hyperlipidaemia, and medically treated hypertension before the first administration such as",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "Renal insufficiency (calculated estimated glomerular filtration rate <60)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "Cardiac insufficiency of New York Heart Association (NYHA) II-IV or other known cardiovascular diseases including hypertension of >160/95 mmHg,",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "Neurological disorders (such as epilepsy) or psychiatric disorders",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "Acute or clinically relevant chronic infections (e.g., human immunodeficiency virus, hepatitis, repeated urogenital infections)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "Any gastrointestinal, hepatic, respiratory, endocrine, or immunological disorder",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "Patients under treatment with any concomitant medication except for the following drugs at the time of informed consent.:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "Statins.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "Antihypertensives (diuretics not allowed)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "alpha-Blockers for benign prostate hypertrophy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "Occasional use of acetylsalicylic acid, ibuprofen, or paracetamol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "Additional inclusion/exclusion criteria apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05881213",
    "statement": "Healthy adults aged between 19 and 55 years at screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05881213",
    "statement": "Those whose body weight 55 kg or over for men and 50 kg or over for women.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05881213",
    "statement": "Those with body mass index (BMI) was more than 18.5 kg/m2 and less than 27.0 kg/m2. ※ BMI (kg/m2) = body weight (kg)/ [height (m)]2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05881213",
    "statement": "If women, those who met any one of the following criteria.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05881213",
    "statement": "Menopause (no natural menstruation for at least 2 years)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05881213",
    "statement": "Surgical infertility (hysterectomy or bilateral oophorectomy, tubal ligation, or infertility by other methods)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05881213",
    "statement": "Male subjects with female sexual partners of childbearing potential must agree to use methods of birth control (using condom) and not donate sperm during the study and for up to 28 days after the last administration of the IP (unless the male subjects or their female partners are infertile).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05881213",
    "statement": "Subjects who have voluntarily given written informed consent to participate in the study and comply with all study requirements after getting a detailed explanation and full understanding of the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05881213",
    "statement": "Subjects with history or current conditions of clinically significant disease, including hepatobiliary (e.g., severe hepatic dysfunction, etc.), renal (e.g., severe renal insufficiency, etc.), nervous, immune, respiratory (e.g., bronchial asthma) urinary, gastrointestinal, endocrine (e.g., patients with diabetic ketoacidosis, diabetic coma and pre-coma, and type 1 diabetes mellitus, etc.), hemato-oncology, or cardiovascular (e.g., heart failure, etc.) or psychiatric disorders.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05881213",
    "statement": "Subjects who are susceptible to dehydration due to inadequate oral intake or who have clinically significant dehydration.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05881213",
    "statement": "Subjects who underwent a test using intravenous administration of radioiodine contrast media (e.g., intravenous urography, venous cholangiography, angiography, or computed tomography using a contrast medium) within 48 hours prior to the first IP administration.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05881213",
    "statement": "Subjects with a history or current conditions of serious urinary tract infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05881213",
    "statement": "Subjects with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05881213",
    "statement": "Subjects with a history of gastrointestinal disorders (e.g., Crohn's disease, ulcerative colitis, etc.) or surgery (except simple appendectomy or hernia surgery) that may affect the absorption of IP.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05881213",
    "statement": "Subjects with a history of clinically significant hypersensitivity to drugs, including components of the IPs (empagliflozin or metformin) or additives.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05881213",
    "statement": "Subjects who were deemed unfit for participation in this study based on the following findings in the screening tests performed within 28 days before the first IP administration.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05881213",
    "statement": "Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) values > 1.25 times the upper limit of normal range.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05881213",
    "statement": "Estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2 when calculated with the modification of diet in renal disease (MDRD) formula.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05881213",
    "statement": "Positive result for hepatitis B, hepatitis C, human immunodeficiency virus (HIV), or syphilis infection test.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05881213",
    "statement": "Systolic blood pressure > 150 mmHg or <90 mmHg, or diastolic blood pressure > 100 mmHg or <50 mmHg which is measured in sitting position after resting for more than 5 minutes.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05881213",
    "statement": "Subjects with a history of drug abuse within a year prior to screening or positive results in urine drug screening tests.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05881213",
    "statement": "Women who are pregnant or breast-feeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05881213",
    "statement": "Subjects who took the following drugs, excluding the topical agents without significant systemic absorption, within the predefined period the investigator judges they could affect the results of the study or compromise the safety of the subject.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05881213",
    "statement": "Any prescription drugs and herbal medicines within 14 days before the first IP administration.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05881213",
    "statement": "Any over-the-counter drugs including health care foods or vitamins within 7 days before the first IP administration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05881213",
    "statement": "Any drugs administered by depot injection or other implantation into the body within 30 days before the first IP administration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05881213",
    "statement": "Subjects who took any drugs that induce or inhibit drug metabolizing enzymes, such as barbital drugs, within 30 days before the first IP administration.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05881213",
    "statement": "Subjects with excessive smoking (>10 cigarette/day), caffeine intake (caffeine:>5 cups/day), or drinking (alcohol: >210 g/week) or who cannot stop from smoking, caffeine intake, and drinking during the hospitalization period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05881213",
    "statement": "Subjects who have consumed foods containing grapefruit within 7 days prior to the first IP administration or cannot stop consuming foods containing grapefruit during the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05881213",
    "statement": "Subjects who were administered any other IPs by participating in other clinical trials within 180 days before the first IP administration (in the case of biological agent, taking account of its half-life, this period can be extended).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05881213",
    "statement": "Subjects who donated whole blood within 60 days or blood components for apheresis within 30 days before the first IP administration.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05881213",
    "statement": "Subjects who received blood transfusion within 30 days before the first IP administration.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05881213",
    "statement": "Subjects judged by the investigators unsuitable for participating in the study based on any other reasons.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05897216",
    "statement": "Those who voluntarily decide to participate and agree to comply with the cautions after fully understand the detailed description of this clinical trial.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05897216",
    "statement": "Healthy adult who aged 19 to 55 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05897216",
    "statement": "Those who meet the criteria of anthropometric data",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05897216",
    "statement": "Man: Body weight ≥ 50 kg, Body mass index 18 to 30 kg/m2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05897216",
    "statement": "Woman: Body weight ≥ 45 kg, Body mass index 18 to 30 kg/m2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05897216",
    "statement": "Those who have medical history of hypersensitivity to active pharmaceutical ingredient (Lobeglitazone, Sitagliptin, Metformin) or additives.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05897216",
    "statement": "Those who have clinically significant disease or medical history of Hepatopathy, Renal dysfunction, Neurological disorder, Immunity disorder, Respiratory disorder, Genitourinary system disorder, Digestive system disorder, Endocrine system disorder, Cardiovascular disorder, Blood tumor, Psychical disorder, Severe urinary tract infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05897216",
    "statement": "Those who have past medical history of gastrointestinal disorder (Crohn's disease, ulcerative colitis, etc. except simple appendectomy or hernia surgery), which affect the absorption of drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05897216",
    "statement": "Those who have Drug abuse (especially sleeping drugs, central analgesics, opiates or psychotropic drugs such as psychotropic drugs) or persons with a history of substance abuse.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05897216",
    "statement": "Those who have the test results written below",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05897216",
    "statement": "AST, ALT > 2 times higher than upper normal level",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05897216",
    "statement": "Total bilirubin > 2 times higher than upper normal level",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05897216",
    "statement": "eGFR (estimated Glomerular Filtration Rate, which is calculated by MDRD) < 60 mL/min/1.73m2",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05897216",
    "statement": "\"Positive\" or \"Reactive\" test result of Hepatitis B & C, HIV, RPR",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05897216",
    "statement": "Under 3 min resting condition, systolic blood pressure >160 mmHg or <90 mmHg, diastolic blood pressure >100 mmHg or <50 mmHg",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05897216",
    "statement": "Those who have determined that the abnormal results are clinically significant in the screening test items (question, vital signs, electrocardiogram, physical test, blood, urine test, etc.).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05897216",
    "statement": "Those who participated in other clinical trials within 180 days of the intended study drug administration and have been administered clinical trial medications (except for those who have not taken the study medication).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05897216",
    "statement": "Those who has taken a drug (Ethical drug, over the counter drug, herbal medicine, or nutritional supplement (vitamin, etc.)) within 14 days prior to first investigational product administration (however, if it is considered that it does not affect the safety and research results of the subject, as determined by the investigator).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05897216",
    "statement": "Those who donated whole blood within 8 weeks prior to first investigational product administration, or who donated or donated components (plasma, platelets) within 4 weeks, and consented to prohibit blood donation from 30 days after the last administration of investigational product.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05897216",
    "statement": "Those who have continuously consumed more than 21 units/week (1 unit of alcohol = 10 g = 12.5 mL) within 6 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05897216",
    "statement": "Those who have more than 10 smokers a day within 6 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05897216",
    "statement": "Those who cannot use clinically acceptable contraceptive methods (e.g., infertility surgery between themselves and partners, intrauterine contraceptive devices, use of diaphragms or condoms) from the time the drug is administered to the last visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05897216",
    "statement": "Those who cannot inhibit the diet (especially grapefruit juice, caffeine) that can affect the absorption, distribution, metabolism, and excretion of the drug from 3 days before the first administration of the investigational product to the last visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05897216",
    "statement": "Those who have genetic problems such as galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05897216",
    "statement": "Those who receive intravenous administration of radioactive iodine contrast agents (for intravenous urography, venous cholangiography, angiography, computed tomography using contrast agents, etc.) within 48 hours before the first administration of investigational product.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05897216",
    "statement": "Those who are pregnant or breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05897216",
    "statement": "Those who are deemed inappropriate to participate in clinical trial by investigators.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01726621",
    "statement": "Subject is 7 years or older at time of screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01726621",
    "statement": "Subject is current insulin pump user for at least 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01726621",
    "statement": "Subject has the following Continuous Glucose Monitoring experience as determined by the Investigator:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01726621",
    "statement": "Has experience and is able to insert/change sensor by herself/himself and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01726621",
    "statement": "Has experience and can recharge the transmitter and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01726621",
    "statement": "Has experience and can read sensor data in real-time on her/his pump screen",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01726621",
    "statement": "Subject has signed a Patient Informed Consent form and is willing to comply with the study procedures;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01726621",
    "statement": "Subject is willing to complete study questionnaires throughout the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01726621",
    "statement": "Must have one of the following clinical diagnosis:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01726621",
    "statement": "Type 1 diabetes, for a minimum of 6 months prior to enrollment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01726621",
    "statement": "Insulin requiring type 2 diabetes, for a minimum of 6 months prior to enrollment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01726621",
    "statement": "Female subject has a positive urine pregnancy screening test.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01726621",
    "statement": "Female subject who plans to become pregnant during the course of study. If a woman becomes pregnant during participation, she will be withdrawn",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01726621",
    "statement": "Subject has any condition that, in the opinion of the Investigator or qualified Investigational Center staff, may preclude him/her from participating in the study and completing study related procedures.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01726621",
    "statement": "Subject has impaired vision or hearing problems that could compromise the handling of the device as determined by Investigator or qualified Investigational Center staff",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01726621",
    "statement": "Subject is actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or investigational study device in the last 2 weeks.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Drugs and Alcohol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Healthy male subjects aged 18 to 55 years inclusive.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Body Mass Index (BMI) is between 19-35kg/m2 (inclusive), with a minimum body weight of 45kg.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Subject must read and write at a comprehension level that is sufficient to provide written informed consent, and be able to understand and comply with protocol requirements, instructions and protocol-stated restrictions.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Subject has provided informed consent to participate in the study as indicated by providing a signed and dated written informed consent form prior to the initiation of any study procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "General",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Presence of any clinically relevant abnormality identified on the screening medical assessment, laboratory examination or 12-lead ECG, or any other medical condition or circumstance making the volunteer unsuitable for participation in the study. These include any unstable medical disorder; disorders that would interfere with the action, absorption, distribution, metabolism, or excretion of bupropion or GSK189075; disorders which may pose a safety concern or interfere with the accurate assessment of safety or efficacy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Laboratory",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Clinically significant abnormalities at Screening including:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Systolic blood pressure outside the range of 90 - 140 mmHg, diastolic blood pressure outside the range of 50 - 90 mmHg, and pulse rate at rest > 100 and < 45 bpm.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Positive tests for hepatitis B surface antigen, hepatitis C antibodies, and HIV.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Positive cotinine, drug and/or alcohol test.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Significant ECG abnormalities are defined as follows:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Parameter Range",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Heart Rate < 40 and >100 bpm",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "PR Interval <120 and > 220 ms",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "QRS duration < 70 and >120 ms",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "QTC Interval (Bazett) > 450 ms",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "ALT, alkaline phosphatase, or total bilirubin ³ 1.5 times the upper limits of normal (Note: Subjects with an increased total bilirubin may enter the study only if direct bilirubin is within normal limits).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Fasting triglycerides >400 mg/dL (>11.3 mmol/L).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Clinically significant abnormalities of T3 and TSH.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Serum creatinine clearance <60ml/min (estimated from serum creatinine (SCr) and demographic data using the MDRD calculation):",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "A validated web-based calculator is found at:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "http://nephron.com/cgi-bin/MDRDSIdefault.cgi",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "To calculate estimated GFR (mL/min/1.73m2) manually:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "= 186 x (SCr in mg/dL)-1.154 x (age)-0.203 x (0.742 if female) x (1.210 if African-American)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "= exp(5.228-1.154 x ln (SCr)-0.203x ln(age)-(0.299 if female) + (0.192 if African American))",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Any other clinically significant laboratory abnormality as determined by the Principal Investigator in consultation with the GSK Medical Monitor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Central Nervous System",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Current diagnosis or a previous history of mania, psychosis, major depression, or other major psychiatric disorder.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Current or past history of seizure disorder or brain injury (traumatic or disease-related); or any condition which, in the opinion of the investigator, predisposes to seizure; those treated with other medications or treatment regimes that lower seizure threshold; those undergoing abrupt discontinuation of alcohol or sedatives (including benzodiazepines or benzodiazepine-like agents).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Note: A single childhood febrile seizure is not exclusionary.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "History or current diagnosis of anorexia nervosa or bulimia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Subjects who, in the investigator's judgement, pose a homicidal or suicidal risk, have ever made a suicide attempt, or have ever been homicidal.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Hepatic and Gastrointestinal systems",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "History of hepatic disease or known hepatic or biliary abnormalities, (with the exception of previously documented diagnosis of Gilbert's syndrome) and/or a history of biliary or gastrointestinal disorder, which might affect absorption, distribution, metabolism, or excretion of drugs (except appendectomy or cholecystectomy more than 12 weeks prior to the study).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Endocrine system",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Untreated or unstable thyroid disease. Subjects taking thyroid medications must be on a stable dosing regimen for at least 4 weeks prior to the first dose of study drug until completion of the Follow-up visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Cardiac system",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Subject has a history of clinically significant cardiac rhythm disorder or QTc interval ³450 milliseconds at Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Subject has history of ischemic heart disease, including stable/unstable angina or acute myocardial infarction.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Uncontrolled hypertension with systolic blood pressure >140mm Hg and diastolic blood pressure >90mm Hg.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Subject has a history of alcohol abuse or an average weekly intake of greater than 21 units per week (one unit = 1 glass of wine = 1 measure of spirits = ½ pint of beer).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Unwilling or unable to abstain from the use of illicit drugs and adhere to other protocol-stated restrictions while participating in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Use of tobacco in any form (smoking cigarettes, cigars, and/or pipes, or chewing tobacco-containing products), for 4 weeks prior to Screening until completion of the Follow-up visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Unwilling or unable to abstain from the use of prescription or non-prescription drugs, vitamins, or dietary/herbal supplements within 1 week prior to the first dose of study drug until completion of the Follow-up visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Subject is currently using medications that may alter gastric/small bowel motility, result in diarrhea, or bind concomitant medications. For example, but not limited to: erythromycin, antacids, prokinetic agents and cholestyramine.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Subject has a history of drug or other allergy that, in the opinion of the Principal Investigator, contraindicates their participation in this study. • Concomitant medications usage that includes:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Use of agents that are known to inhibit or induce cytochrome P450 enzymes within 14 days prior to the first dose of study medication , including grapefruit-containing products and St. John's Wort.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Use of bupropion hydrochloride or GSK189075 within the last 6 months prior to Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Use of anti-depressant medication for clinically significant depression.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 7 days prior to the first dose in Treatment Period 1, unless in the opinion of the Investigator and Sponsor the medication will not interfere with the study procedures or compromise subject safety.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Note: Occasional use of acetaminophen and ibuprofen according to directions provided in the product label may be acceptable during the study, at the discretion of the Principal Investigator. Acetaminophen will be limited to doses up to 2 grams/day and ibuprofen at doses up to 1.2 grams/day.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Drug hypersensitivity",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "History of hypersensitivity to WELLBUTRIN SR, ZYBAN, GSK189075 or any of their constituents or closely related compounds.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "History of sensitivity to heparin or heparin-induced thrombocytopenia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Other",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Past treatment with a new molecular entity (investigational drug) or any other trial during the previous 30 days, or 5 half-lives, whichever is longer. A new molecular entity is defined as any compound not in Phase 3. (The washout period of 30 days is counted from the last dose of study drug in the previous study until the first dose of study drug).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Participation in the study would result in subject's donation of blood in excess of 500mL within a 56-day period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "Adult aged 19 to 80 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "Those diagnosed with type 2 diabetes",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "A person who provides diet and exercise therapy for the management of diabetes from 8 weeks before the screening criteria and can continue diet and exercise therapy during the clinical trial",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "Screening Results of the following criteria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "7% ≤ HbA1c ≤ 10%",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "FPG ≤ 270 mg/dL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "Patients with 20 < BMI ≤ 45 kg/㎡",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "Those who voluntarily signed the informed consent to participate in this study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "Any type of diabetes other than type 2 diabetes",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "Screening when the inspection meets the following criteria",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "AST or ALT more than 3 times the normal upper limit",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "Total bilirubin exceeds twice the normal upper limit",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "eGFR < 60 mL/min/1.73㎡",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "A person with the following medical history or history of surgery/therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "Medically significant history of kidney disease: kidney vascular obstruction disease, nephrectomy, kidney transplantation, etc",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "History of severe gastrointestinal surgery: total gastrectomy, total colon resection, small intestine resection, gastrointestinal anastomosis, gastrointestinal bypass, etc",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "history of acute pancreatitis or pancreatic surgery",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "History of undergoing bariatric surgery within 2 years before screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "Diabetic ketoacidosis, diabetic coma or whole marriage within 1 year prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "Urinary tract infections or genital infections within 1 year prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "Alcohol or drug addiction within 1 year prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "A history of severe heart disease (heart failure, unstable angina, myocardial infarction, congestive heart failure symptoms",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "A person who has a history of significant surgery that causes electrolyte imbalance within 12 weeks before screening, or who is scheduled to undergo significant surgery within 12 weeks after the end of the clinical trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "Hypertension emergency medical history within 12 weeks prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "There is a weight change of more than 10% within 12 weeks prior to screening, and symptoms of polyuria and bipolar disorder",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "A person with a history of malignancy within 5 years prior to screening However, a complete cure or properly controlled basal cell cancer, squamous cell skin cancer, or cervical intraepithelial cancer is allowed, but the history of bladder cancer cannot participate even if it has been more than 5 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "A person who has the following diseases or signs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "Dysuria that is not medically controlled due to tense urinary incontinence, neurotic bladder, prostate hypertrophy, or symptoms of anuria, oliguria, urinary retention",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "Severe diabetic complications (proliferative diabetic retinopathy, nephropathy above stage 4 or severe diabetic neuropathy)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "Chronic diseases that require continuous use of diuretics, systemic steroids or immunosuppressants (alveolar administration, injection)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "Active liver disease, hepatitis, liver failure or cirrhosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "Patients with pituitary or adrenal insufficiency",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "Severe infections requiring the use of persistent antibiotics or immunotherapy drugs, and significant clinically trauma",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "an unstable mental illness that is not medically controlled",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "Severe gastrointestinal diseases: active ulcers, gastrointestinal/intestinal bleeding, active inflammatory bowel syndrome, patients with biliary obstruction, active gastritis not controlled by medication, etc",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "A person who has a history of hypersensitivity to the ingredients of a clinical trial drug, SGLT1/SGLT2 inhibitor or SGLT-2 inhibitor",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "Pregnant or lactating women",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "Participants in interventional clinical trials subject to other IP or medical devices within 12 weeks prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06144788",
    "statement": "If the investigator is deemed unsuitable for the subject of this clinical trial due to other reasons",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Men and women aged 19 years or older as of the date of written consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Patients with type 2 diabetes who have been on up to 3 antidiabetic medications at a stable dosage and regimen for at least 8 weeks prior to the Pre-Baseline Visit (Visit 1-1). For insulin, a fluctuation of within 10% during the 8 weeks prior to the Pre-Baseline Visit (Visit 1-1) is allowed.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Patients with a BMI of 18 to 45 kg/m² at the Screening Visit (Visit 1).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Patients whose test results from the investigational site&#39;s laboratory at the Screening Visit (Visit 1) meet all of the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "HbA1c: 7.0% ≤ HbA1c ≤ 10.0%",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "eGFR: 30 ≤ eGFR &lt; 60 ml/min/1.73 m² (using the CKD-EPI formula)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Patients who are willing to cooperate and participate in this clinical trial after understanding the explanation of the trial and who can voluntarily sign the informed consent form.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Patients whose central laboratory results from the sample collected at the Pre-Baseline Visit (Visit 1-1) show an eGFR of 30 ≤ eGFR &lt; 60 ml/min/1.73 m² (using the CKD-EPI formula).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Patients whose central laboratory results from the sample collected at the Pre-Baseline Visit (Visit 1-1) show an HbA1c of 7.0% ≤ HbA1c ≤ 10.0%.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Patients with a medication compliance rate of 70-130% during the Run-in Period, as confirmed at the Baseline Visit (Visit 2).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Individuals diagnosed with renal diseases other than diabetic chronic kidney disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Patients with uncontrolled hypertension (SBP ≥ 180 mmHg or DBP ≥ 110 mmHg)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Individuals diagnosed with type 1 diabetes (insulin-dependent diabetes) or diabetic ketoacidosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Individuals who are undergoing dialysis at the time of the Screening Visit (Visit 1) or have a history of renal transplantation or medically significant renal disease/surgery (e.g., renal vascular occlusive disease, nephrectomy)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Individuals who have received cytotoxic treatment, immunosuppressive therapy, or immunotherapy for renal disease within 6 months of the Baseline Visit (Visit 2)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Individuals diagnosed with or treated for any of the following diseases within 3 months of the Screening Visit (Visit 1), as determined by the investigator to be clinically significant:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Severe heart disease [heart failure (NYHA class III and IV), ischemic heart disease (angina, myocardial infarction), peripheral vascular disease, individuals who have undergone percutaneous transluminal coronary angioplasty or coronary artery bypass grafting] * NYHA class:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Class I: No limitation on physical activity; no symptoms during ordinary activities",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Class II: Slight limitation on physical activity; no symptoms at rest, but symptoms occur during ordinary activities",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Class III: Marked limitation on physical activity; no symptoms at rest, but symptoms occur with less than ordinary activities",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Class IV: Symptoms present even at rest, and worsened by any physical activity",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, hemodynamically significant aortic or mitral valve stenosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Clinically significant ventricular tachycardia, atrial fibrillation, atrial flutter, arrhythmia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Transient ischemic attack",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Severe cerebrovascular diseases (e.g., stroke, cerebral infarction, cerebral hemorrhage)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Individuals requiring treatment due to dehydration from continuous diarrhea or vomiting, or those at risk of fluid volume depletion",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Individuals unable to take medications orally, or with major gastrointestinal diseases or surgeries (e.g., gastrectomy, gastrointestinal bypass) that may affect drug absorption, distribution, metabolism, or excretion",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Individuals with positive results from the serology tests at the Screening Visit (Visit 1):",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Positive for HIV",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Positive for HBsAg with HBV DNA ≥ 2000 IU/mL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Positive for Anti-HCV",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Individuals with severe liver dysfunction at the Screening Visit (Visit 1) as follows:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "AST or ALT &gt; 3 times the upper limit of normal",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Total bilirubin &gt; 2 times the upper limit of normal",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Individuals with more than a 25% change in eGFR between the Screening Visit (Visit 1) and the Baseline Visit (Visit 2)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Individuals with clinically significant severe infections (e.g., those requiring continuous antibiotic or immunotherapy) or severe trauma, as determined by the investigator",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Individuals with a past or present diagnosis of malignant tumors (participation allowed if cured or if there has been no recurrence in the past 5 years)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Individuals with a history of hypersensitivity to the active ingredient or components of the investigational drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Individuals with a history of alcohol or drug abuse within 12 months of the Screening Visit (Visit 1)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Individuals taking ACE inhibitors, ARBs, or renin inhibitors (allowed if taken at a stable dose and regimen for more than 8 weeks prior to the Pre-Baseline Visit (Visit 1-1))",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Individuals requiring continuous systemic corticosteroid treatment (use of topical corticosteroids for joint, nasal, ocular, or inhalation administration, or temporary systemic corticosteroid use for contrast agent allergies or adverse event treatment/prevention is allowed)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Women of childbearing potential who do not agree to use appropriate contraception* during the trial A. Women over 50 years of age who have been amenorrheic for at least 12 months after discontinuing exogenous hormone therapy B. Women with a history of irreversible surgical infertility (e.g., hysterectomy, bilateral oophorectomy, or bilateral salpingectomy) (tubal ligation not allowed) C. Women under 50 years of age who have been amenorrheic for at least 12 months after discontinuing exogenous hormone therapy and whose luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels are within postmenopausal ranges according to the investigational site&#39;s standards Appropriate contraception: Complete abstinence, tubal ligation, hormonal contraceptives with no known drug interactions [levonorgestrel intrauterine system (IUS) (Mirena), medroxyprogesterone injection], copper intrauterine devices, and partner's vasectomy. Periodic abstinence (e.g., calendar methods, basal body temperature method, or post-ovulation method) and withdrawal are not considered acceptable contraceptive methods.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Men who have not undergone vasectomy and who do not agree to use barrier contraception (e.g., condoms), or whose partners do not agree to use appropriate contraception during the trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Pregnant or breastfeeding women, or women with a positive pregnancy test result at the Screening Visit (Visit 1) or Baseline Visit (Visit 2)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Individuals who received investigational drugs within 8 weeks prior to the Screening Visit (Visit 1) (participation allowed if no investigational drug was administered or if involved in a non-interventional observational study)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Other individuals deemed inappropriate for trial participation at the discretion of the investigator",
    "type": "Exclusion",
    "tags": {}
  }
]